"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,S,US D0444446 S,100-206-876-956-98X,2001-07-03,2001,US 13495301 F,2001-01-03,US 13495301 F,2001-01-03,Modular truck rack,,CARTER BOB,CARTER BOB,,https://lens.org/100-206-876-956-98X,Design Right,yes,12,26,1,1,0,,,D12/406;;1216,0,0,,,,EXPIRED
2,US,A,US 3703356 A,023-354-669-024-032,1972-11-21,1972,US 3703356D A,1971-01-20,US 10797071 A,1971-01-20,PORTABLE FLAME IONIZATION GAS LEAK DETECTOR,,SOUTHERN CROSS CORP,CARTER BOB A,,https://lens.org/023-354-669-024-032,Granted Patent,no,0,1,1,1,0,G01M3/002;;G01M3/002;;G01M3/16;;G01M3/16;;G01M3/20;;G01M3/20;;G01N27/626;;G01N27/626,G01M3/00;;G01M3/16;;G01M3/20;;G01N27/62,23254   EF,0,0,,,,EXPIRED
3,NZ,A,NZ 329871 A,114-242-304-989-731,1998-04-27,1998,NZ 32987198 A,1998-02-26,AU PO542797 A,1997-03-03,WASTEWATER TREATMENT APPARATUS WITH DRAFT TUBE WITHIN AERATION CHAMBER WHICH IS WITHIN MAIN CHAMBER,,SEP TECH IND AUSTRALIA PTY LTD,CARTER KENNETH;;PARKER BOB,,https://lens.org/114-242-304-989-731,Patent Application,no,0,0,2,4,0,Y02W10/10,C02F3/12,,0,0,,,,PENDING
4,AU,B2,AU 696976 B2,147-087-200-502-140,1998-09-24,1998,AU 1998/056375 A,1998-03-02,AU 1998/056375 A;;AU PO542797 A,1997-03-03,Effluent treatment,,SEP TECH IND AUSTRALIA PTY LTD,CARTER KENNETH;;PARKER BOB,,https://lens.org/147-087-200-502-140,Granted Patent,no,3,4,2,4,0,C02F3/1242;;C02F3/1278;;C02F3/223;;C02F2201/003;;Y02W10/10,C02F1/74;;C02F3/02,,0,0,,,,EXPIRED
5,AU,A,AU 1998/056375 A,007-574-796-503-866,1998-09-03,1998,AU 1998/056375 A,1998-03-02,AU 1998/056375 A;;AU PO542797 A,1997-03-03,Effluent treatment,,SEP TECH IND AUSTRALIA PTY LTD,CARTER KENNETH;;PARKER BOB,,https://lens.org/007-574-796-503-866,Patent Application,no,0,0,2,4,0,C02F3/1242;;C02F3/1278;;C02F3/223;;C02F2201/003;;Y02W10/10,C02F1/74;;C02F3/02,,0,0,,,,EXPIRED
6,US,A1,US 2010/0105136 A1,163-304-865-143-312,2010-04-29,2010,US 44409007 A,2007-10-09,US 44409007 A;;US 85004006 P;;US 2007/0021575 W,2006-10-09,CHIMERIC T-CELL RECEPTORS AND T-CELLS TARGETING EGFRVIII ON TUMORS,"Chimeric T-cell receptor proteins have been produced in cells by the construction of nucleic acids and vectors, and the transfection of the vectors into cells. The chimeric proteins comprise, as an extracellular binding portion, a single chain antibody portion that binds to EGFRvIII, a transmembrane portion derived from human CD8α or CD28, and an intracellular signaling portion derived from human CD3ζ. The invention includes nucleic acids, vectors and cells associated with the production of the chimeric membrane protein, as well as methods to treat rumors bearing EGFRvIII, a mutant epidermal growth factor receptor.",GEN HOSPITAL CORP;;CHILDRENS MEDICAL CENTER,CARTER BOB S;;MULLIGAN RICHARD C;;BULLAIN SZOFIA,CHILDREN'S MEDICAL CENTER CORPORATION (2008-01-08);;THE GENERAL HOSPITAL CORPORATION (2007-12-20),https://lens.org/163-304-865-143-312,Patent Application,yes,1,66,4,4,43,C07K14/7051;;C07K14/7051;;C07K14/70517;;C07K14/70517;;C07K14/70521;;C07K14/70521;;C07K14/70578;;C07K14/70578;;C07K16/2863;;C07K16/2863;;C07K2317/34;;C07K2317/34;;C07K2319/00;;C07K2319/00,C12N5/0783;;C07H21/04;;C07K14/725,435/372.3;;536/23.5;;530/350,0,0,,,,DISCONTINUED
7,WO,A1,WO 2020/220038 A1,115-844-331-573-197,2020-10-29,2020,US 2020/0030125 W,2020-04-27,US 201962839038 P,2019-04-26,EXTRACELLULAR VESICLES AND USES THEREOF,"The invention relates to a highly purified population of protoporphyrin IX (PplX)-positive extracellular vesicles (EVs). The invention also relates to a method of identifying a neoplasm in a subject, the method comprising the steps of a) administering a 5-aminolevulinic acid to the subject; and b) detecting, in a biofluid of the subject, PpIX-positive EVs by imaging flow cytometry, wherein an increase in the amount of PpIX-positive EVs compared to a control sample is taken as an indication that the subject has the neoplasm.",MASSACHUSETTS GEN HOSPITAL,BALAJ LEONORA;;CARTER BOB;;JONES PAMELA;;YEKULA ANUDEEP,,https://lens.org/115-844-331-573-197,Patent Application,yes,2,1,1,1,0,A61P17/02;;G01N33/57407;;G01N33/6812,A61K9/14;;A61K31/195;;A61K47/10;;A61P17/02,,0,0,,,,PENDING
8,WO,A9,WO 2011/031877 A9,074-873-424-202-966,2018-04-12,2018,US 2010/0048293 W,2010-09-09,US 24101409 P,2009-09-09,USE OF MICROVESICLES IN ANALYZING NUCLEIC ACID PROFILES,"The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The determination of a biological condition may aid, for example, the diagnosis, prognosis, and therapy treatment selection for a disease in a subject.",MASSACHUSETTS GEN HOSPITAL;;NOERHOLM MIKKEL;;SKOG JOHAN KARL OLOV;;BREAKEFIELD XANDRA O;;CARTER BOB,NOERHOLM MIKKEL;;SKOG JOHAN;;BREAKEFIELD XANDRA;;CARTER BOB,,https://lens.org/074-873-424-202-966,Search Report,yes,0,0,11,11,0,G01N33/57407;;C12Q1/6806;;C12Q2600/158;;C12Q1/6886;;C12Q2600/158;;C12Q1/6806;;G01N33/57407;;C12Q1/6886,G01N33/48,,0,0,,,,PENDING
9,WO,A9,WO 2008/045437 A9,077-381-798-109-924,2008-11-13,2008,US 2007/0021575 W,2007-10-09,US 85004006 P,2006-10-09,CHIMERIC T-CELL RECEPTORS AND T-CELLS TARGETING EGFRVIII ON TUMORS,"Chimeric T-cell receptor proteins have been produced in cells by the construction of nucleic acids and vectors, and the transfection of the vectors into cells. The chimeric proteins comprise, as an extracellular binding portion, a single chain antibody portion that binds to EGFRvIII, a transmembrane portion derived from human CD8a or CD28, and an intracellular signaling portion derived from human CD3?. The invention includes nucleic acids, vectors and cells associated with the production of the chimeric membrane protein, as well as methods to treat rumors bearing EGFRvIII, a mutant epidermal growth factor receptor.",GEN HOSPITAL CORP;;CHILDRENS MEDICAL CENTER;;CARTER BOB S;;MULLIGAN RICHARD C;;BULLAIN SZOFIA,CARTER BOB S;;MULLIGAN RICHARD C;;BULLAIN SZOFIA,,https://lens.org/077-381-798-109-924,Patent Application,no,0,1,4,4,0,C07K14/7051;;C07K14/7051;;C07K14/70517;;C07K14/70517;;C07K14/70521;;C07K14/70521;;C07K14/70578;;C07K14/70578;;C07K16/2863;;C07K16/2863;;C07K2317/34;;C07K2317/34;;C07K2319/00;;C07K2319/00,C07K14/075;;A61K39/395;;C07K16/28;;C07K16/30;;C07K16/46,,0,0,,,,PENDING
10,WO,A2,WO 2008/045437 A2,107-328-535-026-573,2008-04-17,2008,US 2007/0021575 W,2007-10-09,US 85004006 P,2006-10-09,CHIMERIC T-CELL RECEPTORS AND T-CELLS TARGETING EGFRVIII ON TUMORS,"Chimeric T-cell receptor proteins have been produced in cells by the construction of nucleic acids and vectors, and the transfection of the vectors into cells. The chimeric proteins comprise, as an extracellular binding portion, a single chain antibody portion that binds to EGFRvIII, a transmembrane portion derived from human CD8α or CD28, and an intracellular signaling portion derived from human CD3ζ. The invention includes nucleic acids, vectors and cells associated with the production of the chimeric membrane protein, as well as methods to treat rumors bearing EGFRvIII, a mutant epidermal growth factor receptor.",GEN HOSPITAL CORP;;CHILDRENS MEDICAL CENTER;;CARTER BOB S;;MULLIGAN RICHARD C;;BULLAIN SZOFIA,CARTER BOB S;;MULLIGAN RICHARD C;;BULLAIN SZOFIA,,https://lens.org/107-328-535-026-573,Patent Application,yes,0,126,4,4,43,C07K14/7051;;C07K14/7051;;C07K14/70517;;C07K14/70517;;C07K14/70521;;C07K14/70521;;C07K14/70578;;C07K14/70578;;C07K16/2863;;C07K16/2863;;C07K2317/34;;C07K2317/34;;C07K2319/00;;C07K2319/00,C12N15/09,,0,0,,,,PENDING
11,WO,A3,WO 2008/045437 A3,112-496-355-599-247,2008-09-18,2008,US 2007/0021575 W,2007-10-09,US 85004006 P,2006-10-09,CHIMERIC T-CELL RECEPTORS AND T-CELLS TARGETING EGFRVIII ON TUMORS,"Chimeric T-cell receptor proteins have been produced in cells by the construction of nucleic acids and vectors, and the transfection of the vectors into cells. The chimeric proteins comprise, as an extracellular binding portion, a single chain antibody portion that binds to EGFRvIII, a transmembrane portion derived from human CD8α or CD28, and an intracellular signaling portion derived from human CD3ζ. The invention includes nucleic acids, vectors and cells associated with the production of the chimeric membrane protein, as well as methods to treat rumors bearing EGFRvIII, a mutant epidermal growth factor receptor.",GEN HOSPITAL CORP;;CHILDRENS MEDICAL CENTER;;CARTER BOB S;;MULLIGAN RICHARD C;;BULLAIN SZOFIA,CARTER BOB S;;MULLIGAN RICHARD C;;BULLAIN SZOFIA,,https://lens.org/112-496-355-599-247,Search Report,yes,4,0,4,4,0,C07K14/7051;;C07K14/7051;;C07K14/70517;;C07K14/70517;;C07K14/70521;;C07K14/70521;;C07K14/70578;;C07K14/70578;;C07K16/2863;;C07K16/2863;;C07K2317/34;;C07K2317/34;;C07K2319/00;;C07K2319/00,C07K14/075;;A61K39/395;;C07K16/28;;C07K16/30;;C07K16/46,,4,4,053-287-216-295-99X;;068-575-280-302-518;;025-654-757-581-979;;065-995-399-179-264,10.1227/00006123-200608000-00133;;10850460;;10914732;;10.1038/nri1729;;16322746,"BULLAIN S S (REPRINT) ET AL: ""Chimeric T-cell receptor therapy for glioblastoma multiforme"", NEUROSURGERY, (AUG 2006) VOL. 59, NO. 2, PP. 486-486. ISSN: 0148-396X. PB - LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA., August 2006 (2006-08-01), XP009102655;;TANG C K ET AL: ""Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer"", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 60, 1 June 2000 (2000-06-01), pages 3081 - 3087, XP002967802, ISSN: 0008-5472;;BEERS R ET AL: ""Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display"", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 6, no. 7, 1 July 2000 (2000-07-01), pages 2835 - 2843, XP002176480, ISSN: 1078-0432;;KERSHAW MICHAEL H ET AL: ""Supernatural T cells: Genetic modification of T cells for cancer therapy"", NATURE REVIEWS IMMUNOLOGY, vol. 5, no. 12, December 2005 (2005-12-01), pages 928 - 940, XP009102639, ISSN: 1474-1733",PENDING
12,WO,A1,WO 2021/113842 A1,059-911-577-120-217,2021-06-10,2021,US 2020/0063663 W,2020-12-07,US 201962944922 P;;US 202063028407 P,2019-12-06,TERT PROMOTER DROPLET DIGITAL PCR ASSAY FOR THE DIAGNOSIS OF MALIGNANT CANCERS,"Aspects of the present disclosure relate to methods for detecting mutant TERT promoter sequences (e.g., C228T, C250T) that provide several improvements over conventional detection methods, thereby enabling detection of such mutations in biological fluid samples (e.g.,plasma), which contain miniscule amounts of nucleic acids. Such improvements include, but are not limited to, improvements in detection sensitivity and specificity, which allows detection of mutations in a biological sample having a low level of nucleic acids such as a plasma sample from a patient having brain cancer (e.g., glioma).",MASSACHUSETTS GEN HOSPITAL,BALAJ LEONORA;;MURALIDHARAN KOUSHIK;;YEKULA ANUDEEP;;CARTER BOB S,,https://lens.org/059-911-577-120-217,Patent Application,yes,7,0,2,2,5,C12Q1/6886;;C12Q1/6858;;C12Q1/6886;;C12Q2600/156,C12Q1/6827;;C12Q1/686;;C12Q1/6886,,0,0,,,,PENDING
13,US,A1,US 2023/0027906 A1,032-975-786-966-174,2023-01-26,2023,US 202017781423 A,2020-12-07,US 202017781423 A;;US 202063028407 P;;US 201962944922 P;;US 2020/0063663 W,2019-12-06,TERT Promoter Droplet Digital PCR Assay for the Diagnosis of Malignant Cancers,"Aspects of the present disclosure relate to methods for detecting mutant TERT promoter sequences (e.g., C228T, C250T) that provide several improvements over conventional detection methods, thereby enabling detection of such mutations in biological fluid samples (e.g., plasma), which contain miniscule amounts of nucleic acids. Such improvements include, but are not limited to, improvements in detection sensitivity and specificity, which allows detection of mutations in a biological sample having a low level of nucleic acids such as a plasma sample from a patient having brain cancer (e.g., glioma).",MASSACHUSETTS GEN HOSPITAL,BALAJ LEONORA;;MURALIDHARAN KOUSHIK;;YEKULA ANUDEEP;;CARTER BOB S,THE GENERAL HOSPITAL CORPORATION (2022-09-27),https://lens.org/032-975-786-966-174,Patent Application,yes,0,0,2,2,5,C12Q1/6886;;C12Q1/6858;;C12Q1/6886;;C12Q2600/156,C12Q1/6886,,0,0,,,,PENDING
14,US,A,US 4249576 A,172-406-023-595-842,1981-02-10,1981,US 6156679 A,1979-07-30,US 6156679 A,1979-07-30,Retrievable plug for offshore platforms having shear type retaining means,"A reusable plug for sealing the conductor pipe of offshore platforms comprising a cylindrical housing, central body member and pressure equalization means.",HALLIBURTON CO,KNOX L CARTER;;STREICH STEVEN G;;SULLAWAY BOB L,CONTINENTAL EMSCO COMPANY (1994-08-16),https://lens.org/172-406-023-595-842,Granted Patent,yes,7,5,1,1,0,E02B17/0013;;E21B33/134;;F16L55/10;;F16L55/10;;E21B33/134;;E02B17/0013,E02B17/00;;E21B33/134;;F16L55/10,138/89,0,0,,,,EXPIRED
15,WO,A1,WO 2016/007518 A1,051-976-515-123-187,2016-01-14,2016,US 2015/0039385 W,2015-07-07,US 201462021532 P,2014-07-07,AUTOMATIC SEGMENTATION AND QUANTITATIVE PARAMETERIZATION OF BRAIN TUMORS IN MRI,"Techniques, systems, and devices are described for implementing automatic segmentation and quantitative parameterization of MRI images. For example, the disclosed method includes processing the MRI image to correct any distortions; performing a preliminary segmentation of the MRI image to assign a tissue label of a set of tissue labels to one or more preliminary volumes of voxels of the MRI image; comparing each voxel of the MRI image with the one or more preliminary volumes of voxels with an assigned tissue label and assigning each voxel of the MRI image a probability of being associated with each tissue label of the set of tissue labels; and assigning each voxel of the MRI image a tissue label according to its greatest probability among probabilities for each voxel being associated with the set of tissue labels.",UNIV CALIFORNIA,CHEN CLARK;;STEED TYLER;;CARTER BOB S;;DALE ANDERS M,,https://lens.org/051-976-515-123-187,Patent Application,yes,7,10,3,3,0,G01R33/5608;;G06T7/0012;;G06T2207/10088;;G06T2207/20128;;G06T2207/30016;;G06T7/11;;G06V2201/03;;G06V10/764;;G06V10/7788;;G06T7/0012;;G06T2207/10088;;G06T2207/20128;;G06T2207/30016;;G06T7/11;;G01R33/5608;;G06V2201/03;;G06V2201/031;;G06F18/24147;;G06F18/41;;G06F18/2415;;G06V10/764;;G06V10/7788;;G06T7/187;;G06T2207/20081;;G06T2207/30096,G06V10/764,,0,0,,,,PENDING
16,US,B2,US 10169685 B2,035-107-321-183-072,2019-01-01,2019,US 201515323530 A,2015-07-07,US 201515323530 A;;US 201462021532 P;;US 2015/0039385 W,2014-07-07,Automatic segmentation and quantitative parameterization of brain tumors in MRI,"Techniques, systems, and devices are described for implementing automatic segmentation and quantitative parameterization of MRI images. For example, the disclosed method includes processing the MRI image to correct any distortions; performing a preliminary segmentation of the MRI image to assign a tissue label of a set of tissue labels to one or more preliminary volumes of voxels of the MRI image; comparing each voxel of the MRI image with the one or more preliminary volumes of voxels with an assigned tissue label and assigning each voxel of the MRI image a probability of being associated with each tissue label of the set of tissue labels; and assigning each voxel of the MRI image a tissue label according to its greatest probability among probabilities for each voxel being associated with the set of tissue labels.",UNIV CALIFORNIA,CHEN CLARK;;STEED TYLER;;CARTER BOB S;;DALE ANDERS M,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2015-07-05),https://lens.org/035-107-321-183-072,Granted Patent,yes,7,5,3,3,0,G01R33/5608;;G06T7/0012;;G06T2207/10088;;G06T2207/20128;;G06T2207/30016;;G06T7/11;;G06V2201/03;;G06V10/764;;G06V10/7788;;G06T7/0012;;G06T2207/10088;;G06T2207/20128;;G06T2207/30016;;G06T7/11;;G01R33/5608;;G06V2201/03;;G06V2201/031;;G06F18/24147;;G06F18/41;;G06F18/2415;;G06V10/764;;G06V10/7788;;G06T7/187;;G06T2207/20081;;G06T2207/30096,G06T7/11;;G01R33/56;;G06T7/00;;G06T7/187;;G06V10/764,,43,42,067-084-615-211-43X;;025-606-207-383-613;;008-401-964-610-216;;046-790-993-975-302;;032-042-147-850-410;;080-513-827-971-661;;002-796-015-264-48X;;081-816-662-743-699;;114-556-826-062-660;;123-008-616-569-550;;050-541-732-697-786;;031-818-054-450-257;;062-836-401-504-605;;008-714-661-490-12X;;043-099-997-684-689;;010-663-283-182-094;;003-735-461-355-696;;039-197-603-248-580;;004-348-623-369-422;;002-034-769-416-645;;000-125-181-498-310;;011-543-929-020-220;;011-312-511-703-704;;085-656-742-202-556;;095-773-278-696-411;;184-446-291-593-247;;000-679-757-085-450;;031-136-752-436-374;;023-459-652-549-183;;046-019-657-946-925;;056-180-494-985-439;;000-211-465-944-790;;002-015-261-929-841;;056-967-412-924-149;;107-231-653-430-242;;020-391-746-039-013;;024-900-976-807-186;;026-223-754-328-507;;028-984-112-805-307;;091-712-215-361-775;;062-797-804-086-955;;028-519-256-561-598,pmc3866108;;24358132;;10.1371/journal.pone.0081895;;18091357;;10.1203/pdr.0b013e31815ed071;;16019235;;10.1016/j.neuroimage.2005.05.046;;15006671;;10.1016/j.neuroimage.2003.10.012;;pmc3910500;;24120142;;10.1016/j.cell.2013.09.034;;10.1371/journal.pone.0008918;;20169195;;pmc2820542;;9931268;;10.1006/nimg.1998.0395;;21725140;;pmc3153124;;10.1088/0031-9155/56/14/021;;24110443;;10.1109/embc.2013.6610256;;10.2307/1932409;;10.1073/pnas.0801279105;;18362333;;pmc2278224;;10.1016/s0896-6273(02)00569-x;;11832223;;10.1016/s0933-3657(00)00073-7;;11154873;;23790354;;10.1016/j.mri.2013.05.002;;17354756;;10.1007/11866763_8;;10.1148/radiol.13120118;;23392431;;pmc3632807;;21601840;;10.1016/j.compbiomed.2011.04.010;;10.1016/j.neuroimage.2009.11.044;;pmc2819607;;19944768;;21880566;;10.1109/tmi.2011.2138152;;10.1016/s1361-8415(01)00036-6;;11516708;;10.1006/nimg.2002.1132;;10.1016/s1053-8119(02)91132-8;;12377157;;21979382;;10.1016/j.neuroimage.2011.09.015;;16300968;;10.1016/j.neuroimage.2005.09.046;;20044633;;10.1001/jama.2013.280319;;24193082;;10.1109/tsmc.1979.4310076;;14697002;;10.1016/s1076-6332(03)00506-3;;pmc2430604;;15501092;;10.1016/j.neuroimage.2004.07.051;;10.1002/hbm.10062;;pmc6871816;;12391568;;10.1016/j.nicl.2013.10.003;;pmc3830067;;24273728;;10.3174/ajnr.a4171;;25414001;;pmc7964326;;10.1016/0730-725x(95)00012-6;;8569446;;10.1016/j.ccr.2009.12.020;;10.3410/f.718384247.793495043;;pmc2818769;;20129251;;pmc3049580;;21119666;;10.1038/sj.bjc.6606031;;11410304;;10.1016/s0167-8140(01)00371-1;;10.1056/nejmra0708126;;18669428;;10.1016/j.neuroimage.2008.10.055;;19059349;;pmc3705006;;10.1007/s10278-012-9568-1;;23319111;;11293691;;10.1109/42.906424;;pmc3515056;;22591720;;10.1016/j.acra.2012.03.026;;10.1007/978-3-642-33454-2_46;;23286152;;10.1371/journal.pone.0025451;;21998659;;pmc3187774,"Anbeek et al., “Automatic segmentation of eight tissue classes in neonatal brain MRI”, PloS one 2013, 8, e81895.;;Anbeek et al., “Probabilistic brain tissue segmentation in neonatal magnetic resonance imaging”, Pediatric research 2008, 63, pp. 158-163.;;Anbeek et al., “Probabilistic segmentation of brain tissue in MR imaging”, NeuroImage 2005, 27, pp. 795-804.;;Anbeek et al., “Probabilistic segmentation of white matter lesions in MR imaging”, NeuroImage 2004, 21, pp. 1037-1044.;;Brennan et al., “The somatic genomic landscape of glioblastoma”, Cell 2013, 155, pp. 462-477.;;Cerami et al., “Automated network analysis identities core pathways in glioblastoma”, PLoS One 2010, 5, e8918.;;Dale et al., “Cortical surface-based analysis I. Segmentation and surface reconstruction”, NeuroImage 1999, 9, pp. 179-194.;;Deeley et al., “Comparison of manual and automatic segmentation methods for brain structures in the presence of space-occupying lesions: a multi-expert study”, Physics in Medicine and Biology 2011, 56, pp. 4557-4577.;;Diaz et al., “An automatic brain tumor segmentation tool. Conference proceedings”, Annual International Conference Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society 2013, pp. 3339-3342.;;Dice, L.R., “Measures of the Amount of Ecologic Association Between Species”, Ecology 1945, 26, pp. 297-302.;;Diehn et al., “Identification of noninvasive imaging surrogates for brain tumor gene-expression modules”, Proc Natl Acad Sci U S A 2008, 105, pp. 5213-5218.;;Fischl et al., “Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain”, Neuron 2002, 33, pp. 341-355.;;Fletcher-Heath et al., “Automatic segmentation of non-enhancing brain tumors in magnetic resonance images”, Artificial Intelligence in Medicine 2001, 21, pp. 43-63.;;Gordillo et al., “State of the art survey on MRI brain tumor segmentation”, Magnetic resonance imaging 2013, 31, pp. 1426-1438.;;Grabner et al., “Symmetric atlasing and model based segmentation: an application to the hippocampus in older adults”, Medical image computing and computer-assisted intervention: MICCAI International Conference on Medical Image Computing and Computer-Assisted Intervention 2006, 9, pp. 58-66.;;Gutman et al., “MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set”, Radiology 2013, 267, pp. 560-569.;;Harati et al., “Fully automated tumor segmentation based on improved fuzzy connectedness algorithm in brain MR images”, Computers in Biology and Medicine 2011, 41, pp. 483-492.;;Holland et al., “Efficient correction of inhomogeneous static magnetic field-induced distortion in Echo Planar Imaging”, NeuroImage 2010, 50, pp. 175-183.;;Iglesias et al., “Robust brain extraction across datasets and comparison with publicly available methods”, IEEE transactions on medical imaging 2011, 30, pp. 1617-1634.;;Jenkinson et al., “A global optimisation method for robust affine registration of brain images”, Medical image analysis 2001, 5, pp. 143-156.;;Jenkinson et al., “Improved optimization for the robust and accurate linear registration and motion correction of brain images”, NeuroImage 2002, 17, pp. 825-841.;;Jenkinson et al., FSL, NeuroImage 2012, 62, pp. 782-790.;;Jovicich et al., “Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data”, NeuroImage 2006, 30, pp. 436-443.;;Minniti et al., “Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents”, Anticancer research 2009, 29, pp. 5171-5184.;;Omuro et al., “Glioblastoma and other malignant gliomas: a clinical review”, JAMA: The journal of the American Medical Association 2013, 310, pp. 1842-1850.;;Otsu, “A Threshold Selection Method from Gray-Level Histograms.” Systems, Man and Cybernetics, IEEE Transactions on Systems, Man and Cybernetics, 1979, 9, pp. 62-66.;;Prastawa et al., “Automatic brain tumor segmentation by subject specific modification of atlas priors”, Academic Radiology 2003, 10, pp. 1341-1348.;;Smith et al., “Advances in functional and structural MR image analysis and implementation as FSL”, NeuroImage 2004, 23 Suppl 1, pp. S208-S219.;;Smith, S.M., “Fast robust automated brain extraction”, Human brain mapping 2002, 17, pp. 143-155.;;Steenwijk et al., “Accurate white matter lesion segmentation by k nearest neighbor classification with tissue type priors (kNN-TTPs)”, NeuroImage Clinical 2013, 3, pp. 462-469.;;Steed et al., “Iterative Probabilistic Voxel Labeling: Automated Segmentation for Analysis of the Cancer Imaging Archive Glioblastoma Images”, Original Research Brain, 2015, pp. 678-685.;;Vaidyanathan et al., “Comparison of supervised MRI segmentation methods for tumor volume determination during therapy”, Magnetic Resonance Imaging 1995, 13, pp. 719-728.;;Verhaak et al., “Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1”, Cancer Cell 2010, 17, pp. 98-110.;;Vitucci et al., “Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy”, Br J Cancer 2011, 104, pp. 545-553.;;Weltens et al. “Interobserver variations in gross tumor volume delineation of brain tumors on computed tomography and impact of magnetic resonance imaging”, Radiotherapy and Oncology, 2001, 60, pp. 49-59.;;Wen et al., “Malignant gliomas in adults”, The New England Journal of Medicine 2008, 359, pp. 492-507.;;Woolrich et al., “Bayesian analysis of neuroimaging data in FSL”, NeuroImage 2009, 45, pp. S173-S186.;;Wu et al., “Semi-automatic segmentation of brain tumors using population and individual information”, Journal of Digital Imaging 2013, 26, pp. 786-796.;;Zhang et al., “Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm”, IEEE transactions on medical imaging 2001, 20, pp. 45-57.;;Zhu et al., “Semi-automatic segmentation software for quantitative clinical brain glioblastoma evaluation”, Academic Radiology 2012, 19, pp. 977-985.;;Zikic et al., “Decision forests for tissue-specific segmentation of high-grade gliomas in multi-channel MR”, MICCAI International Conference on Medical Image Computing and Computer-Assisted Intervention 2012;15:369-76.;;Zinn et al., “Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme”, PloS one 2011, 6, e25451.;;International Search Report and Written Opinion of International Application No. PCT/US2015/039385; dated Sep. 29, 2015.",ACTIVE
17,US,A1,US 2017/0147908 A1,058-946-523-861-881,2017-05-25,2017,US 201515323530 A,2015-07-07,US 201515323530 A;;US 201462021532 P;;US 2015/0039385 W,2014-07-07,Automatic Segmentation And Quantitative Parameterization Of Brain Tumors In MRI,"Techniques, systems, and devices are described for implementing automatic segmentation and quantitative parameterization of MRI images. For example, the disclosed method includes processing the MRI image to correct any distortions; performing a preliminary segmentation of the MRI image to assign a tissue label of a set of tissue labels to one or more preliminary volumes of voxels of the MRI image; comparing each voxel of the MRI image with the one or more preliminary volumes of voxels with an assigned tissue label and assigning each voxel of the MRI image a probability of being associated with each tissue label of the set of tissue labels; and assigning each voxel of the MRI image a tissue label according to its greatest probability among probabilities for each voxel being associated with the set of tissue labels.",UNIV CALIFORNIA,CHEN CLARK;;STEED TYLER;;CARTER BOB S;;DALE ANDERS M,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2015-07-05),https://lens.org/058-946-523-861-881,Patent Application,yes,0,15,3,3,0,G01R33/5608;;G06T7/0012;;G06T2207/10088;;G06T2207/20128;;G06T2207/30016;;G06T7/11;;G06V2201/03;;G06V10/764;;G06V10/7788;;G06T7/0012;;G06T2207/10088;;G06T2207/20128;;G06T2207/30016;;G06T7/11;;G01R33/5608;;G06V2201/03;;G06V2201/031;;G06F18/24147;;G06F18/41;;G06F18/2415;;G06V10/764;;G06V10/7788;;G06T7/187;;G06T2207/20081;;G06T2207/30096,G01R33/56;;G06T7/00;;G06T7/11;;G06T7/187;;G06V10/764,,0,0,,,,ACTIVE
18,US,A1,US 2019/0292239 A1,008-115-758-263-981,2019-09-26,2019,US 201916291829 A,2019-03-04,US 201916291829 A;;US 201715619917 A;;US 201414239687 A;;US 2012/0051412 W;;US 201161525278 P,2011-08-19,VEGF-BINDING PROTEIN FOR BLOCKADE OF ANGIOGENESIS,"Provided are chimeric VEGF-binding proteins and nucleic acids (e.g., a vector) encoding chimeric VEGF-binding proteins, methods and host cells for producing these proteins and nucleic acids, and pharmaceutical compositions containing these proteins and nucleic acids. Also provided are methods of treating an angiogenic disease or disorder that include administering at least one of the chimeric VEGF-binding proteins or at least one of the nucleic acids (e.g., a vector) encoding a chimeric VEGF-binding protein.",CHILDRENS MEDICAL CENTER;;MASSACHUSETTS GEN HOSPITAL;;HARVARD COLLEGE,CARTER BOB;;LEE JENG-SHIN;;BULLAIN SZOFIA S;;MULLIGAN RICHARD C,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2014-02-15);;CHILDREN'S MEDICAL CENTER CORPORATION (2014-03-17);;THE GENERAL HOSPITAL CORPORATION (2014-03-25),https://lens.org/008-115-758-263-981,Patent Application,yes,3,3,12,12,8,A61K38/00;;C07K14/475;;C07K2319/30;;A61P35/00;;A61K38/00;;C07K14/475;;C07K2319/30;;A61K48/00;;C12N15/11;;A61K39/001109;;C07K2317/24;;C12N15/1136;;A61K35/42;;C07K14/71,C07K14/71;;C07K14/475,,0,0,,,,PENDING
19,EP,A1,EP 3461912 A1,037-548-410-360-030,2019-04-03,2019,EP 18199345 A,2010-09-09,US 24101409 P;;EP 10816090 A;;US 2010/0048293 W,2009-09-09,USE OF MICROVESICLES IN ANALYZING NUCLEIC ACID PROFILES,"The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The present application is directed to the determination of about 1600 genes which have been found to be differentially expressed in microvesicles present in serum of glioblastoma patients. .
",MASSACHUSETTS GEN HOSPITAL,NOERHOLM MIKKEL;;SKOG JOHAN KARL OLOV;;BREAKEFIELD XANDRA O;;CARTER BOB,,https://lens.org/037-548-410-360-030,Patent Application,yes,32,0,11,11,0,G01N33/57407;;C12Q1/6806;;C12Q2600/158;;C12Q1/6886;;C12Q2600/158;;C12Q1/6806;;G01N33/57407;;C12Q1/6886,C12Q1/6806;;C12Q1/6886;;G01N33/48,,45,42,003-870-745-672-716;;094-463-059-022-302;;017-559-987-535-067;;096-297-459-857-191;;096-756-470-790-629;;091-106-410-640-235;;038-967-031-002-391;;006-635-819-665-420;;098-975-268-154-365;;074-448-800-565-123;;056-649-011-137-95X;;033-155-296-715-092;;117-777-238-559-353;;033-916-592-216-662;;011-332-943-473-533;;092-084-934-441-087;;037-047-957-053-389;;146-606-185-618-094;;068-716-621-588-961;;044-998-298-479-606;;029-238-328-272-724;;040-796-118-388-539;;109-340-557-373-319;;050-961-782-167-741;;014-524-302-477-134;;109-553-992-963-291;;007-668-424-494-396;;104-779-719-063-110;;014-252-478-665-343;;094-463-059-022-302;;089-155-244-656-088;;064-520-071-952-414;;140-591-885-755-375;;115-663-447-615-245;;084-525-238-501-841;;003-870-745-672-716;;081-905-315-069-593;;137-253-096-323-115;;046-201-607-879-85X;;043-885-019-636-545;;034-821-953-053-761;;008-453-634-162-718,19011622;;pmc3423894;;10.1038/ncb1800;;10.1038/ki.2010.106;;pmc4451567;;20428099;;10.1186/1471-2407-12-22;;pmc3329625;;22251860;;7534908;;pmc306737;;10.1093/nar/23.4.675;;10.1038/ncb1725;;18425114;;10963673;;pmc27718;;10.1073/pnas.97.18.10101;;10.1007/s001099900038;;10606205;;10.1111/j.2517-6161.1995.tb02031.x;;10.1016/j.bios.2006.06.023;;16891110;;10.1152/ajprenal.00434.2006;;17229675;;pmc2271070;;pmc280436;;3260032;;10.1073/pnas.85.12.4397;;pmc1859890;;10.1073/pnas.0608651103;;17090687;;10.1093/bioinformatics/bti681;;16174683;;9843981;;10.1073/pnas.95.25.14863;;pmc24541;;10.1016/0092-8674(79)90200-9;;369706;;232212;;10.1016/0076-6879(79)68013-8;;10.1038/nbt1385;;18278033;;2308948;;10.1073/pnas.87.5.1874;;pmc53586;;10.1002/bies.950150707;;7691058;;pmc1253826;;16203992;;10.1073/pnas.0409904102;;10.1021/ac701688q;;18186614;;10.1016/s0140-6736(78)91629-x;;pmc393021;;281713;;10.1073/pnas.75.11.5631;;10.1038/sj.ki.5002486;;17700640;;pmc286648;;10.1073/pnas.86.4.1173;;2919166;;10.1126/science.3413476;;3413476;;10.1038/nm1708;;18408729;;17174896;;10.1016/j.cell.2006.10.037;;6655695;;10.1016/0022-2836(83)90094-3;;10.1038/ki.2010.106;;pmc4451567;;20428099;;10.1126/science.4071043;;4071043;;18097410;;10.1038/nature06385;;pmc3090667;;8278394;;pmc42947;;10.1073/pnas.91.1.360;;10.1073/pnas.86.8.2766;;2565038;;pmc286999;;pmc2192324;;10.1084/jem.183.3.1161;;8642258;;19011622;;pmc3423894;;10.1038/ncb1800;;16369550;;10.1038/nmeth842;;10.1016/j.ygyno.2008.04.033;;18589210;;pmc1894934;;10.1261/rna.575107;;17545563;;10.1126/science.270.5235.484;;7570003;;10.1016/j.humpath.2003.08.026;;14745734;;8472349;;0008472349;;10.1093/clinchem/39.4.561,"SKOG JOHAN ET AL: ""Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers"", NATURE CELL BIOLOGY, MACMILLAN MAGAZINES LTD, vol. 10, no. 12, 1 December 2008 (2008-12-01), pages 1470 - 1476, XP002526160, ISSN: 1465-7392, [retrieved on 20081116], DOI: 10.1038/NCB1800;;MIRANDA K C ET AL: ""Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease"", KIDNEY INTERNATIONAL, NATURE PUBLISHING GROUP, NEW YORK, vol. 78, no. 2, 1 July 2010 (2010-07-01), pages 191 - 199, XP002686137, ISSN: 1523-1755, [retrieved on 20100428], DOI: 10.1038/KI.2010.106;;MIKKEL NOERHOLM ET AL: ""RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls"", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 17 January 2012 (2012-01-17), pages 22, XP021118100, ISSN: 1471-2407, DOI: 10.1186/1471-2407-12-22;;""Molecular Cloning: A Laboratory Manual"", 15 January 2001, COLD SPRING HARBOR LABORATORY;;""PCR Basics: From Background to Bench"", 15 October 2000, SPRINGER VERLAG;;ZWEIG; CAMPBELL: ""Clustering Analysis, Principle Component Analysis, other analytic tools such as Linear Discriminant Analysis"", RECEIVER OPERATING CHARACTERISTIC CURVE ANALYSIS, 1993;;ABRAVAYA, K.; J.J. CARRINO; S. MULDOON; H.H. LEE: ""Detection of point mutations with a modified ligase chain reaction (Gap-LCR"", NUCLEIC ACIDS RES., vol. 23, 1995, pages 675 - 682, XP002210106;;AL-NEDAWI, K.; B. MEEHAN; J. MICALLEF; V. LHOTAK; L. MAY; A. GUHA; J. RAK: ""Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells"", NAT CELL BIOL., vol. 10, 2008, pages 619 - 624, XP002526161, DOI: doi:10.1038/ncb1725;;ALTER, O.; P.O. BROWN; D. BOTSTEIN: ""Singular value decomposition for genome-wide expression data processing and modeling"", PROC NATL ACAD SCI US A, vol. 97, 2000, pages 10101 - 10106, XP002962133, DOI: doi:10.1073/pnas.97.18.10101;;BALZAR, M.; M.J. WINTER; C.J. DE BOER; S.V. LITVINOV: ""The biology of the 17-1A antigen (Ep-CAM"", JMOLMED., vol. 77, 1999, pages 699 - 712, XP000925817, DOI: doi:10.1007/s001099900038;;BENJAMINI, J.; Y. HOCHBERG: ""Controlling the false discovery rate: a practical and powerful approach to multiple testing"", J ROY STATIST SOC SER B (METHODOLOGICAL), vol. 57, 1995, pages 289 - 300;;BOSSI, A.; F. BONINI; A.P. TURNER; S.A. PILETSKY: ""Molecularly imprinted polymers for the recognition of proteins: the state of the art"", BIOSENS BIOELECTRON., vol. 22, 2007, pages 1131 - 1137, XP005730920, DOI: doi:10.1016/j.bios.2006.06.023;;CHERUVANKY, A.; H. ZHOU; T. PISITKUN; J.B. KOPP; M.A. KNEPPER; P.S. YUEN; R.A. STAR: ""Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator"", AM JPHYSIOL RENAL PHYSIOL., vol. 292, 2007, pages f1657 - f1661;;COTTON, R.G.; N.R. RODRIGUES; R.D. CAMPBELL: ""Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations"", PROC NATL ACAD SCI USA, vol. 85, 1988, pages 4397 - 4401, XP002086182, DOI: doi:10.1073/pnas.85.12.4397;;CRISTOFANILLI, M.; J. MENDELSOHN: ""Circulating tumor cells in breast cancer: Advanced tools for ''tailored'' therapy?"", PROC NATL ACAD SCI USA, vol. 103, 2006, pages 17073 - 17074;;DABNEY, A.R.: ""Classification of microarrays to nearest centroids"", BIOINFORMATICS, vol. 21, 2005, pages 4148 - 4154;;EISEN, M.B.; P.T. SPELLMAN; P.O. BROWN; D. BOTSTEIN: ""Cluster analysis and display of genome-wide expression patterns"", PROC NATL ACAD SCI USA, vol. 95, 1998, pages 14863 - 14868, XP002939285, DOI: doi:10.1073/pnas.95.25.14863;;FISCHER, S.G.; L.S. LERMAN: ""Length-independent separation of DNA restriction fragments in two-dimensional gel electrophoresis"", CELL, vol. 16, 1979, pages 191 - 200, XP023910996, DOI: doi:10.1016/0092-8674(79)90200-9;;FISCHER, S.G.; L.S. LERMAN: ""Two-dimensional electrophoretic separation of restriction enzyme fragments of DNA"", METHODS ENZYMOL., vol. 68, 1979, pages 183 - 191, XP009066767, DOI: doi:10.1016/0076-6879(79)68013-8;;GEISS, G.K.; R.E. BUMGARNER; B. BIRDITT; T. DAHL; N. DOWIDAR; D.L. DUNAWAY; H.P. FELL; S. FERREE; R.D. GEORGE; T. GROGAN: ""Direct multiplexed measurement of gene expression with color-coded probe pairs"", NAT BIOTECHNOL., vol. 26, 2008, pages 317 - 325, XP002505107, DOI: doi:10.1038/NBT1385;;GUATELLI, J.C.; K.M. WHITFIELD; D.Y. KWOH; K.J. BARRINGER; D.D. RICHMAN; T.R. GINGERAS: ""Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication"", PROC NATL ACAD SCI USA, vol. 87, 1990, pages 1874 - 1878, XP000368702, DOI: doi:10.1073/pnas.87.5.1874;;HAHN, P.J.: ""Molecular biology of double-minute chromosomes"", BIOESSAYS, vol. 15, 1993, pages 477 - 484, XP002908185, DOI: doi:10.1002/bies.950150707;;HAKONARSON, H.; U.S. BJORNSDOTTIR; E. HALAPI; J. BRADFIELD; F. ZINK; M. MOUY; H. HELGADOTTIR; A.S. GUDMUNDSDOTTIR; H. ANDRASON; A.: ""Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients"", PROC NATL ACADSCI USA, vol. 102, 2005, pages 14789 - 14794;;JOHNSON, S.; D. EVANS; S. LAURENSON; D. PAUL; A.G. DAVIES; P.K. FERRIGNO; C. WALTI: ""Surface-immobilized peptide aptamers as probe molecules for protein detection"", ANAL CHEM., vol. 80, 2008, pages 978 - 983, XP002536007, DOI: doi:10.1021/AC701688Q;;KAN, Y.W.; A.M. DOZY: ""Antenatal diagnosis of sickle-cell anaemia by D.N.A. analysis of amniotic-fluid cells"", LANCET, vol. 2, 1978, pages 910 - 912;;KAN, Y.W.; A.M. DOZY: ""Polymorphism of DNA sequence adjacent to human beta-globin structural gene: relationship to sickle mutation"", PROC NATL ACAD SCI USA, vol. 75, 1978, pages 5631 - 5635, XP009021082, DOI: doi:10.1073/pnas.75.11.5631;;KELLER, S.; C. RUPP; A. STOECK; S. RUNZ; M. FOGEL; S. LUGERT; H.D. HAGER; M.S. ABDEL-BAKKY; P. GUTWEIN; P. ALTEVOGT: ""CD24 is a marker of exosomes secreted into urine and amniotic fluid"", KIDNEY INT., vol. 72, 2007, pages 1095 - 1102, XP009106564, DOI: doi:10.1038/sj.ki.5002486;;KWOH, D.Y.; G.R. DAVIS; K.M. WHITFIELD; H.L. CHAPPELLE; L.J. DIMICHELE; T.R. GINGERAS: ""Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format"", PROC NATL ACAD SCI USA, vol. 86, 1989, pages 1173 - 1177, XP000368676, DOI: doi:10.1073/pnas.86.4.1173;;LANDEGREN, U.; R. KAISER; J. SANDERS; L. HOOD: ""A ligase-mediated gene detection technique"", SCIENCE, vol. 241, 1988, pages 1077 - 1080, XP000676556, DOI: doi:10.1126/science.3413476;;LI, J.; L. WANG; H. MAMON; M.H. KULKE; R. BERBECO; G.M. MAKRIGIORGOS: ""Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing"", NAT MED., vol. 14, 2008, pages 579 - 584, XP055001155, DOI: doi:10.1038/nm1708;;LIU, Q.; J.C. GREIMANN; C.D. LIMA: ""Reconstitution, activities, and structure of the eukaryotic RNA exosome"", CELL, vol. 127, 2006, pages 1223 - 1237;;MIELE, E.A.; D.R. MILLS; F.R. KRAMER: ""Autocatalytic replication of a recombinant RNA"", JMOL BIOL., vol. 171, 1983, pages 281 - 295, XP024020805, DOI: doi:10.1016/0022-2836(83)90094-3;;MIRANDA, K.C.; D.T. BOND; M. MCKEE; J. SKOG; T.G. PAUNESCU; N. DA SILVA; D. BROWN; L.M. RUSSO: ""Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease"", KIDNEY INT., vol. 78, 2010, pages 191 - 199, XP055107901, DOI: doi:10.1038/ki.2010.106;;MYERS, R.M.; Z. LARIN; T. MANIATIS: ""Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes"", SCIENCE, vol. 230, 1985, pages 1242 - 1246, XP001022204, DOI: doi:10.1126/science.4071043;;NAGRATH, S.; L.V. SEQUIST; S. MAHESWARAN; D.W. BELL; D. IRIMIA; L. ULKUS; M.R. SMITH; E.L. KWAK; S. DIGUMARTHY; A. MUZIKANSKY: ""Isolation of rare circulating tumour cells in cancer patients by microchip technology"", NATURE, vol. 450, 2007, pages 1235 - 1239, XP002681217;;NAKAZAWA, H.; D. ENGLISH; P.L. RANDELL; K. NAKAZAWA; N. MARTEL; B.K. ARMSTRONG; H. YAMASAKI: ""UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement"", PROC NATL ACAD SCI USA, vol. 91, 1994, pages 360 - 364;;ORITA, M.; H. IWAHANA; H. KANAZAWA; K. HAYASHI; T. SEKIYA: ""Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms"", PROC NATL ACAD SCI USA, vol. 86, 1989, pages 2766 - 2770, XP000310584;;RAPOSO, G.; H.W. NIJMAN; W. STOORVOGEL; R. LIEJENDEKKER; C.V. HARDING; C.J. MELIEF; H.J. GEUZE: ""B lymphocytes secrete antigen-presenting vesicles"", J EXP MED., vol. 183, 1996, pages 1161 - 1172, XP002060486, DOI: doi:10.1084/jem.183.3.1161;;SKOG, J.; T. WURDINGER; S. VAN RIJN; D.H. MEIJER; L. GAINCHE; M. SENA-ESTEVES; W.T. CURRY, JR.; B.S. CARTER; A.M. KRICHEVSKY; X.O.: ""Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers"", NAT CELL BIOL., vol. 10, 2008, pages 1470 - 1476, XP002633335, DOI: doi:10.1038/ncb1800;;STEEMERS, F.J.; W. CHANG; G. LEE; D.L. BARKER; R. SHEN; K.L. GUNDERSON: ""Whole-genome genotyping with the single-base extension assay"", NAT METHODS, vol. 3, 2006, pages 31 - 33, XP009155366, DOI: doi:10.1038/nmeth842;;TAYLOR, D.D.; C. GERCEL-TAYLOR: ""MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer"", GYNECOL ONCOL., vol. 110, 2008, pages 13 - 21, XP022795052, DOI: doi:10.1016/j.ygyno.2008.04.033;;VAN DIJK, E.L.; G. SCHILDERS; G.J. PRUIJN: ""Human cell growth requires a functional cytoplasmic exosome, which is involved in various mRNA decay pathways"", RNA, vol. 13, 2007, pages 1027 - 1035;;VELCULESCU, V.E.; L. ZHANG; B. VOGELSTEIN; K.W. KINZLER: ""Serial analysis of gene expression"", SCIENCE, vol. 270, 1995, pages 484 - 487, XP001024449, DOI: doi:10.1126/science.270.5235.484;;WENT, P.T.; A. LUGLI; S. MEIER; M. BUNDI; M. MIRLACHER; G. SAUTER; S. DIRNHOFER: ""Frequent EpCam protein expression in human carcinomas"", HUM PATHOL., vol. 35, 2004, pages 122 - 128, XP002592037, DOI: doi:10.1016/S0046-8177(03)00502-1;;ZWEIG, M.H.; G. CAMPBELL: ""Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine"", CLIN CHEM., vol. 39, 1993, pages 561 - 577, XP009041551",ACTIVE
20,US,A1,US 2013/0040833 A1,082-445-902-940-904,2013-02-14,2013,US 201013395284 A,2010-09-09,US 201013395284 A;;US 39528410 P;;US 2010/0048293 W,2010-05-12,USE OF MICROVESICLES IN ANALYZING NUCLEIC ACID PROFILES,"The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The determination of a biological condition may aid, for example, the diagnosis, prognosis, and therapy treatment selection for a disease in a subject.",GEN HOSPITAL CORP;;NOERHOLM MIKKEL;;SKOG JOHAN KARL OLOV;;BREAKEFIELD XANDRA O;;CARTER BOB,NOERHOLM MIKKEL;;SKOG JOHAN KARL OLOV;;BREAKEFIELD XANDRA O;;CARTER BOB,THE GENERAL HOSPITAL CORPORATION (2012-05-25),https://lens.org/082-445-902-940-904,Patent Application,yes,1,12,1,1,0,C12Q1/6806;;C12Q1/6806,C40B30/04;;C40B40/06,506/9;;506/16,0,0,,,,DISCONTINUED
21,US,B2,US 11519036 B2,118-838-971-308-234,2022-12-06,2022,US 201916520130 A,2019-07-23,US 201916520130 A;;US 201514792212 A;;US 201213395284 A;;US 2010/0048293 W;;US 24101409 P,2009-09-09,Use of microvesicles in analyzing nucleic acid profiles,"The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The determination of a biological condition may aid, for example, the diagnosis, prognosis, and therapy treatment selection for disease in a subject.",MASSACHUSETTS GEN HOSPITAL,NOERHOLM MIKKEL;;SKOG JOHAN KARL OLOV;;BREAKEFIELD XANDRA O;;CARTER BOB,THE GENERAL HOSPITAL CORPORATION (2012-05-25),https://lens.org/118-838-971-308-234,Granted Patent,yes,122,0,11,11,0,G01N33/57407;;C12Q1/6806;;C12Q2600/158;;C12Q1/6886;;C12Q2600/158;;C12Q1/6806;;G01N33/57407;;C12Q1/6886,G01N33/574;;C12Q1/6806;;C12Q1/6886,,201,195,096-297-459-857-191;;059-972-670-324-344;;056-447-666-258-79X;;096-756-470-790-629;;019-094-409-659-899;;094-145-542-836-45X;;038-967-031-002-391;;003-777-488-229-038;;043-008-346-498-421;;058-057-251-272-53X;;107-207-497-715-915;;098-975-268-154-365;;020-479-675-672-474;;084-223-751-887-294;;108-863-424-571-449;;007-543-763-038-628;;131-241-922-717-428;;042-767-012-961-843;;006-361-700-266-670;;032-980-216-347-271;;040-602-255-683-86X;;117-973-521-102-496;;053-368-478-727-670;;074-448-800-565-123;;038-027-836-901-95X;;007-953-100-837-914;;008-169-442-127-311;;006-175-044-218-654;;085-008-815-773-136;;110-079-365-492-021;;029-505-718-599-646;;037-086-877-392-593;;056-649-011-137-95X;;005-132-051-599-655;;039-332-742-631-60X;;032-097-726-617-021;;007-892-810-337-491;;029-649-006-050-914;;005-007-596-121-261;;023-294-457-551-357;;018-565-258-437-405;;026-852-842-403-812;;083-666-637-068-259;;062-111-065-443-998;;010-356-237-480-031;;115-523-071-944-15X;;011-332-943-473-533;;092-084-934-441-087;;001-797-371-270-008;;002-300-036-783-156;;007-668-424-494-396;;016-699-621-843-135;;104-779-719-063-110;;007-029-146-454-907;;068-070-471-116-271;;055-474-944-189-665;;087-364-860-109-449;;007-922-091-394-514;;027-213-098-929-669;;000-033-908-324-568;;031-743-189-505-696;;014-252-478-665-343;;038-217-868-297-942;;094-463-059-022-302;;010-166-310-094-798;;089-155-244-656-088;;064-520-071-952-414;;026-407-920-422-598;;140-591-885-755-375;;051-459-944-033-491;;035-841-291-273-865;;081-312-966-056-426;;019-873-570-396-901;;017-559-987-535-067;;133-434-018-301-911;;012-770-630-971-204;;115-663-447-615-245;;059-600-694-698-124;;001-568-098-749-368;;088-284-894-785-185;;049-520-233-784-529;;139-401-846-708-319;;073-557-183-456-939;;084-525-238-501-841;;011-484-591-741-698;;010-198-027-850-97X;;035-943-600-535-599;;144-549-939-323-292;;071-987-550-650-889;;017-024-470-517-316;;099-848-173-992-707;;047-153-314-853-499;;061-464-488-333-923;;005-422-391-218-711;;044-234-693-509-73X;;003-870-745-672-716;;063-795-978-664-337;;081-905-315-069-593;;056-468-366-456-260;;036-706-039-016-917;;037-831-230-791-689;;082-698-269-977-263;;035-261-521-322-351;;037-047-957-053-389;;020-472-936-008-079;;054-058-075-827-661;;065-582-035-556-385;;064-659-207-370-98X;;023-639-145-891-636;;140-534-257-440-881;;108-227-043-768-89X;;080-104-543-170-347;;071-059-168-106-856;;063-832-514-833-024;;068-716-621-588-961;;050-672-300-487-304;;025-152-639-070-836;;077-306-525-803-267;;013-054-067-427-283;;010-021-248-114-286;;051-975-606-511-447;;040-654-525-673-51X;;012-496-262-398-002;;000-132-490-637-551;;079-084-151-188-862;;068-501-711-849-792;;000-493-229-497-149;;020-496-927-165-060;;029-238-328-272-724;;069-785-693-151-14X;;040-796-118-388-539;;109-340-557-373-319;;002-908-197-051-488;;015-975-560-883-441;;023-112-838-780-460;;050-961-782-167-741;;015-761-936-434-094;;090-760-863-238-249;;029-612-487-060-400;;053-358-014-201-671;;030-947-914-777-140;;014-536-124-122-370;;068-700-228-645-070;;014-524-302-477-134;;109-553-992-963-291;;033-213-763-441-91X;;086-967-785-914-873;;025-771-101-910-509;;092-509-114-764-092;;067-207-313-773-418;;137-253-096-323-115;;115-919-863-782-954;;030-807-529-057-177;;034-108-469-016-754;;119-797-859-844-668;;029-347-021-076-182;;135-163-530-485-247;;015-453-955-064-354;;046-201-607-879-85X;;043-885-019-636-545;;029-671-078-972-249;;020-486-878-827-208;;034-821-953-053-761;;059-594-671-507-462;;069-739-770-688-833;;065-957-414-569-619;;005-359-841-040-887;;063-375-682-056-905;;095-988-867-714-743;;010-923-397-538-050;;056-919-229-643-094;;044-867-537-834-856;;077-202-946-269-836;;030-997-389-321-940;;039-773-515-186-554;;130-680-203-388-320;;049-017-522-554-561;;042-492-518-038-183;;101-082-823-932-25X;;027-956-185-347-031;;029-073-154-965-420;;085-007-113-448-158;;008-732-506-726-349;;003-697-375-976-627;;082-209-562-648-389;;061-597-199-265-054;;041-065-338-098-733;;048-937-636-972-345;;115-371-065-346-241;;014-710-154-057-478;;109-423-000-481-113;;119-797-859-844-668;;043-637-817-489-241;;017-552-931-242-415;;057-355-067-723-854,7534908;;pmc306737;;10.1093/nar/23.4.675;;10.1126/scisignal.267pe27;;19383978;;pmc1370605;;15208450;;10.1261/rna.5250604;;10.1038/ncb1725;;18425114;;pmc1599972;;16983084;;10.1073/pnas.0603529103;;10.1007/s00262-005-0075-9;;16283305;;10.1007/s001099900038;;10606205;;10.1038/sj.bjc.6601894;;15188009;;pmc2409828;;10.1016/s0168-9525(01)02320-4;;11418223;;pmc33481;;10.1073/pnas.101129998;;11353826;;pmc2063735;;10.1083/jcb.200508014;;16533950;;10.1016/j.bios.2006.06.023;;16891110;;10.1002/1097-0142(19940501)73:9<2333::aid-cncr2820730915>3.0.co;2-4;;8168038;;18006428;;10.1093/cvr/cvm071;;16951158;;10.1158/0008-5472.can-06-1547;;10.1038/nature07385;;pmc2671642;;18772890;;4053066;;pmc3160337;;10.1371/journal.pone.0023937;;21886843;;15952905;;10.1517/14712598.5.6.737;;10.1038/cr.2008.282;;18766170;;10.1039/b916199f;;20126692;;pmc3136803;;pmc1292995;;10.1093/nar/gni178;;16314309;;18288938;;10.2174/156800908783497104;;10.1152/ajprenal.00434.2006;;17229675;;pmc2271070;;12567189;;10.1038/ng1094;;10.1002/path.2106;;17139617;;16039986;;10.1016/j.bbrc.2005.07.030;;17671216;;10.1158/0008-5472.can-06-3456;;10.1016/j.tcb.2008.11.003;;19144520;;pmc2546968;;18632860;;10.1128/jvi.00646-08;;10.1161/circgenetics.110.957415;;20921333;;19426115;;10.1517/14712590902932889;;pmc280436;;3260032;;10.1073/pnas.85.12.4397;;19488871;;10.1007/978-1-60327-192-9_5;;10.1002/ijc.23849;;18823011;;21093148;;10.1016/j.canlet.2010.10.019;;17536014;;10.1182/blood-2007-03-078709;;10.1038/nmeth898;;16791214;;18670422;;pmc2820391;;10.1038/nm.1789;;pmc2893390;;10.1126/science.1187532;;20508131;;10.1073/pnas.1133470100;;pmc166396;;12857956;;21196075;;10.1016/j.eururo.2010.12.031;;10.1373/clinchem.2003.028506;;14718398;;17476321;;pmc1851990;;10.1371/journal.pone.0000399;;10.1073/pnas.0707628104;;17890317;;pmc2000384;;10.1093/molehr/gag046;;12802047;;10.1016/0092-8674(79)90200-9;;369706;;232212;;10.1016/0076-6879(79)68013-8;;19906727;;pmc2808858;;10.1093/nar/gkp995;;21731696;;10.1371/journal.pone.0021300;;pmc3120860;;10.1038/nm1708;;18408729;;10.4049/jimmunol.176.3.1375;;16424164;;17174896;;10.1016/j.cell.2006.10.037;;10.1002/cyto.a.20531;;18307272;;17206148;;10.1038/nm1530;;17146468;;10.1038/nrg1982;;pmc39218;;10.1073/pnas.93.11.5177;;8643549;;10.1038/77498;;10888925;;10.1056/nejmoa0800668;;18596266;;pmc3551471;;10.1073/pnas.0334355100;;pmc149965;;12592035;;10.1172/jci29959;;pmc1978418;;17885688;;6655695;;10.1016/0022-2836(83)90094-3;;17460779;;pmc1854851;;10.1593/neo.07133;;10.1038/ki.2010.106;;pmc4451567;;20428099;;19138409;;10.1186/1479-5876-7-4;;pmc2631476;;10.1126/science.4071043;;4071043;;18097410;;10.1038/nature06385;;pmc3090667;;10.1016/s0084-4071(08)79032-8;;8278394;;pmc42947;;10.1073/pnas.91.1.360;;12644709;;10.1073/pnas.0637450100;;pmc153627;;10.1373/49.5.727;;12709362;;pmc2696767;;10.1038/sj.bjc.6605058;;19401683;;10.1007/bf02484510;;15700833;;10.1186/1471-2407-12-22;;pmc3329625;;22251860;;10.1016/j.bbrc.2009.06.034;;19523920;;15294875;;10.1093/hmg/ddh238;;10.1073/pnas.86.8.2766;;2565038;;pmc286999;;10.1038/ncb2000;;19966785;;18772396;;pmc2820389;;10.1126/science.1164382;;10.1200/jco.2006.08.0705;;17538175;;10.1074/mcp.r600004-mcp200;;16837576;;pmc3145108;;10.1038/nature08658;;20016485;;16637463;;pmc2192324;;10.1084/jem.183.3.1161;;8642258;;16791265;;10.1038/sj.leu.2404296;;10.1016/j.clinthera.2014.05.008;;24952934;;17765966;;10.1016/j.leukres.2007.07.021;;10.1007/s00018-008-8496-1;;18818873;;10.1136/gut.52.1.101;;pmc1773535;;12477769;;19424061;;10.1097/mnh.0b013e32832c9da2;;10.1016/j.molcel.2006.03.029;;16603397;;18230780;;10.1001/jama.299.4.425;;pmc2614237;;14583498;;10.1186/1743-422x-7-248;;pmc2949849;;20858246;;10.1016/j.ceb.2009.03.007;;19442504;;19011622;;pmc3423894;;10.1038/ncb1800;;pmc17321;;11050243;;10.1073/pnas.97.22.12216;;16369550;;10.1038/nmeth842;;10.1034/j.1600-0854.2002.30502.x;;11967126;;10.1093/nar/gkq929;;20952405;;pmc3013785;;10.1002/0471142905.hg1011s57;;17974913;;10.1101/gad.1596707;;17894858;;pmc2556756;;10.1186/cc6133;;10.1038/nbt1385;;18278033;;9858920;;pmc2386537;;18516289;;10.1593/neo.07986;;10.1093/ndt/gfn058;;18310721;;18854152;;10.1016/j.cell.2008.09.022;;17257890;;10.1016/j.mrrev.2006.11.002;;11551510;;10.1016/s0092-8674(01)00484-6;;10.1182/blood-2010-02-270926;;20651067;;16627561;;10.1373/clinchem.2005.063289;;10.1073/pnas.87.19.7797-a;;pmc516580;;2217213;;10.1073/pnas.87.19.7797b;;10.1073/pnas.87.19.7797a;;10.1007/s00702-009-0288-8;;19680595;;10.1002/bies.950150707;;7691058;;10.1016/s0092-8674(00)81683-9;;10647931;;10.3410/f.13200063.14542237;;21088844;;10.1007/s00401-010-0781-z;;16236164;;pmc1298339;;10.1186/1479-5876-3-38;;12814669;;10.1016/s0302-2838(03)00201-x;;10.1158/1078-0432.ccr-07-0700;;17785564;;10.1200/jco.2008.17.6297;;pmc2738430;;19164214;;19641175;;10.1093/jnci/djp240;;10.1371/journal.pone.0003694;;19002258;;pmc2577891;;10.1038/sj.cdd.4402237;;17932500;;17875710;;10.1158/0008-5472.can-07-1936;;10.2174/138920208785133235;;pmc2694555;;19517027;;10.1002/ijc.20657;;15499615;;12970751;;10.1038/sj.onc.1206928;;10.1021/ac701688q;;18186614;;10.1126/science.1164368;;18772397;;pmc2848990;;10.1016/s0140-6736(78)91629-x;;pmc393021;;281713;;10.1073/pnas.75.11.5631;;19378339;;10.1002/ijc.24379;;pmc2788025;;10.1016/j.bbrc.2009.10.001;;19818334;;10.3389/fonc.2013.00234;;24062987;;pmc3769647;;10.1038/sj.ki.5002486;;17700640;;10.1083/jcb.127.2.441;;pmc2120214;;7929587;;15095315;;10.1002/ijc.11649;;11923846;;10.1038/nbt0402-387;;pmc2139771;;9128257;;10.1083/jcb.137.2.481;;16302729;;10.1111/j.1349-7006.2010.01650.x;;20624164;;19520761;;10.1373/clinchem.2008.121962;;pmc286648;;10.1073/pnas.86.4.1173;;2919166;;10.1126/science.3413476;;3413476;;pmc2998181;;10.1158/0008-5472.can-07-3224;;18245462;;10.1016/j.ctrv.2006.01.003;;16488082;;10.1111/j.1464-410x.2005.05943.x;;16359435;;10.1186/1745-6150-2-35;;18053135;;pmc2219957;;18687791;;10.2353/jmoldx.2008.080067;;pmc2518735;;10.1016/j.ygyno.2008.04.033;;18589210;;pmc2361848;;15655551;;10.1038/sj.bjc.6602316;;18679793;;10.1007/s10549-008-0143-x;;12154376;;10.1038/nri855;;18228490;;10.1126/science.1200801;;21233348;;pmc3701432;;16254181;;10.1126/science.1117679;;17486113;;10.1038/ncb1596;;pmc1894934;;10.1261/rna.575107;;17545563;;10.1126/science.270.5235.484;;7570003;;18322038;;10.1128/mmbr.00033-07;;pmc2268285;;10.1158/0008-5472.can-07-6838;;pmc5802396;;18632641;;10.1016/j.humpath.2003.08.026;;14745734;;17337785;;10.1385/ir:36:1:247;;10.1373/clinchem.2005.052340;;16081506;;10.1126/science.1145720;;17932254;;pmc2204063;;18231617;;10.1016/s0513-5117(09)79085-4;;18223223;;10.1158/1078-0432.ccr-07-1966;;19266099;;pmc2648987;;10.1371/journal.pone.0004722;;10.1006/viro.1997.8499;;9126269;;15193025;;pmc8095894;;10.1111/j.1750-3639.2004.tb00045.x;;10.1002/ijc.2910530522;;8449609;;21630462;;10.1002/pmic.201100022;;10.1200/jco.2004.10.062;;15169800;;pmc2997214;;10.1038/nbt0394-320;;16258065;;pmc1283450;;10.1073/pnas.0507904102;;10.1080/09553000010017108;;11258843;;pmc1024103;;13481124;;10.1136/jcp.10.4.360;;10.2144/96206st02;;8780872;;16487731;;10.1016/j.bcmd.2005.12.001;;10.1016/j.imlet.2006.09.005;;17067686;;10.4161/cam.1.3.5114;;19262134;;pmc2634021;;17790039;;10.1126/science.241.4872.1441;;10.1093/nar/29.13.2850;;11433032;;pmc55780;;18684837;;10.1128/jvi.01016-08;;pmc2566279;;10.1093/dnares/9.2.35;;12056413;;12086878;;10.1016/s1535-6108(02)00030-2;;11237013;;10.1038/35057149;;6254393;;10.1016/0003-2697(80)90519-9;;15550054;;10.1111/j.1538-7836.2004.00972.x;;18228490;;7585629;;10.1002/pros.20490;;16921506;;16282176;;10.1056/nejmoa051918,"Abravaya et al., “Detection of point mutations with a modified ligase chain reaction (Gap-LCR)”, Nucleic Acids Res 23(4) 675-682 (1995).;;Affymetriix, “Gene Chip Human Genome U133 set”, Apr. 20, 2001 URL: http://www.affymetrix.com/products/arrays/specific/hgu133.asp.;;Alessi et al., “New insights into mTOR signaling: mTORC2 and beyond”, Sci Signal 2(67) pe27 (2009).;;Allawi et al., Quantitation of microRNAs using a modified Invader assay, RNA 10(7) 1153-1161 (2004).;;Al-Nedawi et al., “Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells”, Nat Cell Biol 10(5) 619-624 (2008).;;Ason et al., “Differences in vertebrate microRNA expression”, Proc Natl Acad Sci USA 103(39) 14385-14389 (2006).;;Baj-Krzyworzeka et al., “Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes”, Cancer Immunol Immunother 55(7) 808-818 (2006).;;Balzar et al., “The biology of the 17-1A antigen (Ep-CAM)”, J Mol Med (Berl) 77(10) 699-712 (1999).;;Bamford et al., “The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website”, Br J Cancer 91 (2) 355-358 (2004).;;Benner et al., “Evolution, language and analogy in functional genomics”, Trends Genet 17(7) 414-418 (2001).;;Bergsmedh et al., “Horizontal transfer of oncogenes by uptake of apoptotic bodies”, Proc Natl Acad Sci USA 98(11) 6407-6411 (2001).;;Booth et al., “Exosomes and HIV Gag bud from endosome-like domains of the T cell plasma membrane”, J Cell Biol 172(6) 923-935 (2006).;;Bossi et al., “Molecularly imprinted polymers for the recognition of proteins: the state of the art”, Biosens Bioelectron 22(6) 1131-1137 (2007).;;Bratthauer et al., “Expression of LINE-1 retrotransposons in human breast cancer”, Cancer 73(9) 2333-2336 (1994).;;Burghoff et al., “Horizontal gene transfer from human endothelial cells to rat cardiomyocytes after intracoronary transplantation”, Cardiovasc Res 77(3) 534-543 (2008).;;Cadieux et al., “Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation”, Cancer Res 66(17) 8469-8476 (2006).;;Cancer Genome Altas Research Network, “Comprehensive genomic characterization defines human glioblastoma genes and core pathways”, Nature 455(7216) 1061-1068 (2008).;;Carr et al., “Circulating membrane vesicles in leukemic blood”, Cancer Res 45(11 Pt 2) 5944-5951 (1985).;;Cermelli et al., “Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease”, PLoS One 6(8) e23937 (2011).;;Chaput et al., “The potential of exosomes in immunotherapy”, Expert Opin Biol Ther 5(6) 737-747 (2005).;;Chen et al., “Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases”, Cell Res 18(10 997-1006 (2008).;;Chen et al., “Microfluidic isolation and transcriptome analysis of serum microvesicles”, Lab Chip 10(4) 505-511 (2010).;;Chen et al., “Real-time quantification of microRNAs by stem-loop RT-PCR”, Nucleic Acids Res 33(20) e1779 (2005).;;Cheng et al., “Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery”, Curr Cancer Drug Targets 8(1) 2-6 (2008).;;Cheruvanky et al., “Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator”, Am J Physciol Renal Physiol 292(5) F1657-F1661 (2007).;;Cheung et al., “Natural variation in human gene expression assessed in lymphoblastoid cells”, Nat Genet 33(3) 422-425 (2003).;;Cho et al., “Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features”, J Pathol 211 (3) 269-277 (2007).;;Ciafre et al., “Extensive modulation of a set of microRNAs in primary glioblastoma”, Biochem Biophys Res Commun 334(4) 1351-1358 (2005).;;Clayton et al., “Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2”, Cancer Res 67(15) 7458-7466 (2007).;;Cocucci et al., “Shedding microvesicles: artefacts no more”, Trends Cell Biol 19(2) 43-51 (2009).;;Contreras-Galindo et al., “Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer”, J Virol 82(19) 9329-9336 (2008).;;Corsten et al., “Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease”, Circ Cardiovasc Genet 3(6) 499-506 (2010).;;Cortez et al., “MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases”, Expert Opin Biol Ther 9(6) 703-711 (2009).;;Cotton et al., “Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations”, Proc Natl Acad Scie USA 85(12) 4397-4401 (1988).;;Cowell et al., “Application of oligonucleotides arrays for coincident comparative genomic hybridization, ploidy status and loss of heterozygosity studies in human cancers”, Methods Mol Biol 556: 47-65 (2009).;;Daskalos et al., “Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer”, Int J Cancer 124(1) 81-87 (2009).;;Day et al., “PCA3: from basic molecular science to the clinical lab”, Cancer Lett 301(1) 1-6 (2011).;;Deregibus et al., “Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA”, Blood 110(7) 2440-2448 (2007).;;Diehl et al., “BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions”, Nat Methods 3(7) 551-559 (2006).;;Diehl et al., “Circulating mutant DNA to assess tumor dynamics”, Nat Med 14(9) 985-990 (2008).;;Dowling et al., “mTORCI-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs”, Science 328 (5982) 1172-1176 (2010).;;Dressman et al., “Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations”, Proc Natl Acad Sci USA 100(15) 8817-8822 (2003).;;Duijvesz et al., “Exosomes as biomarker treasure chests for prostate cancer”, Eur Urol 59(5) 823-831 (2011).;;El-Hefnawy et al., “Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics”, Clin Chem 50(3) 564-573 (2004).;;Estecio et al., “LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability”, PLoS One 2(5) e399 (2007).;;Fabbri et al., “MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B”, Proc Natl Acad Sci USA 104(4) 15805-15810 (2007).;;Fiorentino et al., “The minisequencing method: an alternative strategy for preimplantation genetic diagnosis of single gene disorders”, Mol Human Reprod 9(7) 399-410 (2003).;;Fischer et al., “Length-independent separation of DNA restriction fragments in two-dimensional gel electrophoresis”, Cell 16(1) 191-200 (1979).;;Fischer et al., “Two-dimensional electrophoretic separation of restriction enzyme fragments of DNA”, Methods Enzymol 68: 183-191 (1979).;;Forbes et al., “COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer”, Nucleic Acids Res 38(Database issue) D652-D657 (2010).;;Lee et al., “MicroRNA expression and clinical outcome of small cell lung cancer”, PLoS On3e 6(6) e21300 (2011).;;Li et al., “Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing”, Nat Med 14(50 579-584 (2008).;;Liu et al., “Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function”, J Immunol 1767(3) 1375-1385 (2006).;;Liu et al., “Reconstitution, activities, and structure of the eukaryotic RNA exosome”, Cell 127(6) 1223-1237 (2006).;;Lo et al., “Automated gating of flow cytometry data via robust model-based clustering”, Cytometry 73(4) 321-332 (2008).;;Lo et al., “Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection”, Nat Med 13(2) 218-223 (2007).;;Lo et al., “Prenatal diagnosis: progress through plasma nucleic acids”, Nat Rev Genet 8(1) 71-77 (2007).;;Lower et al., “The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences”, Proc Natl Acad Sci USA 93(11) 5177-5184 (1996).;;Mack et al., “Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection”, Nat Med 6(7) 769-775 (2000).;;Maheswaran et al., “Detection of mutations in EGFR in circulating lung-cancer cells”, N Engl J Med 359(4) 366-377 (2008).;;Mallardo et al., “Isolation and characterization of Staufen-containing ribonucleoprotein particles from rat brain”, Proc Natl Acad Sci USA 100(4) 2100-2105 (2003).;;Maron et al., “Gene expression analysis in pregnant women and their infants identifies unique fetal biomarkers that circulate in maternal blood”, J Clin Invest 117(10) 3007-3019 (2007).;;Miele et al., “Autocatalytic replication of a recombinant RNA”, J Mol Biol 171(3) 281-295 (1983).;;Millimaggi et al., “Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells”, Neoplasia 9(4) 349-357 (2007).;;Miranda et al., “Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease”, Kidney Int 78(2) 191-199 (2010).;;Mitchell et al., “Can urinary exosomes act as treatment response markers in prostate cancer?”, J Transl Med 7:4 (2009).;;Myers et al., “Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes”, Science 230(4731) 1242-1246 (1985).;;Nagrath et al., “Isolation of rare circulating tumour cells in cancer patients by microchip technology”, Nature 450 (7173) 1235-1239 (2007).;;Nakanishi et al., “PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance”, J Urol 179(5) 1804-1809 (2008).;;Nakazawa et al., “UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement”, Proc Natl Acad Sci USA 91 (1) 360-364 (1994).;;Ng et al., “mRNA of placental origin is readily detectable in maternal plasma”, Proc Natl Acad Sci USA 100(8) 4748-4753 (2003).;;Ng et al., “The concentration of circulating corticotropin-releasing hormone mRNA in maternal plasma is increased in preeclampsia”, Clin Chem 49(5) 727-731 (2003).;;Nilsson et al., “Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer”, Br J Cancer 100(10) 1603-1607 (2009).;;Nishikawa et al., Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma, Brain Tumor Pathol 21(2) 53-56 (2004).;;Noerholm et al., “RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls”, BMC Cancer 12: 22 (2012).;;Novakova et al., “MicroRNA involvement in glioblastoma pathogenesis”, Biochem Biophys Res Commun 386(1) 1-5 (2009).;;Oliveira et al., “Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status”, Hum Mol Genet 13(19) 2303-2311 (2004).;;Orita et al., “Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms”, Proc Natl Acad Sci USA 86*8) 3766-3770 (1989).;;Ostrowski et al., “Rab27a and Rab27b control different steps of the exosome secretion pathway”, Nat Cell Biol 12 (K1) 19-30 sup pp. 1-13 (2010).;;Parsons et al., “An integrated genomic analysis of human glioblastoma multiforme”, Science 321(5897) 1807-1813 (2008).;;Pelloski et al., “Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma”, J Clin Oncol 25(16) 2288-2294 (2007).;;Pisitkun et al., “Discovery of urinary biomarkers”, Mol Cell Proteomics 5(10) 1760-1771 (2006).;;Pleasance et al., “A comprehensive catalogue of somatic mutations from a human cancer genome”, Nature 463 (7278) 191-196 (2010).;;Rak et al., “Genetic determinants of cancer coagulopathy, angiogenesis and disease progression”, Vnitr Lek 52(Suppl 1) 135-138 (2006).;;Raposo et al., “B lymphocytes secrete antigen-presenting vesicles”, J Exp Med 183(3) 1161-1173 (1996).;;Ratajczak et al., “Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication”, Leukemia 20(9) 1487-1495 (2006).;;Revenfeld et al., “Diagnostic and prognostic potential of extracellular vesicles in peripheral blood”, Clin Ther 36(6) 830-846 (2014).;;Roman-Gomez et al., “Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia”, Leuk Res 32(3) 487-490 (2008).;;Ruprecht et al., “Endogenous retroviruses and cancer”, Cell Mol Life Sci 65(21) 3366-3382 (2008).;;Ryan et al,. “A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up”, Gut 52(1) 101-108 (2003).;;Saal et al., “MicroRNAs and the kidney: coming of age”, Curr Opin Nephrol Hypertens 18(4) 317-323 (2009).;;Sarbassov et al., “Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB”, Mol Cell 22(2) 159-168 (2006).;;Schetter et al., “MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma”, JAMA 299(4) 425-436 (2008).;;Shinojima et al., “Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme”, Cancer Res 63(20) 6962-6970 (2003).;;Silva et al., “Selective gene silencing by viral delivery of short hairpin RNA”, Virol J 7: 248 (2010).;;Simons et al., “Exosomes—vesicular carriers for intercellular communication”, Curr Opin Cell Biol 21(4) 575-581 (2009).;;Skog et al., “Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers”, Nat Cell Biol 10(12) 1470-1476 (2008).;;Srikantan et al., “PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer”, Proc Natl Acad Sci USA 97(22) 12216-12221 (2000).;;Steemers et al., “Whole-genome genotyping with the single-base extension assay”, Nat Methods 3(1) 31-33 (2006).;;Stoorvogel et al., “The biogenesis and functions of exosomes”, Traffic 3(5) 321-330 (2002).;;Forbes et al., “COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer”, Nuclec Acids Res 39(Database issue) D945-D950 (2011).;;Forbes et al., “The Catalogue of Somatic Mutations in Cancer (COSMIC)”, Supplement 57:10.11.1-10.11.26 (2008).;;Furnari et al., “Malignant astrocytic glioma: genetics, biology, and paths to treatment”, Genes Dev 21(21) 2683-2710 (2007).;;Gambim et al., “Platelet-derived exosomes induce endothelial cell apoptosis through peroxynitrite generation: experimental evidence for a novel mechanism of septic vascular dysfunction”, Crit Care 11(5) R107 (2007).;;Geiss et al., “Direct multiplexed measurement of gene expression with color-coded probe pairs”, Nat Biotechnol 26(3) 317-325 (2008).;;GenBank (Accession NM_005896) submitted Jan. 31, 2003.;;Gene Annot, “Probes for MYC availible on Affymetrix arrays HG-U95, HG-U133, HG-U133 Plus 2.0”, Weizmann Institue of Science found at URL http://genecards.weizmann.ac.il/cgi-bin/geneannot/ga_search.pl (Apr. 20, 2001, retrieved from the Internet on May 21, 2003).;;Ginestra et al., “The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness”, Anticancer 18(5A) 3433-3437 (1998).;;Golan et al., “Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic marker”, Neoplasia 10(6) 521-533 (2008).;;Gonzales et al., “Urinary exosomes: is there a future?”, Nephrol Dial Transplant 23(6) 1799-1801 (2008).;;Goodier et al., “Retrotransposons revisited: the restraint and rehabilitation of parasites”, Cell 135(1) 23-35 (2008).;;Gormally et al., “Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance”, Mutat Res 635(2-3) 10-117 (2007).;;Greco et al., “Argosomes: a potential vehicle for the spread of morphogens through epithelia”, Cell 106(5) 633-645 (2001).;;Green et al., “The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status”, Blood 116(15) 277-2782 (2010).;;Groskopf et al., “Aptima PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer”, Clin Chem 52(6) 1089-1095 (2006).;;Guatelli et al., “Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication”, Proc Natl Acad Sci USA 87(19) 7797 (1990).;;Guescini et al., “Astrocytes and Glioblastoma cells release exosomes carrying mtDNA”, J Neural Transm (Vienna) 117(1) 1-4 (2010).;;Hahn, “Molecular biology of double-minute chromosomes”, Bioessays 15(7) 477-484 (1993).;;Hanahan et al., “The hallmarks of cancer”, Cell 100(1) 57-70 (2000).;;Hartman et al., “Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas”, Acta Neuropathol 120(6) 707-718 (2010).;;Heimberger et al., “The natural history of EGFR and EGFRvIII in glioblastoma patients”, J Transl Med 3: 38 (2005).;;Hessels et al., “DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer”, Eur Urol 44(1) 8-15 (2003).;;Hessels et al., “Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer”, Clin Cancer Res 13(17) 5103-5108 (2007).;;Hildebrant et al., “Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy”, J Clin Oncol 27(6) 857-871 (2009).;;Holdhoff et al., Analysis of circulating tumor DNA to confirm somatic KRAS mutations, J Natl Cancer Inst 101(18) 1284-1285 (2009).;;Hunter et al., “Detection of microRNA expression in human peripheral blood microvesicles”, PLoS One 3(11) e3694 (2008).;;Iero et al., “Tumour-released exosomes and their implications in cancer immunity”, Cell Death Differ 15(1) 80/88 (2008).;;Iorio et al., “MicroRNA signatures in human ovarian cancer”, Cancer Res 67(18) 8699-8707 (2007).;;Itadani et al., “Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation”, Curr Genomics 9(5) 349-360 (2008).;;Janowska-Wieczorek et al., “Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer”, Int J Cancer 113(5) 752-760 (2005).;;Ji et al., “MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer”, Oncogene 22(39) 8031-8041 (2003).;;Johnson et al., “Surface-immobilized peptide aptamers as probe molecules for protein detection”, Anal Chem 80(4) 978-983 (2008).;;Jones et al., “Core signaling pathways in human pancreatic cancers revealed by global genomic analyses”, Science 321(5897) 1801-1806 (2008).;;Kan et al., “Antenatal diagnosis of sickle-cell anaemia by D.N.A. analysis of amniotic-fluid cells”, Lancet 2(8096) 910-912 (1978).;;Kan et al., “Polymorphism of DNA sequence adjacent to human beta-globin structural gene: relationship to sickle mutation”, Proc Natl Acad Sci 75(11) 5631-5635 (1978).;;Kang et al., “Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers”, Int J Cancer 125 (2) 353-355 (2009).;;Kato et al., “A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation”, Biochem Biophys Res Commun 390(3) 547-551 (2009).;;Katoh et al., “Association of endogenous retroviruses and long terminal repeats with human disorders”, Front Oncol 3:234 (2013).;;Keller et al., “CD24 is a marker of exosomes secreted into urine and amniotic fluid”, Kidney Int 72(9) 1095-1102 (2007).;;Kislauski et al., “Sequences responsible for intracellular localization of beta-actin messenger RNA also affect cell phenotype”, J Cell Biol 127(2) 441-451 (1994).;;Kleiman et al., “HERV-K(HML-2) GAG/ENV antibodies as indicator for therapy effect in patients with germ cell tumors”, Int J Cancer 110(3) 459-461 (2004).;;Klein et al., “Combined transcriptome and genome analysis of single micrometastatic cells”, Nat Biotechnol 20(4) 387-392 (2002).;;Klemke et al., “Regulation of cell motility by mitogen-activated protein kinase”, J Cell Biol 137(2) 481-492 (1997).;;Koga et al., “Purification, characterization and biological significance of tumor-derived exosomes”, Anticancer Res 25 (6A) 3703-3707 (2005).;;Kosaka et al., “Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis”, Cancer Sci 101 (10) 2087-2092 (2010).;;Kristensen et al., “PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment”, Clin Chem 55(8) 1471-1483 (2009).;;Krupp, “Stringent RNA quality control using Agilent 2100 bioanalyzer”, Applicant note, Agilent. (2005).;;Kwoh et al., “Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format”, Proc Natl Acad Sci USA 86(4) 1173-1177 (1989).;;Landegren et al., “A ligase-mediated gene detection technique”, Science 241(4869) 1077-1080 (1988).;;Laxman et al., “A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer”, Cancer Res 68(3) 645-649 (2008).;;Halatsch et al. “Epidermal growth factor receptor inhibition for the treatment of the glioblastoma multiforme and other malignant brain tumors.” Cancer Treatment Reviews, 32: 74-89, (2006).;;Schalken “Validation of molecular targets in prostate cancer.” BJU International, 96: 23-29 (2005).;;Smalheiser. “Exosomal transfer of proteins and RNAs at synapses in the nervous system.” Biology Direct 2(1): 1-15 (2007).;;Tam et al., “The emergent role of microRNAs in molecular diagnostics of cancer”, J Mol Diagn 10(5) 411-414 (2008).;;Taylor et al., “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer”, Gynecol Oncol 110(1) 13-21 (2008).;;Taylor et al., “Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects”, Br J Cancer 92(2) 305-311 (2005).;;Tewes et al., “Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies”, Breast Cancer Res Treat 115(3) 581-590 (2009).;;Thery et al., “Exosomes: composition, biogenesis and function”, Nat Rev Immunol 2(8) 569-579 (2002).;;Thery et al., “Isolation and characterization of exosomes from cell culture supernatants and biological fluids”, Curr Protoc Cell Biol Chp3(Unit 3.22) (2006).;;Ting et al., “Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers”, Science 331 (6017) 593-596 (2011).;;Tomlins et al., “Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer”, Science 310 (5748) 644-648 (2005).;;Valadi et al., “Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells”, Nat Cell Biol 9(6) 654-659 (2007).;;Van Dijk et al., “Human cell growth requires a functional cytoplasmic exosome, which is involved in various mRNA decay pathways”, RNA 13(7) 1027-1035 (2007).;;Velculescu et al., “Serial analysis of gene expression”, Science 270(5235) 484-487 (1995).;;Voisset et al., “Human RNA “rumor” viruses: the search for novel human retroviruses in chronic disease”, Microbiol Mol Biol Rev 72(1) 157-196 (2008).;;Wang-Johanning et al., “Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients”, Cancer Res 68(14) 5869-5877 (2008).;;Went et al., “Frequent EpCam protein expression in human carcinomas”, Hum Pathol 35(1) 122-128 (2004).;;Wieckowski et al.,. “Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles”, Immunol Res 36(1-3) 247-254 (2006).;;Wong et al., “Circulating placental RNA in maternal plasma is associated with a preponderance of 5′ mRNA fragments: implications for noninvasive prenatal diagnosis and monitoring”, Clin Chem 51 (10) 1786-1795 (2005).;;Wood et al., “The genomic landscapes of human breast and colorectal cancers”, Science 318(5853) 1108-1113 (2007).;;Wright et al., “Newer potential biomarkers in prostate cancer”, Rev Urol 9(4) 207-213 (2007).;;Yan et al., “IDH1 and IDH2 mutations in gliomas”, N Engl J Med 360(8) 765-773 (2009).;;Yoshimoto et al., “Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples”, Clin Cancer Res 14(2) 488-493 (2008).;;Yu et al., “Oncogenic events regulating tissue factor expression”, Hematology Meeting Reports 1(9) 18-20 (2005).;;Yuan et al., “Transfer of microRNAs by embryonic stem cell microvesicles”, PLoS One 4(3) e4772 (2009).;;Bess et al., “Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations.” Virology 230(1):134-144 (1997).;;Biernat et al., “Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas”, Brain Pathol 14(2) 131-136 (2004).;;Chabert et al., “Cell culture of tumors alters endogenous poly(ADPR)polymerase expression and activity”, Int J Cancer 53(5) 837-842 (1993).;;Choi et al., “Proteomic analysis of microvesicles derived from human colorectal cancer ascites.”, Proteomic 11(13) 2745-2751 (2011).;;Cooperberg et al., “The changing face of low-risk prostate cancer: trends in clinical presentation and primary management”, J Clin Oncol 22(11) 2141-9 (2004).;;Dermer “Another anniversary for the war on cancer.” Nature Biotechnology 12(3):320 (1994).;;Diehl et al., “Detection and quantification of mutations in the plasma of patients with colorectal tumors.” PNAS 102 (45) 16268-16373 (2005).;;Eastham et al., “Relationship between clonogenic cell survival, DNA damage and chromosomal radiosensitivity in nine human cervix carcinoma cell lines” Int. Journal Radiat. Biol 77(3) 295-302 (2001).;;Grant et al., “The proteins of normal urine.” Journal of Clinical Pathology 10(4):360-367 (1957).;;Huang et al. “Optimization of DNase I Removal of Contaminating DNA from RNA for Use in Quantitative RNA-PCR.” Biotechniques 20(6): 1012-1020 (1996).;;Johnstone. “Exosomes biological significance: A concise review.” Blood Cells, Molecules, and Diseases 36(2): 315-321 (2006).;;Keller et al., “Exosomes: from biogenesis and secretion to biological function”, Immunol Lett 107(2) 102-8 (2006).;;Lotvall at al. “Cell to Cell Signalling via Exosomes Through esRNA.” Cell Adhesion & Migration 1(3): 156-158 (2007).;;May “How Many Species are there on Earth?”, Science 241(1) 1441-1449 (1998).;;Moderk et al., “Genome-wide detection of alternatives splicing in expressed sequences of human genes”, Nucleic Acids Research 29(13) 2850-2859 (2001).;;Perkel. “Finding Points to Possible Blood Test for Brain Tumors.” HealthDay News [retrieved Apr. 18, 2019] https://www.medicinenet.com/script/main/art.asp?articlekey=94287 1-3 (2008).;;Ruprecht et al., “Human endogenous retrovirus family HERV-K(HML-2) RNA transcripts are selectively packaged into retroviral particles produced by the human germ cell tumor line Tera-1 and originate mainly from a provirus on chromosome 22q11.21” J Virol 82(20) 10008-10016 (2008).;;Saito-Hisaminto et al., “Genome-Wide Profiling of Gene Expression in 29 Normal Human Tissues with cDNA Microarray”, DNA Research 9 35-45 (2002).;;Singh et al., “Gene Expression correlates of clinical prostate cancer behavior”, Cancer Cell 1(2) 203-209 (2002).;;The International SNP Map Working Group., “A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms” NATURE 409 928-933 (2001).;;Tullis et al., “Calcium protects DNase I from proteinase K: a new method for the removal of contaminating RNase from DNase I.” Analytical Biochemistry 107(1):260-264 (1980).;;Yu et al., “Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells”, J Throm Haemost 2(11) 2065-2067 (2004).;;Thery et al. “Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids” Curr Protoc Cell Biol Chapter 3 Unit 3.22 1-29 (2006).;;Moscatello et al., “Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors”, Cancer Res 55(23) 5536-5539 (1995).;;Schmidt et al., “Quantitative multi-gene expression profiling of primary prostate cancer”, Prostate 66(14) 1521-34 (2006).;;Mellinghoff et al., “Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors”, N Engl J Med 353(19) 2012-2024 (2005).",ACTIVE
22,EP,B1,EP 2744508 B1,072-916-197-791-717,2017-11-08,2017,EP 12826108 A,2012-08-17,US 201161525278 P;;US 2012/0051412 W,2011-08-19,VEGF-BINDING PROTEIN FOR BLOCKADE OF ANGIOGENESIS,,CHILDREN'S MEDICAL CENTER CORP;;HARVARD COLLEGE;;MASSACHUSETTS GEN HOSPITAL,CARTER BOB;;LEE JENG-SHIN;;BULLAIN SZOFIA S;;MULLIGAN RICHARD C,,https://lens.org/072-916-197-791-717,Granted Patent,yes,3,0,12,12,0,A61K38/00;;C07K14/475;;C07K2319/30;;A61P35/00;;A61K38/00;;C07K14/475;;C07K2319/30;;A61K48/00;;C12N15/11;;A61K39/001109;;C07K2317/24;;C12N15/1136;;A61K35/42;;C07K14/71,A61K38/18;;A61K39/395;;A61P35/00;;C07K14/515,,3,0,,,"HOLASH JOCELYN ET AL: ""VEGF-Trap: A VEGF blocker with potent antitumor effects"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 99, no. 17, 20 August 2002 (2002-08-20), pages 11393-11398, XP002300698, ISSN: 0027-8424, DOI: 10.1073/PNAS.172398299;;BETTY Y Y TAM ET AL: ""VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis"", NATURE MEDICINE, vol. 12, no. 7, 25 June 2006 (2006-06-25), pages 793-800, XP055188501, ISSN: 1078-8956, DOI: 10.1038/nm1428;;F. BAFFERT: ""Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling"", AJP: HEART AND CIRCULATORY PHYSIOLOGY, vol. 290, no. 2, 7 October 2005 (2005-10-07), pages H547-H559, XP055188503, ISSN: 0363-6135, DOI: 10.1152/ajpheart.00616.2005",ACTIVE
23,EP,A4,EP 2475988 A4,115-229-984-341-575,2013-03-06,2013,EP 10816090 A,2010-09-09,US 24101409 P;;US 2010/0048293 W,2009-09-09,USE OF MICROVESICLES IN ANALYZING NUCLEIC ACID PROFILES,,GEN HOSPITAL CORP,NOERHOLM MIKKEL;;SKOG JOHAN KARL OLOV;;BREAKEFIELD XANDRA O;;CARTER BOB,,https://lens.org/115-229-984-341-575,Search Report,no,4,0,11,11,0,G01N33/57407;;C12Q1/6806;;C12Q2600/158;;C12Q1/6886;;C12Q2600/158;;C12Q1/6806;;G01N33/57407;;C12Q1/6886,C12Q1/68;;G01N33/48,,6,5,003-870-745-672-716;;137-253-096-323-115;;081-312-966-056-426;;094-463-059-022-302;;017-559-987-535-067,19011622;;pmc3423894;;10.1038/ncb1800;;10.1016/j.ygyno.2008.04.033;;18589210;;pmc2696767;;10.1038/sj.bjc.6605058;;19401683;;10.1038/ki.2010.106;;pmc4451567;;20428099;;10.1186/1471-2407-12-22;;pmc3329625;;22251860,"SKOG JOHAN ET AL: ""Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers"", NATURE CELL BIOLOGY, MACMILLAN MAGAZINES LTD, vol. 10, no. 12, 1 December 2008 (2008-12-01), pages 1470 - 1476, XP002526160, ISSN: 1465-7392, [retrieved on 20081116], DOI: 10.1038/NCB1800;;TAYLOR D D ET AL: ""MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer"", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 110, no. 1, 1 July 2008 (2008-07-01), pages 13 - 21, XP022795052, ISSN: 0090-8258, [retrieved on 20080625], DOI: 10.1016/J.YGYNO.2008.04.033;;NILSSON J ET AL: ""Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer"", BRITISH JOURNAL OF CANCER, HARCOURT PUBLISHERS, vol. 100, no. 10, 1 May 2009 (2009-05-01), pages 1603 - 1607, XP008149487, ISSN: 0007-0920, [retrieved on 20090428], DOI: 10.1038/SJ.BJC.6605058;;MIRANDA K C ET AL: ""Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease"", KIDNEY INTERNATIONAL, NATURE PUBLISHING GROUP, NEW YORK, vol. 78, no. 2, 1 July 2010 (2010-07-01), pages 191 - 199, XP002686137, ISSN: 1523-1755, [retrieved on 20100428], DOI: 10.1038/KI.2010.106;;MIKKEL NOERHOLM ET AL: ""RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls"", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 17 January 2012 (2012-01-17), pages 22, XP021118100, ISSN: 1471-2407, DOI: 10.1186/1471-2407-12-22;;See also references of WO 2011031877A1",ACTIVE
24,US,A1,US 2018/0127483 A1,100-273-756-251-977,2018-05-10,2018,US 201715619917 A,2017-06-12,US 201715619917 A;;US 201414239687 A;;US 2012/0051412 W;;US 201161525278 P,2011-08-19,VEGF-BINDING PROTEIN FOR BLOCKADE OF ANGIOGENESIS,"Provided are chimeric VEGF-binding proteins and nucleic acids (e.g., a vector) encoding chimeric VEGF-binding proteins, methods and host cells for producing these proteins and nucleic acids, and pharmaceutical compositions containing these proteins and nucleic acids. Also provided are methods of treating an angiogenic disease or disorder that include administering at least one of the chimeric VEGF-binding proteins or at least one of the nucleic acids (e.g., a vector) encoding a chimeric VEGF-binding protein.",CHILDRENS MEDICAL CENTER;;MASSACHUSETTS GEN HOSPITAL;;HARVARD COLLEGE,CARTER BOB;;LEE JENG-SHIN;;BULLAIN SZOFIA S;;MULLIGAN RICHARD C,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2014-02-15);;CHILDREN'S MEDICAL CENTER CORPORATION (2014-03-17);;THE GENERAL HOSPITAL CORPORATION (2014-03-25),https://lens.org/100-273-756-251-977,Patent Application,yes,0,0,12,12,8,A61K38/00;;C07K14/475;;C07K2319/30;;A61P35/00;;A61K38/00;;C07K14/475;;C07K2319/30;;A61K48/00;;C12N15/11;;A61K39/001109;;C07K2317/24;;C12N15/1136;;A61K35/42;;C07K14/71,C07K14/71;;C07K14/475,,0,0,,,,ACTIVE
25,EP,B1,EP 2475988 B1,021-631-743-684-857,2018-11-14,2018,EP 10816090 A,2010-09-09,US 24101409 P;;US 2010/0048293 W,2009-09-09,USE OF MICROVESICLES IN ANALYZING NUCLEIC ACID PROFILES,,MASSACHUSETTS GEN HOSPITAL,NOERHOLM MIKKEL;;SKOG JOHAN KARL OLOV;;BREAKEFIELD XANDRA O;;CARTER BOB,,https://lens.org/021-631-743-684-857,Granted Patent,yes,8,0,11,11,0,G01N33/57407;;C12Q1/6806;;C12Q2600/158;;C12Q1/6886;;C12Q2600/158;;C12Q1/6806;;G01N33/57407;;C12Q1/6886,C12Q1/6886;;C12Q1/6806;;C12Q1/6809,,5,0,,,"SKOG JOHAN ET AL: ""Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers"", NATURE CELL BIOLOGY, MACMILLAN MAGAZINES LTD, vol. 10, no. 12, 1 December 2008 (2008-12-01), pages 1470-1476, XP002526160, ISSN: 1465-7392, DOI: 10.1038/NCB1800 [retrieved on 2008-11-16];;TAYLOR D D ET AL: ""MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer"", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 110, no. 1, 1 July 2008 (2008-07-01), pages 13-21, XP022795052, ISSN: 0090-8258, DOI: 10.1016/J.YGYNO.2008.04.033 [retrieved on 2008-06-25];;NILSSON J ET AL: ""Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer"", BRITISH JOURNAL OF CANCER, HARCOURT PUBLISHERS, vol. 100, no. 10, 1 May 2009 (2009-05-01), pages 1603-1607, XP008149487, ISSN: 0007-0920, DOI: 10.1038/SJ.BJC.6605058 [retrieved on 2009-04-28];;MIRANDA K C ET AL: ""Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease"", KIDNEY INTERNATIONAL, NATURE PUBLISHING GROUP, NEW YORK, vol. 78, no. 2, 1 July 2010 (2010-07-01), pages 191-199, XP002686137, ISSN: 1523-1755, DOI: 10.1038/KI.2010.106 [retrieved on 2010-04-28];;MIKKEL NOERHOLM ET AL: ""RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls"", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 17 January 2012 (2012-01-17), page 22, XP021118100, ISSN: 1471-2407, DOI: 10.1186/1471-2407-12-22",ACTIVE
26,DK,T3,DK 2744508 T3,020-749-203-656-182,2018-02-19,2018,DK 12826108 T,2012-08-17,US 201161525278 P;;US 2012/0051412 W,2011-08-19,VEGF-BINDENDE PROTEIN TIL BLOKERING AF ANGIOGENESE,,HARVARD COLLEGE;;MASSACHUSETTS GEN HOSPITAL;;CHILDRENS MEDICAL CT CORP,CARTER BOB;;LEE JENG SHIN;;BULLAIN SZOFIA S;;MULLIGAN RICHARD C,,https://lens.org/020-749-203-656-182,Granted Patent,no,0,0,12,12,0,A61K38/00;;C07K14/475;;C07K2319/30;;A61P35/00;;A61K38/00;;C07K14/475;;C07K2319/30;;A61K48/00;;C12N15/11;;A61K39/001109;;C07K2317/24;;C12N15/1136;;A61K35/42;;C07K14/71,A61K38/18;;A61K39/395;;A61P35/00;;C07K14/515,,0,0,,,,ACTIVE
27,WO,A1,WO 2013/028541 A1,034-783-449-132-597,2013-02-28,2013,US 2012/0051412 W,2012-08-17,US 201161525278 P,2011-08-19,VEGF-BINDING PROTEIN FOR BLOCKADE OF ANGIOGENESIS,"Provided are chimeric VEGF-binding proteins and nucleic acids (e.g., a vector) encoding chimeric VEGF-binding proteins, methods and host cells for producing these proteins and nucleic acids, and pharmaceutical compositions containing these proteins and nucleic acids. Also provided are methods of treating an angiogenic disease or disorder that include administering at least one of the chimeric VEGF-binding proteins or at least one of the nucleic acids (e.g., a vector) encoding a chimeric VEGF-binding protein.",CHILDRENS MEDICAL CENTER;;HARVARD COLLEGE;;GEN HOSPITAL CORP;;CARTER BOB;;LEE JENG-SHIN;;BULLAIN SZOFIA S;;MULLIGAN RICHARD C,CARTER BOB;;LEE JENG-SHIN;;BULLAIN SZOFIA S;;MULLIGAN RICHARD C,,https://lens.org/034-783-449-132-597,Patent Application,yes,10,2,12,12,8,A61K38/00;;C07K14/475;;C07K2319/30;;A61P35/00;;A61K38/00;;C07K14/475;;C07K2319/30;;A61K48/00;;C12N15/11;;A61K39/001109;;C07K2317/24;;C12N15/1136;;A61K35/42;;C07K14/71,A61K38/18;;A61K39/395;;A61P35/00;;C07K14/515,,52,40,008-498-336-394-659;;085-051-035-249-265;;085-051-035-249-265;;020-413-940-276-383;;022-843-989-846-490;;045-708-790-881-865;;048-807-766-092-463;;039-889-533-551-521;;013-094-728-517-718;;101-124-508-168-864;;025-007-303-045-409;;071-184-126-713-765;;007-162-670-158-912;;093-923-341-079-116;;044-135-659-393-274;;073-614-865-710-154;;127-861-233-397-521;;042-838-870-694-53X;;076-649-834-185-907;;025-352-695-711-710;;055-746-983-524-055;;129-244-884-577-63X;;002-326-446-448-604;;053-453-087-648-015;;022-126-576-934-730;;020-714-847-964-914;;047-244-419-712-119;;109-974-585-608-837;;039-802-943-466-050;;006-653-525-137-912;;018-351-311-634-843;;052-058-533-253-034;;031-362-546-580-039;;082-984-043-695-164;;008-498-336-394-659;;085-528-415-223-353;;090-460-004-972-58X;;046-566-185-640-006;;079-725-496-815-734;;060-957-594-177-919,12177445;;10.1073/pnas.172398299;;pmc123267;;10.1002/j.1460-2075.1996.tb00872.x;;pmc452229;;8890165;;10.1002/j.1460-2075.1996.tb00872.x;;pmc452229;;8890165;;9099677;;10.1074/jbc.272.16.10382;;10.1006/bbrc.1997.6156;;9070853;;9393862;;10.1016/s0092-8674(00)80456-0;;2536900;;10.1038/337525a0;;1827828;;10.1084/jem.173.6.1483;;pmc2190830;;10.1016/s0021-9258(18)47298-5;;7929268;;10.1385/1-59259-679-7:191;;14959830;;9482916;;pmc19394;;10.1073/pnas.95.5.2509;;8788172;;10.1089/hum.1996.7.2-215;;10688913;;pmc16256;;10.1073/pnas.050581197;;10.1073/pnas.97.7.3428;;10.1128/jvi.77.12.7034-7040.2003;;pmc156185;;12768022;;10.1073/pnas.91.6.2076;;pmc43312;;8134351;;10.1097/00001756-200107030-00037;;11435930;;11177544;;10.1089/104303401450988;;9445046;;10.1128/jvi.72.2.1438-1445.1998;;pmc124624;;10.1038/8470;;10229239;;10.1126/science.3055301;;3055301;;16373573;;10.1126/science.1119776;;10500044;;10.1161/01.cir.100.13.1423;;10.1023/a:1012218401036;;11806243;;10.1136/ard.59.suppl_1.i65;;pmc1766630;;11053092;;16821113;;10.1007/s10456-006-9030-4;;pmc1850001;;10.1016/s0002-9440(10)65280-7;;10027392;;10.1161/01.res.0000132745.76882.70;;15155527;;10.1093/humupd/4.5.736;;10027628;;pmc112106;;10846091;;10.1128/jvi.74.13.6077-6086.2000;;10830716;;10.1038/sj.cgt.7700156;;10.1038/sj.gt.3300965;;10467368;;10.1002/3527607536;;10.1002/9783527612833;;6201207;;10.1002/bip.360220167;;12177445;;10.1073/pnas.172398299;;pmc123267;;10.1073/pnas.081615298;;11274374;;pmc31881;;15175435;;10.1056/nejmoa032691;;14965381;;10.1089/10430340460732490;;11606410;;10.1158/0008-5472.can-04-1833;;15867360,"HOLASH J. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 99, 2002, pages 11393 - 11398;;DAVIS-SMYTH T., EMBO, vol. 15, 1996, pages 4919 - 4927;;DAVIS-SMYTH T., J EMBO, vol. 15, 1996, pages 4919 - 4927;;BARLEON, J. BIOL. CHEM., vol. 272, 1997, pages 10382 - 10388;;CUNNINGHAM, BIOCHEM. BIOPHYS. RES. COMM., vol. 231, 1997, pages 596 - 599;;WIESMANN C., CELL, vol. 91, 1997, pages 695 - 704;;CAPON, NATURE, vol. 337, 1989, pages 525 - 531;;ANGAL S. ET AL., MOL. IMMUNO., vol. 130, 1993, pages 105 - 108;;CANFIELD; MORRISON, J EXP MED., vol. 173, no. 6, 1 June 1991 (1991-06-01), pages 1483 - 1491;;PARK, J. BIOL. CHEM., vol. 269, 1994, pages 25646 - 25654;;MANIATIS ET AL.: ""Molecular Cloning - A Laboratory Manual"", 1982, COLD SPRING HARBOR;;""DNA Cloning"", vol. I, II, I, IRL PRESS LTD.;;SAMBROOK ET AL.: ""Molecular Cloning, A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;FRED M. AUSUBEL ET AL.: ""Current Protocols in Molecular Biology (CPMB"", JOHN WILEY AND SONS, INC.;;JOHN E. COLIGAN, ET AL: ""Current Protocols in Protein Science (CPPS"", JOHN WILEY AND SONS, INC.;;GRIESBECK C., MOL. BIOTECHNOL., vol. 34, 2006, pages 213 - 233;;FUHRMANN M., METHODS MOL MED., vol. 94, 2004, pages 191 - 195;;HE TC., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 2509 - 2514;;HUMAN GENE THERAPY, vol. 7, 1996, pages 215 - 222;;DAVIDSON ET AL., PNAS, vol. 97, no. 7, 2000, pages 3428 - 3432;;PASSINI ET AL., J. VIROL, vol. 77, no. 12, 2003, pages 7034 - 7040;;BOBO ET AL., PNAS, vol. 91, no. 6, 1994, pages 2076 - 2080;;NGUYEN ET AL., NEUROREPORT, vol. 12, no. 9, 2001, pages 1961 - 1964;;AURICCHIO, A., HUMAN GENE THERAPY, vol. 12, 2001, pages 71 - 76;;SUMMERFORD, C.; R. SAMULSKI, J. VIROL., vol. 72, 1998, pages 1438 - 1445;;SUMMERFORD, C.; R. SAMULSKI, NAT. MED., vol. 5, 1999, pages 587 - 588;;SPIRIN AS., SCIENCE, vol. 242, 1988, pages 1162;;CHANG G., SCIENCE, vol. 310, 2005, pages 1950 - 1953;;IRUELA-ARISPE ET AL., CIRCULATION, vol. 100, 1999, pages 1423 - 1431;;DONOVAN ET AL., ANGIOGENESIS, vol. 4, 2001, pages 113 - 121;;PALEOLOG, E. M., ARTHRITIS RES., vol. 4, no. 3, 2002, pages S81 - S90;;KOCH, A. E., ANN. RHEUM. DIS., vol. 59, no. I, 2000, pages I65 - I71;;SCHULTHEISS C., ANGIOGENESIS, vol. 9, no. 2, 2006, pages 59 - 65;;GRAMMAS P., AM. J. PATH., vol. 154, no. 2, 1999, pages 337 - 342;;EBBA BRAKENHIELM, CIRCULATION RESEARCH, vol. 94, 2004, pages 1579;;HEALY, DL., HUMAN REPRODUCTION UPDATE, vol. 4, 1998, pages 736 - 740;;""HARRY'S COSMETICOLOGY"", 1982, CHEMICAL PUBLISHING;;""REMINGTON'S PHARMACEUTICAL SCIENCES. 18th ed."", 1990, MACK PUBLISHING CO.;;LOEHR B. I., J. VIROL., vol. 74, 2000, pages 6077 - 6086;;ZOU Y., CANCER GENE THER., vol. 7, no. 5, May 2000 (2000-05-01), pages 683 - 696;;ZHANG Y. P., GENE THER., vol. 6, 1999, pages 1438 - 1447;;MARTIN SCHLEEF: ""DNA-Pharmaceuticals: Formulation and Delivery in Gene Therapy, DNA Vaccination and Immunotherapy"", December 2005, WILEY PUBLISHER;;""Plasmids for Therapy and Vaccination"", May 2001;;U. SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547;;R. LANGER ET AL., CHEM. TECH., vol. 12, 1982, pages 98;;HOLASH, J.; DAVIS, S.; PAPADOPOULOS, N.; CROLL, S. D.; HO, L.; RUSSELL, M.; BOLAND, P.; LEIDICH, R.; HYLTON, D.; BUROVA, E.: ""VEGF-Trap: a VEGF blocker with potent antitumor effects"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, 2002, pages 11393 - 11398, XP002611390, DOI: doi:10.1073/pnas.172398299;;KUO, C. J.; FARNEBO, F.; YU, E. Y.; CHRISTOFFERSON, R.; SWEARINGEN, R. A.; CARTER, R.; VON RECUM, H. A.; YUAN, J.; KAMIHARA, J.; F: ""Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, 2001, pages 4605 - 4610, XP002205625, DOI: doi:10.1073/pnas.081615298;;HURWITZ, H.; FEHRENBACHER, L.; NOVOTNY, W.; CARTWRIGHT, T.; HAINSWORTH, J.; HEIM, W.; BERLIN, J.; BARON, A.; GRIFFING, S.; HOLMGRE: ""Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer"", NEW ENGLAND JOURNAL OF MEDICINE, vol. 350, 2004, pages 2335 - 2342, XP002302382;;FLOTTE, T. R.; BRANTLY, M. L.; SPENCER, L. T.; BYRNE, B. J.; SPENCER, C. T.; BAKER, D. J.; HUMPHRIES, M.: ""Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults"", HUMAN GENE THERAPY, vol. 15, 2004, pages 93 - 128, XP002517683, DOI: doi:10.1089/10430340460732490;;KISKER, O.; BECKER, C. M.; PROX, D.; FANNON, M.; D'AMATO, R.; FLYNN, E.; FOGLER, W. E.; SIM, B. K.; ALLRED, E. N.; PIRIE-SHEPHERD,: ""Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model"", CANCER RESEARCH, vol. 61, 2001, pages 7669 - 7674;;TJIN THAM SJIN, R. M.; SATCHI-FAINARO, R.; BIRSNER, A. E.; RAMANUJAM, V. M.; FOLKMAN, J.; JAVAHERIAN, K: ""A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity"", CANCER RESEARCH, vol. 65, 2005, pages 3656 - 3663, XP055269465, DOI: doi:10.1158/0008-5472.CAN-04-1833;;See also references of EP 2744508A4",PENDING
28,US,B2,US 9701731 B2,038-781-281-441-56X,2017-07-11,2017,US 201214239687 A,2012-08-17,US 201214239687 A;;US 201161525278 P;;US 2012/0051412 W,2011-08-19,VEGF-binding protein for blockade of angiogenesis,"Provided are chimeric VEGF-binding proteins and nucleic acids (e.g., a vector) encoding chimeric VEGF-binding proteins, methods and host cells for producing these proteins and nucleic acids, and pharmaceutical compositions containing these proteins and nucleic acids. Also provided are methods of treating an angiogenic disease or disorder that include administering at least one of the chimeric VEGF-binding proteins or at least one of the nucleic acids (e.g., a vector) encoding a chimeric VEGF-binding protein.",CARTER BOB;;LEE JENG-SHIN;;BULLAIN SZOFIA S;;MULLIGAN RICHARD C;;CHILDREN'S MEDICAL CENTER CORP;;MASSACHUSETTS GEN HOSPITAL;;HARVARD COLLEGE,CARTER BOB;;LEE JENG-SHIN;;BULLAIN SZOFIA S;;MULLIGAN RICHARD C,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2014-02-15);;CHILDREN'S MEDICAL CENTER CORPORATION (2014-03-17);;THE GENERAL HOSPITAL CORPORATION (2014-03-25),https://lens.org/038-781-281-441-56X,Granted Patent,yes,6,1,12,12,8,A61K38/00;;C07K14/475;;C07K2319/30;;A61P35/00;;A61K38/00;;C07K14/475;;C07K2319/30;;A61K48/00;;C12N15/11;;A61K39/001109;;C07K2317/24;;C12N15/1136;;A61K35/42;;C07K14/71,C12P21/00;;A61K38/00;;C07K14/475;;C07K14/71;;C12N1/21;;C12N15/09,,36,30,059-047-140-038-449;;042-579-115-970-808;;127-861-233-397-521;;015-680-387-839-237;;020-413-940-276-383;;044-135-659-393-274;;047-244-419-712-119;;022-843-989-846-490;;007-162-670-158-912;;085-051-035-249-265;;046-566-185-640-006;;020-714-847-964-914;;109-974-585-608-837;;008-498-336-394-659;;090-460-004-972-58X;;129-244-884-577-63X;;079-725-496-815-734;;053-453-087-648-015;;085-528-415-223-353;;073-614-865-710-154;;140-562-976-790-990;;013-094-728-517-718;;051-389-130-698-194;;022-126-576-934-730;;042-838-870-694-53X;;076-649-834-185-907;;060-957-594-177-919;;045-708-790-881-865;;032-437-527-638-24X;;002-262-303-908-829,10036766;;10.1016/s0168-1656(98)00134-5;;11578098;;10.1211/0022357011776603;;11177544;;10.1089/104303401450988;;10.1158/1535-7163.mct-10-0813;;21252283;;9099677;;10.1074/jbc.272.16.10382;;10.1073/pnas.91.6.2076;;pmc43312;;8134351;;10.1161/01.res.0000132745.76882.70;;15155527;;10.1006/bbrc.1997.6156;;9070853;;10688913;;pmc16256;;10.1073/pnas.050581197;;10.1073/pnas.97.7.3428;;10.1002/j.1460-2075.1996.tb00872.x;;pmc452229;;8890165;;14965381;;10.1089/10430340460732490;;pmc1850001;;10.1016/s0002-9440(10)65280-7;;10027392;;10.1093/humupd/4.5.736;;10027628;;12177445;;10.1073/pnas.172398299;;pmc123267;;15175435;;10.1056/nejmoa032691;;10500044;;10.1161/01.cir.100.13.1423;;11606410;;10.1136/ard.59.suppl_1.i65;;pmc1766630;;11053092;;10.1073/pnas.081615298;;11274374;;pmc31881;;10.1097/00001756-200107030-00037;;11435930;;10.1186/ar575;;12110126;;pmc3240151;;10.1016/s0021-9258(18)47298-5;;7929268;;10.1038/gt.2008.115;;18633446;;16821113;;10.1007/s10456-006-9030-4;;9445046;;10.1128/jvi.72.2.1438-1445.1998;;pmc124624;;10.1038/8470;;10229239;;10.1158/0008-5472.can-04-1833;;15867360;;9393862;;10.1016/s0092-8674(00)80456-0;;10.1152/ajpheart.00616.2005;;16172161;;10.1038/nm1428;;16799557,"Palù et al. (1999). In pursuit of new developments for gene therapy. Journal of Biotechnology. 68:1-13.;;Phillips, A.J. (2001). The challenge of gene therapy and DNA delivery. Journal of Pharmacy and Pharmacology. 53:1169-1174.;;Auricchio et al., “Isolation of Highly Infectious and Pure Adeno-Associated Virus Type 2 vectors with a Single-Step Gravity-Flow Column,” Human Gene Therapy 12:71-76 (2001).;;Bagley et al., “sFLT01: A Novel Fusion Protein with Antiangiogenic Activity,” Molecular Cancer Therapeutics 10:404-415 (2011).;;Barleon et. al., “Protein Chemistyr and Structure: Mapping of the Sites for Ligand Binding and Receptor Dimerization at the Extracellular Domain of the Vascular Endothelial Growth Factor Receptor FLT-1,” J. Biol. Chern. 272:10382-10388 (1997).;;Bobo et al., “Convection-enhanced delivery of macromolecules in the brain,” Proc. Natl. Acad. Sci. U.S.A. 91(6):2076-2080 (1994).;;Bråkenhielm et al., “Angiogenesis Inhibitor, TNP-470, Prevents Diet-Induced and Genetic Obesity in Mice,” Circulation Research 94:1579-1588 (2004).;;Cunningham et al., “Identification of the Extracellular Domains of Flt-1 That Mediate Ligand Interactions,” Biochem. Biophys. Res. Comm. 231: 596-599 (1997).;;Davidson et al., “Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system,” Proc. Natl. Acad. Sci. U.S.A. 97(7):3428-3432 (2000).;;Davis-Smyth et. al., “The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade,” EMBO J. 15:4919-4927 (1996).;;Flotte et al., “Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAt-deficient adults,” Human Gene Therapy 15:93-128 (2004).;;Grammas et al., “Microvessels from Alzheimer's Disease Brains Kill Neurons in Vitro,” Am. J. Path. 154(2):337-342 (1999).;;Healy et al., “Angiogenesis: a new theory for endometriosis,” Human Reproduction Update 4:736-740 (1998).;;Holash et al., “VEGF-Trap: A VEGF blocker with potent antitumor effects,” Proc. Natl. Acad. Sci. U.S.A. 99:11393-11398 (2002).;;Hurwitz et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” New Engl. J. Med. 350:2335-2342 (2004).;;International Preliminary Report on Patentability issued in PCT/US2012/051412 on Feb. 25, 2014 (6 pages).;;International Search Report and Written Opinion issued in PCT/US2012/51412 on Dec. 7, 2012 (8 pages).;;Iruela-Arispe et al., “Inhibition of Angiogenesis by Thrombospondin-1 Is Mediated by 2 Independent Regions Within the Type 1 Repeats,” Circulation 100:1423-1431 (1999).;;Kisker et al., “Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model,” Cancer Research 61:7669-7674 (2001).;;Koch, A. E., “The role of angiogenesis in rheumatoid arthritis: recent developments,” Ann. Rheum. Dis. 59(Suppl. 1):i65-i71 (2000).;;Kuo et al., “Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer,” Proc. Natl. Acad. Sci. U.S.A. 98:4605-4610 (2001).;;Nguyen et al., “Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain,” Neuroreport 12(9):1961-1964 (2001).;;Paleolog, E. M., “Angiogenesis in rheumatoid arthritis,” Arthritis Res. 4(Suppl. 3), S81-S90 (2002).;;Park et al., “Placenta Growth Factor: Potentiation of Vascular Endothelial Growth Factor Bioactivity, In Vitro and In Vivo, and High Affinity Bidning to Flt-1 But Not to Flk-1KDR*,” J. Biol. Chem. 269:25646-25654 (1994).;;Passini et al., “Intraventricular Brain Injection of Adeno-Associated Virus Type 1 (AAV1) in Neonatal Mice Results in Complementary Patterns of Neuronal Transduction to AAV2 and Total Long-Term Correction of Storage Lesions in the Brains of β-Glucuronidase-Deficient Mice,” J. Virol. 77(12):7034-7040 (2003).;;Pechan et al., “Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization,” Gene Therapy 16:10-16 (2009).;;Schultheiss et al., “In vivo characterization of endothelial cell activation in a transgenic mouse model of Alzheimer's disease,” Angiogenesis 9(2):59-65 (2006).;;Summerford and Samulski, “Membrain-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions,” J. Virol. 72:1438-1445 (1998).;;Summerford and Samulski, “Viral receptors and vector purification: New approaches for generating clinical-grade reagents,” Nat. Med. 5:587-588 (1999).;;Tjin Tham Sjin et al., “A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity,” Cancer Research 65:3656-3663 (2005).;;Wiesmann et al., “Crystal Structure at 1.7 Å Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor,” Cell 91:695-704 (1997).;;Communication issued in European Patent Appl. No. 12826108.8, mailed on Feb. 24, 2016 (4 pages).;;Baffert et al., “Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling,” Am. J. Physiol. Heart Circ. Physiol., 290:H547-H559 (2006).;;European Search Report issued in European Patent Appl. No. 12826108.8, mailed on May 20, 2015 (4 pages).;;Tam et al., “VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis,” Nature Medicine, 12(7):793-800 (2006).;;Communication issued in European Patent Appl. No. 12826108.8, mailed on Jun. 2, 2015 (5 pages).",ACTIVE
29,US,B2,US 10407728 B2,168-134-625-556-33X,2019-09-10,2019,US 201514792212 A,2015-07-06,US 201514792212 A;;US 201213395284 A;;US 2010/0048293 W;;US 24101409 P,2009-09-09,Use of microvesicles in analyzing nucleic acid profiles,"The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The determination of a biological condition may aid, for example, the diagnosis, prognosis, and therapy treatment selection for disease in a subject.",MASSACHUSETTS GEN HOSPITAL,NOERHOLM MIKKEL;;SKOG JOHAN KARL OLOV;;BREAKEFIELD XANDRA O;;CARTER BOB,THE GENERAL HOSPITAL CORPORATION (2012-05-25),https://lens.org/168-134-625-556-33X,Granted Patent,yes,118,1,11,11,0,G01N33/57407;;C12Q1/6806;;C12Q2600/158;;C12Q1/6886;;C12Q2600/158;;C12Q1/6806;;G01N33/57407;;C12Q1/6886,C12Q1/68;;C12Q1/6806;;C12Q1/6886;;G01N33/574,,199,192,094-463-059-022-302;;081-312-966-056-426;;017-559-987-535-067;;003-870-745-672-716;;137-253-096-323-115;;096-297-459-857-191;;059-972-670-324-344;;056-447-666-258-79X;;096-756-470-790-629;;019-094-409-659-899;;094-145-542-836-45X;;038-967-031-002-391;;003-777-488-229-038;;043-008-346-498-421;;058-057-251-272-53X;;107-207-497-715-915;;098-975-268-154-365;;020-479-675-672-474;;084-223-751-887-294;;108-863-424-571-449;;131-241-922-717-428;;042-767-012-961-843;;006-361-700-266-670;;032-980-216-347-271;;040-602-255-683-86X;;117-973-521-102-496;;053-368-478-727-670;;074-448-800-565-123;;038-027-836-901-95X;;007-953-100-837-914;;008-169-442-127-311;;006-175-044-218-654;;085-008-815-773-136;;110-079-365-492-021;;029-505-718-599-646;;037-086-877-392-593;;056-649-011-137-95X;;005-132-051-599-655;;039-332-742-631-60X;;032-097-726-617-021;;007-892-810-337-491;;005-007-596-121-261;;029-649-006-050-914;;023-294-457-551-357;;018-565-258-437-405;;026-852-842-403-812;;083-666-637-068-259;;062-111-065-443-998;;010-356-237-480-031;;115-523-071-944-15X;;011-332-943-473-533;;092-084-934-441-087;;037-831-230-791-689;;001-797-371-270-008;;036-706-039-016-917;;082-698-269-977-263;;035-261-521-322-351;;037-047-957-053-389;;020-472-936-008-079;;054-058-075-827-661;;065-582-035-556-385;;064-659-207-370-98X;;023-639-145-891-636;;140-534-257-440-881;;108-227-043-768-89X;;080-104-543-170-347;;146-606-185-618-094;;063-832-514-833-024;;068-716-621-588-961;;050-672-300-487-304;;025-152-639-070-836;;077-306-525-803-267;;013-054-067-427-283;;010-021-248-114-286;;051-975-606-511-447;;040-654-525-673-51X;;012-496-262-398-002;;000-132-490-637-551;;079-084-151-188-862;;068-501-711-849-792;;000-493-229-497-149;;020-496-927-165-060;;029-238-328-272-724;;069-785-693-151-14X;;109-340-557-373-319;;040-796-118-388-539;;002-908-197-051-488;;015-975-560-883-441;;023-112-838-780-460;;050-961-782-167-741;;015-761-936-434-094;;090-760-863-238-249;;029-612-487-060-400;;053-358-014-201-671;;030-947-914-777-140;;014-536-124-122-370;;068-700-228-645-070;;014-524-302-477-134;;109-553-992-963-291;;033-213-763-441-91X;;002-300-036-783-156;;007-668-424-494-396;;104-779-719-063-110;;016-699-621-843-135;;007-029-146-454-907;;055-474-944-189-665;;068-070-471-116-271;;087-364-860-109-449;;007-922-091-394-514;;027-213-098-929-669;;000-033-908-324-568;;031-743-189-505-696;;007-543-763-038-628;;014-252-478-665-343;;038-217-868-297-942;;094-463-059-022-302;;089-155-244-656-088;;064-520-071-952-414;;026-407-920-422-598;;140-591-885-755-375;;035-841-291-273-865;;051-459-944-033-491;;081-312-966-056-426;;017-559-987-535-067;;133-434-018-301-911;;012-770-630-971-204;;115-663-447-615-245;;059-600-694-698-124;;001-568-098-749-368;;088-284-894-785-185;;049-520-233-784-529;;139-401-846-708-319;;073-557-183-456-939;;084-525-238-501-841;;011-484-591-741-698;;010-198-027-850-97X;;035-943-600-535-599;;144-549-939-323-292;;071-987-550-650-889;;017-024-470-517-316;;099-848-173-992-707;;047-153-314-853-499;;061-464-488-333-923;;044-234-693-509-73X;;003-870-745-672-716;;005-422-391-218-711;;063-795-978-664-337;;081-905-315-069-593;;056-468-366-456-260;;067-207-313-773-418;;115-919-863-782-954;;137-253-096-323-115;;015-453-955-064-354;;046-201-607-879-85X;;043-885-019-636-545;;029-671-078-972-249;;020-486-878-827-208;;034-821-953-053-761;;059-594-671-507-462;;069-739-770-688-833;;065-957-414-569-619;;005-359-841-040-887;;063-375-682-056-905;;010-923-397-538-050;;044-867-537-834-856;;077-202-946-269-836;;030-997-389-321-940;;039-773-515-186-554;;130-680-203-388-320;;049-017-522-554-561;;042-492-518-038-183;;085-007-113-448-158;;003-697-375-976-627;;057-355-067-723-854;;010-166-310-094-798;;082-209-562-648-389;;043-637-817-489-241;;019-873-570-396-901;;061-597-199-265-054;;041-065-338-098-733;;017-552-931-242-415;;048-937-636-972-345;;115-371-065-346-241;;119-797-859-844-668;;135-163-530-485-247;;095-988-867-714-743;;109-423-000-481-113;;056-919-229-643-094;;101-082-823-932-25X;;014-710-154-057-478;;029-073-154-965-420;;008-732-506-726-349,10.1038/ki.2010.106;;pmc4451567;;20428099;;pmc2696767;;10.1038/sj.bjc.6605058;;19401683;;10.1186/1471-2407-12-22;;pmc3329625;;22251860;;19011622;;pmc3423894;;10.1038/ncb1800;;10.1016/j.ygyno.2008.04.033;;18589210;;7534908;;pmc306737;;10.1093/nar/23.4.675;;10.1126/scisignal.267pe27;;19383978;;pmc1370605;;15208450;;10.1261/rna.5250604;;10.1038/ncb1725;;18425114;;pmc1599972;;16983084;;10.1073/pnas.0603529103;;10.1007/s00262-005-0075-9;;16283305;;10.1007/s001099900038;;10606205;;10.1038/sj.bjc.6601894;;15188009;;pmc2409828;;10.1016/s0168-9525(01)02320-4;;11418223;;pmc33481;;10.1073/pnas.101129998;;11353826;;pmc2063735;;10.1083/jcb.200508014;;16533950;;10.1016/j.bios.2006.06.023;;16891110;;10.1002/1097-0142(19940501)73:9<2333::aid-cncr2820730915>3.0.co;2-4;;8168038;;18006428;;10.1093/cvr/cvm071;;16951158;;10.1158/0008-5472.can-06-1547;;4053066;;pmc3160337;;10.1371/journal.pone.0023937;;21886843;;15952905;;10.1517/14712598.5.6.737;;10.1038/cr.2008.282;;18766170;;10.1039/b916199f;;20126692;;pmc3136803;;pmc1292995;;10.1093/nar/gni178;;16314309;;18288938;;10.2174/156800908783497104;;10.1152/ajprenal.00434.2006;;17229675;;pmc2271070;;12567189;;10.1038/ng1094;;10.1002/path.2106;;17139617;;16039986;;10.1016/j.bbrc.2005.07.030;;17671216;;10.1158/0008-5472.can-06-3456;;10.1016/j.tcb.2008.11.003;;19144520;;pmc2546968;;18632860;;10.1128/jvi.00646-08;;10.1161/circgenetics.110.957415;;20921333;;19426115;;10.1517/14712590902932889;;pmc280436;;3260032;;10.1073/pnas.85.12.4397;;19488871;;10.1007/978-1-60327-192-9_5;;10.1002/ijc.23849;;18823011;;21093148;;10.1016/j.canlet.2010.10.019;;17536014;;10.1182/blood-2007-03-078709;;18670422;;pmc2820391;;10.1038/nm.1789;;10.1038/nmeth898;;16791214;;pmc2893390;;10.1126/science.1187532;;20508131;;10.1073/pnas.1133470100;;pmc166396;;12857956;;21196075;;10.1016/j.eururo.2010.12.031;;10.1373/clinchem.2003.028506;;14718398;;17476321;;pmc1851990;;10.1371/journal.pone.0000399;;10.1073/pnas.0707628104;;17890317;;pmc2000384;;10.1093/molehr/gag046;;12802047;;10.1016/0092-8674(79)90200-9;;369706;;232212;;10.1016/0076-6879(79)68013-8;;10.1002/0471142905.hg1011s57;;19906727;;pmc2808858;;10.1093/nar/gkp995;;10.1093/nar/gkq929;;20952405;;pmc3013785;;17974913;;10.1101/gad.1596707;;17894858;;pmc2556756;;10.1186/cc6133;;10.1038/nbt1385;;18278033;;9858920;;pmc2386537;;18516289;;10.1593/neo.07986;;10.1093/ndt/gfn058;;18310721;;18854152;;10.1016/j.cell.2008.09.022;;17257890;;10.1016/j.mrrev.2006.11.002;;11551510;;10.1016/s0092-8674(01)00484-6;;10.1182/blood-2010-02-270926;;20651067;;16627561;;10.1373/clinchem.2005.063289;;2308948;;10.1073/pnas.87.5.1874;;pmc53586;;10.1007/s00702-009-0288-8;;19680595;;10.1002/bies.950150707;;7691058;;10.1016/s0092-8674(00)81683-9;;10647931;;10.3410/f.13200063.14542237;;21088844;;10.1007/s00401-010-0781-z;;16236164;;pmc1298339;;10.1186/1479-5876-3-38;;12814669;;10.1016/s0302-2838(03)00201-x;;10.1158/1078-0432.ccr-07-0700;;17785564;;10.1200/jco.2008.17.6297;;pmc2738430;;19164214;;19641175;;10.1093/jnci/djp240;;10.1371/journal.pone.0003694;;19002258;;pmc2577891;;10.1038/sj.cdd.4402237;;17932500;;17875710;;10.1158/0008-5472.can-07-1936;;10.2174/138920208785133235;;pmc2694555;;19517027;;10.1002/ijc.20657;;15499615;;12970751;;10.1038/sj.onc.1206928;;10.1021/ac701688q;;18186614;;10.1126/science.1164368;;18772397;;pmc2848990;;pmc393021;;281713;;10.1073/pnas.75.11.5631;;10.1016/s0140-6736(78)91629-x;;19378339;;10.1002/ijc.24379;;pmc2788025;;10.1016/j.bbrc.2009.10.001;;19818334;;10.3389/fonc.2013.00234;;24062987;;pmc3769647;;10.1038/sj.ki.5002486;;17700640;;10.1083/jcb.127.2.441;;pmc2120214;;7929587;;15095315;;10.1002/ijc.11649;;11923846;;10.1038/nbt0402-387;;pmc2139771;;9128257;;10.1083/jcb.137.2.481;;16302729;;10.1111/j.1349-7006.2010.01650.x;;20624164;;19520761;;10.1373/clinchem.2008.121962;;pmc286648;;10.1073/pnas.86.4.1173;;2919166;;10.1126/science.3413476;;3413476;;pmc2998181;;10.1158/0008-5472.can-07-3224;;18245462;;21731696;;10.1371/journal.pone.0021300;;pmc3120860;;10.1038/nm1708;;18408729;;17174896;;10.1016/j.cell.2006.10.037;;10.4049/jimmunol.176.3.1375;;16424164;;10.1002/cyto.a.20531;;18307272;;17146468;;10.1038/nrg1982;;17206148;;10.1038/nm1530;;pmc39218;;10.1073/pnas.93.11.5177;;8643549;;10.1038/77498;;10888925;;10.1056/nejmoa0800668;;18596266;;pmc3551471;;10.1073/pnas.0334355100;;pmc149965;;12592035;;10.1172/jci29959;;pmc1978418;;17885688;;10.1038/nature07385;;pmc2671642;;18772890;;6655695;;10.1016/0022-2836(83)90094-3;;17460779;;pmc1854851;;10.1593/neo.07133;;10.1038/ki.2010.106;;pmc4451567;;20428099;;10.1126/science.4071043;;4071043;;18097410;;10.1038/nature06385;;pmc3090667;;10.1016/s0084-4071(08)79032-8;;8278394;;pmc42947;;10.1073/pnas.91.1.360;;10.1373/49.5.727;;12709362;;12644709;;10.1073/pnas.0637450100;;pmc153627;;pmc2696767;;10.1038/sj.bjc.6605058;;19401683;;10.1186/1471-2407-12-22;;pmc3329625;;22251860;;10.1016/j.bbrc.2009.06.034;;19523920;;15294875;;10.1093/hmg/ddh238;;10.1073/pnas.86.8.2766;;2565038;;pmc286999;;10.1038/ncb2000;;19966785;;18772396;;pmc2820389;;10.1126/science.1164382;;10.1200/jco.2006.08.0705;;17538175;;10.1074/mcp.r600004-mcp200;;16837576;;pmc3145108;;10.1038/nature08658;;20016485;;16637463;;pmc2192324;;10.1084/jem.183.3.1161;;8642258;;16791265;;10.1038/sj.leu.2404296;;10.1016/j.clinthera.2014.05.008;;24952934;;17765966;;10.1016/j.leukres.2007.07.021;;10.1007/s00018-008-8496-1;;18818873;;10.1136/gut.52.1.101;;pmc1773535;;12477769;;19424061;;10.1097/mnh.0b013e32832c9da2;;10.1016/j.molcel.2006.03.029;;16603397;;18230780;;10.1001/jama.299.4.425;;pmc2614237;;14583498;;10.1016/j.ceb.2009.03.007;;19442504;;19011622;;pmc3423894;;10.1038/ncb1800;;10.1186/1743-422x-7-248;;pmc2949849;;20858246;;pmc17321;;11050243;;10.1073/pnas.97.22.12216;;16369550;;10.1038/nmeth842;;10.1034/j.1600-0854.2002.30502.x;;11967126;;18687791;;10.2353/jmoldx.2008.080067;;pmc2518735;;pmc2361848;;15655551;;10.1038/sj.bjc.6602316;;10.1016/j.ygyno.2008.04.033;;18589210;;17486113;;10.1038/ncb1596;;pmc1894934;;10.1261/rna.575107;;17545563;;10.1126/science.270.5235.484;;7570003;;18322038;;10.1128/mmbr.00033-07;;pmc2268285;;10.1158/0008-5472.can-07-6838;;pmc5802396;;18632641;;10.1016/j.humpath.2003.08.026;;14745734;;17337785;;10.1385/ir:36:1:247;;10.1373/clinchem.2005.052340;;16081506;;10.1126/science.1145720;;17932254;;pmc2204063;;18231617;;10.1016/s0513-5117(09)79085-4;;19266099;;pmc2648987;;10.1371/journal.pone.0004722;;15193025;;pmc8095894;;10.1111/j.1750-3639.2004.tb00045.x;;10.1002/ijc.2910530522;;8449609;;21630462;;10.1002/pmic.201100022;;10.1200/jco.2004.10.062;;15169800;;pmc2997214;;10.1038/nbt0394-320;;16258065;;pmc1283450;;10.1073/pnas.0507904102;;10.1080/09553000010017108;;11258843;;10.1016/j.imlet.2006.09.005;;17067686;;17790039;;10.1126/science.241.4872.1441;;16282176;;10.1056/nejmoa051918;;19138409;;10.1186/1479-5876-7-4;;pmc2631476;;10.1093/nar/29.13.2850;;11433032;;pmc55780;;7585629;;10.1007/bf02484510;;15700833;;18684837;;10.1128/jvi.01016-08;;pmc2566279;;10.1093/dnares/9.2.35;;12056413;;10.1002/pros.20490;;16921506;;12086878;;10.1016/s1535-6108(02)00030-2;;11237013;;10.1038/35057149;;18228490;;16254181;;10.1126/science.1117679;;18223223;;10.1158/1078-0432.ccr-07-1966;;15550054;;10.1111/j.1538-7836.2004.00972.x;;10.1006/viro.1997.8499;;9126269;;pmc1024103;;13481124;;10.1136/jcp.10.4.360;;6254393;;10.1016/0003-2697(80)90519-9;;16487731;;10.1016/j.bcmd.2005.12.001;;10.4161/cam.1.3.5114;;19262134;;pmc2634021,"Miranda et al., Kidney International, 78(2):191-199 (2010). “Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease.”;;Nilsson et al., British Journal of Cancer, 100(10):1603-1607 (2009). “Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer.”;;Noerholm et al., BMC Cancer, 12(1): p. 22 (2012). “RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls.”;;Skog et al., Nature Cell Biology, 10(12):1470-1476 (2008). “Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.”;;Taylor et al., Gynecological Oncology, 110(1):13-21 (2008). “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer.”;;Abravaya et al., “Detection of point mutations with a modified ligase chain reaction (Gap-LCR)”, Nucleic Acids Res 23(4) 675-682 (1995).;;Affymetrix, “Gene chip human genome U133 set”, URL: http://www/affymetrix.com/products/arrays/specific/hgu133.asp; retrieved from the Internet May 21, 2003.;;Alessi et al., “New Insights into mTOR Signaling: mTORC2 and Beyond”, Sci Signal 2(67) pe 27 (2009).;;Allawi et al., “Quantitation of microRNAs using a modified Invader assay”, RNA 10(7) 1153-1161 (2004).;;Al-Nedawi et al., “Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour mils”, Nat Cell Biol 10(5) 619-624 (2008).;;Ason et al., “Differences in vertebrate microRNA expression”, PNAS 103(39) 14385-14389 (2006).;;Baj Krzyworzeka et al., “Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes”, Cancer Immunol Immunother 55(7) 808-818 (2006).;;Balzar et al., “The biology of the 17-1A antigen (Ep-CAM)”, J Mol Med (Berl) 77(10) 699-712 (1999).;;Bamford et al., “The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website”, Br J Cancer 91(2) 355-358 (2004).;;Benner et al., “Evolution, language and analogy in functional genomics”, Trends Genet 17(7) 414-418 (2001).;;Bergsmedh et al., “Horizontal transfer of oncogenes by uptake of apoptotic bodies”, Proc Natl Acad Sci USA 98(11) 6407-6411 (2001).;;Booth et al., “Exosomes and HIV Gag bud from endosome-like domains of the T cell plasma membrane”, J Cell Biol 172(6) 923-935 (2006).;;Bossi et al., “Molecularly imprinted polymers for the recognition of proteins: The state of the art”, Biosens Bioelectron 22(6) 1131-1137 (2007).;;Bratthauer et al., “Expression of LINE-1 Retrotransposons in Human Breast Cancer”, Cancer 73(9) 2333-2336 (1994).;;Burghoff et al., “Horizontal gene transfer from human endothelial cells to rat cardiomyocytes after intracoronary transplantation”, Cardiovasc 77(3) 534-543 (2008).;;Cadieux et al., “Genome-wide Hypomethylation in Human Glioblastomas Associated with Specific Copy Number Alteration, Methylenetetrahydrofolate Reductase Allele Status, and Increased Proliferation”, Cancer Res 66(17) 8469-8476 (2006).;;Carr et al., “Circulating Membrane Vesicles in Leukemic Blood”, Cancer 45(11 Pt 2) 5944-5951 (1985).;;Cermelli et al., “Circulating microRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver Disease”, PLoS One 6(8) e23937 (2011).;;Chaput et al., “The potential of exosomes in immunotherapy”, Expert Opinion on Biological Therapy 5(6) 737-747 (2005).;;Chen et al., “Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases”, Cell Res 18(10) 997-1006 (2008).;;Chen et al., “Microfluidic isolation and transcriptome analysis of serum microvesicles”, Lab Chip 10(4) 505-511 (2010).;;Chen et al., “Real-time quantification of microRNAs by stem-loop RT-PCR”, Nucleic Acids Res 33(20) e179 (2005).;;Cheng et al., “Advances of AKT Pathway in Human Oncogenesis and as a Target for Anti-Cancer Drug Discovery”, Curr Cancer Drug Targets 8(1) 2-6 (2008).;;Cheruvanky et al., “Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator”, Am J Physiol Renal Physiol 292(5) F1657-1661 (2007).;;Cheung et al., “Natural variation in human gene expression assessed in lymphoblastoid cells”, Nat Genet 33(3) 422-425 (2003).;;Cho et al., “Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features”, J Pathol 211(3) 269-277 (2007).;;Ciafre et al., “Extensive modulation of a set of microRNAs in primary glioblastoma”, BiochemBiophys Res Commun 334(4) 1351-1358 (2005).;;Clayton et al., “Human Tumor-Derived Exosomes Selectively Impair Lymphocyte Responses to Interleukin-2”, Cancer Res 67(15) 7458-7466 (2007).;;Cocucci et al., “Shedding microvesicles: artefacts no more”, Trends Cell Biol 19(2) 43-51 (2009).;;Contreras-Galindo et al., “Human Endogenous Retrovirus K (HML-2) Elements in the Plasma of People with Lymphoma and Breast Cancer”, J Virol 82(19) 9329-9336 (2008).;;Corsten et al., “Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease”, Circ Cadriovasc Genet 3(6) 4999-506 (2010).;;Cortez et al., “MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases”, Expert Opin Biol Ther 9(6) 703-711 (2009).;;Cotton et al., “Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations”, Proc Natl Acad Sci USA 85(12) 4397-4401 (1988).;;Cowell et al., “Application of Oligonucleotides Arrays for Coincident Comparative Genomic Hybridization, Ploidy Status and Loss of Heterozygosity Studies in Human Cancers”, Methods Mol Biol 556; 47-65 (2009).;;Daskalos et al., “Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer”, Int J Cancer 124(1) 81-87 (2009).;;Day et al., “PCA3: From basic molecular science to the clinical lab”, Cancer Lett 301(1) 106 (2011).;;Deregibus et al., “Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial mils by a horizontal transfer of mRNA”, Blood 110(7) 2440-2448 (2007).;;Diehl et al., “Circulating mutant DNA to assess tumor dynamics”, Nat Med 14(9) 985-990 (2008).;;Diehl et al., “BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions”, Nature Methods 3(7) 551-559 (2006).;;Dowling et al., “mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs”, Science 328 (5982) 11672-1176 (2010).;;Dressman et al., “Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations”, Proc Natl Acad Sci USA 100(15) 8817-8822 (2003).;;Duijvesz et al., “Exosomes as Biomarker Treasure Chests for Prostate Cancer”, Eur Urol 59(5) 823-831 (2011).;;El-Hefnawy et al., “Characterization of Amplifiable, Circulating RNA in Plasma and its Potential as a Tool for Cancer Diagnostics”, Clin Chem 50(3) 564-573 (2004).;;Estecio et al., “LINE-1 Hypomethylation in Cancer is Highly Variable and Inversely Correlated with Microsatellite Instability”, PLoS One 2(5) e399 (2007).;;Fabbri et al., “MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B”, Proc Natl Acad Sci USA 104(40) 15805-15810 (2007).;;Fiorentino et al., “The minisequencing method: an alternative strategy for preimplantation genetic diagnosis of single gene disorders”, Mol Hum Reprod 9(7) 399-410 (2003).;;Fischer et al., “Length-Independent Separation of DNA Restriction Fragments in Two-Dimensional Gel Electrophoresis”, Cell 16(1) 191-200 (1979).;;Fischer et al., “Two-Dimensional Electrophoretic Separation of Restriction Enzyme Fragments of DNA”, Methods Enzymol 68; 183-191 (1979).;;Forbes et al., “The Catalogue of Somatic Mutations in Cancer (COSMIC)”, Curr Proctoc Hum Genet Chapter 10 Unit 10;11 (2008).;;Forbes et al., “COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer”, Nucleic Acids Res 38(Databases issue D652-657 (2010).;;Forbes et al., “COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer”, Nucleic Acids Res 39(Database issue) D945-950 (2011).;;Furnari et al., “Malignant astrocytic glioma: genetics, biology, and paths to treatment”, Genes Dev 21(21) 2683-2710 (2007).;;Gambim et al., “Platelet-derived exosomes induce endothelial cell apoptosis through peroxynitrite generation: experimental evidence for a novel mechanism of septic vascular dysfunction”, Critical Care 11(5) R107 (2007).;;Geiss et al., “Direct multiplexed measurement of gene expression with color-coded probe pairs”, Nat Biotechnol 26(3) 317-325 (2008).;;GeneBank (Accession NM_005896 submitted Jan 31, 2003).;;Ginestra et al., “The Amount and Proteolytic Content of Vesicles Shed by Human Cancer Cell Lines Correlates with their in Vitro Invasiveness”, Anticancer Res 18(5A) 3433-3437 (1998).;;Golan et al., “Human Endogenous Retrovirus (HERV-K) Reverse Transcriptase as a Breast Cancer Prognostic Marker”, Neoplasia 10(6) 521-533 (2008).;;Gonzales et al., “Urinary exosomes: is there a future?”, Nephrology Dialysis Tranplantation 23(6) 1799-1801 (2008).;;Goodier et al., “Retrotransposons Revisited: the Restraint and Rehabilitation of Parasites”, Cell 135(1) 23-35 (2008).;;Gormally et al., “Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance”, Mutat Res 635(2-3) 105-117 (2007).;;Greco et al., “Argosomes: a Potential Vehicle for the Spread of Morphogens through Epithelia”, Cell 106(5) 633-645 (2001).;;Green et al., “The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status”, Blood 116(15) 2779-2783 (2010).;;Groskopf et al., “APTIMA PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Dancer”, Clin Chem 52(6) 1089-1095 (2006).;;Guatelli et al., “Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication”, Proc Natl Acad Sci USA 87(5) 1874-1878 (1990).;;Guescini et al., “Astrocytes and Glioblastoma cells release exosomes carrying mtDNA”, J Neural Transm (Vienna) 117(1) 1-4 (2010).;;Hahn, “Molecular Biology of Double-Minute Chromosomes”, Bioessays 15(7) 477-484 (1993).;;Hanahan et al., “The Hallmarks of Cancer”, Cell 100(1) 57-70 (2000).;;Hartmann et al., “Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas”, Acta Neuropathol 120(6) 707-718 (2010).;;Heimberger et al., “The natural history of EGFR and EGFRvIII in glioblastoma patients”, J Transl Med 3; 38 (2005).;;Hessels et al., “DD3 PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer”, European Urology 44(1) 8-16 (2003).;;Hessels et al., “Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer”, Clin Cancer Res 13(17) 5103-5108 (2007).;;Hildebrant et al., “Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated with Chemoradiotherapy”, Journal of Clinical Oncology 27(6) 857-871 (2009).;;Holdhoff et al., “Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations”, J Natl Cancer Inst 101 (18) 1284-1285 (2009).;;Hunter et al., “Detection of microRNA Expression in Human Peripheral Blood Microvesicles”, PLoS One 3(11) e3694 (2008).;;Iero et al., “Tumour-released exosomes and their implications in cancer immunity”, Cell Death Differ 15(1) 80-88 (2008).;;Iorio et al., “MicroRNA Signatures in Human Ovarian Cancer”, Cancer Res 67(18) 8699-8707 (2007).;;Itadani et al., “Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation”, Curr Genomics 9(5) 349-360 (2008).;;Janowska-Wieczorek et al., “Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer”, Int J Cancer 113(5) 752-760 (2005).;;Ji et al., “MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer”, Oncogene 22(39) 8031-8041 (2003).;;Johnson et al., “Surface-Immobilized Peptide Aptamers as Probe Molecules for Protein Detection”, Anal Chem 80(4) 978-983 (2008).;;Jones et al., “Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses”, Science 321(5897) 1801-1806 (2008).;;Kan et al., “Polymorphism of DNA sequence adjacent to human beta-globin structural gene: relationship to sickle mutation”, Proc Natl Acad Sci USA 75(11) 5631-5635 (1978).;;Kan et al., “Antenatal diagnosis of sickle-cell anaemia by D.N.A. analysis of amniotic-fluid cells”, Lancet 2(8096) 910-912 (1978).;;Kang et al., “Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers”, Int J Cancer 125 (2) 353-355 (2009).;;Kato et al., “A Monoclonal Antibody IMab-1 Specifically Recognizes IDH1R132H, the Most Common Glioma-Derived Mutation”, Biochem Biophys Res Commun 390(3) 547-551 (2009).;;Katoh et al., “Association of endogenous retroviruses and long terminal repeats with human disorders”, Front Oncol 3; 234 (2013).;;Keller et al., “CD24 is a marker of exosomes secreted into urine and amniotic fluid”, Kidney Int 72(9) 1095-1102 (2007).;;Kislauskis et al., “Sequences Responsible for Intracellular Localization of beta-Actin Messenger RNA Also Affect Cell Phenotype”, J Cell Biol 127(2) 441-451 (1994).;;Kleiman et al., “HERV-K(HML-2) GAG/ENV antibodies as indicator for therapy effect in patients with germ cell tumors”, Int J Cancer 110(3) 459-461 (2004).;;Klein et al., “Combined transcriptome and genome analysis of single micrometastatic cells”, Nat Biotechnol 20(4) 387-392 (2002).;;Klemke et al., “Regulation of Cell Motility by Mitogen-activated Protein Kinase”, J Cell Biol137(2) 481-492 (1997).;;Koga et al., “Purification, Characterization and Biological Significance of Tumor-derived Exosomes”, Anticancer Res25(6A) 3703-3707 (2005).;;Kosaka et al., “Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis”, Cancer Sci 101(10) 2087-2092 (2010).;;Kristensen et al., “PCR-based Methods for Detecting Single-Locus DNA Methylation Biomarkers in Cancer Diagnostics, Prognostics, and Response to Treatment”, Clinical Chemestry 55(8) 1471-1483 (2009).;;Krupp et al., “Stringent RNA quality control using the Agilent 2100 bioanalyzer”, Agilent Technologies Application Notes (2005).;;Kwoh et al., “Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format”, Proc Natl Acad Sci USA 86(4) 1173-1177 (1989).;;Landegren et al., “A Ligase-Mediated Gene Detection Technique”, Science 241(4869) 1077-1080 (1988).;;Laxman et al., “A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate Cancer”, Cancer Res 68(3) 645-549 (2008).;;Lee et al., “MicroRNA Expression and Clinical Outcome of Small Cell Lung Cancer”, MicroRNA expression and clinical Dutcome of small cell lung cancer, PLoS One 6(6) e21300 (2011).;;Li et al., “Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing”, Nat Med 14(5) 579-584 (2008).;;Liu et al., “Reconstitution, Activities, and Structure of the Eukaryotic RNA Exosome”, Cell 127(6) 1233-1237 (2006).;;Liu et al., “Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function”, J Immunol 176(3) 1375-1385 (2006).;;Lo et al., “Automated gating of flow cytometry data via robust model-based clustering”, Cytometry 73(4) 321-332 (2008).;;Lo et al., “Prenatal diagnosis: progress through plasma nucleic acids”, Nat Rev Genet 8(1) 71-77 (2007).;;Lo et al., “Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection”, Nat Med 13(2) 218-223 (2007).;;Lower et al., “The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences”, Proc Natl Acad Sci USA 93(11) 5177-5184 (1996).;;Mack et al., “Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection”, Nat Med 6(7) 769-775 (2000).;;Maheswaran et al., “Detection of mutations in EGFR in circulating lung-cancer cells”, N Engl J Med 359(4) 366-377 (2008).;;Mallardo et al., “Isolation and characterization of Staufen-containing ribonucleoprotein particles from rat brain”, Prco Natl Acad Sci USA 100(4) 2100-2105 (2003).;;Maron et al., “Gene expression analysis in pregnant women and their infants identifies unique fetal biomarkers that circulate in maternal blood”, J Clin Invest 117(10) 3007-3019 (2007).;;McLendon et al., “Comprehensive genomic characterization defines human glioblastoma genes and core pathways”, Nature 455(7216) 1061-1068 (2008).;;Miele et al., “Autocatalytic Replication of a Recombinant RNA”, J Mol Biol 171(3) 281-295 (1983).;;Millimaggi et al., “Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells”, Neoplasia 9(4) 349-357 (2007).;;Miranda et al., “Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease”, Kidney Int 78(2) 191-199 (2010).;;Myers et al., “Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes”, Science 230(4731) 1242-1246 (1985).;;Nagrath et al., “Isolation of rare circulating tumour cells in cancer patients by microchip technology”, Nature 450 (7173) 1235-1239 (2007).;;Nakanishi et al., “PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance”, J Urol 179(5) 1804-1809 (2008).;;Nakazawa et al., “UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement”, Proc Natl Acad Sci USA 91(1) 360-364 (1994).;;Ng et al., “The concentration of circulating corticotropin-releasing hormone mRNA in maternal plasma is increased in preeclampsia”, Clin Chem 49(5) 727-731 (2003).;;Ng et al., “mRNA of placental origin is readily detectable in maternal plasma”, Proc Natl Acad Sci USA 100(8) 4748-4753 (2003).;;Nilsson et al., “Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer”, Br J Cancer 100(10) 1603-1607 (2009).;;Noerholm et al., “RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls”, BMC Cancer 12; 22 (2012).;;Novakova et al., “MicroRNA involvement in glioblastoma pathogenesis”, Biochem Biophys Res Commun 386(1) 1-5 (2009).;;Oliveira et al., “Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair lefects and hMLH1 methylation status”, 13(19) 2303-2311 (2004).;;Orita et al., “Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms”, Proc Natl Acad Sci USA 86(8) 2766-2770 (1989).;;Ostriwski et al., “Rab27a and Rab27b control different steps of the exosome secretion pathway”, Nat Cell Biol 12(1) 19-30 (2010).;;Parsons et al., “An integrated genomic analysis of human glioblastoma multiforme”, Science 321(5897) 1807-1812 (2008).;;Pelloski et al., “Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma”, J Clin Oncol 25(16) 2288-2294 (2007).;;Pisitkun et al., “Discovery of Urinary Biomarkers”, molecular & Cellular Proteomics 5(10) 176-1771 (2006).;;Pleasance et al., “A comprehensive catalogue of somatic mutations from a human cancer genome”, Nature 463 (7278)191-196 (2010).;;“Probes for MYC availible on Affymetrix arrays HG-U95, HG-U133, and HG-U133 Plus 2.0”, Internet Citation, Apr. 20, 2001. Weizman Institute of Science http://genegards.weizman.ac.il/cgi-bin/geneannot/GA_serach.pl.;;Rak et al., “Genetic determinants of cancer coagulopathy, angiogenesis and disease progression”, Vnitr Lek 52(Suppl 1) 135-138 (2006).;;Raposo et al., “B lymphocytes secrete antigen-presenting vesicles”, J Exp Med 183(3) 1161-1172 (1996).;;Ratajczak et al., “Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication”, Leukemia 20(9) 1487-1495 (2006).;;Revenfeld et al., “Diagnostic and prognostic potential of extracellular vesicles in peripheral blood”, Clin Ther 36(6) 330-846 (2014).;;Roman-Gomez et al., “Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia”, Leuk Res 32(3) 487-490 (2008).;;Ruprecht et al., “Endogenous retroviruses and cancer”, Cell Mol Life Sci 65(21) 3366-3382 (2008).;;Ryan et al., “A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up”, Gut 52(1) 101-108 (2003).;;Saal et al., “MicroRNAs and the kidney: coming of age”, Curr Opin Nephrol Hypertens 18(4) 317-323 (2009).;;Sarbassov et al., “Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB”, Mol Cell 22(2) 159-168 (2006).;;Schetter et al., “MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma”, JAMA 299(4) 425-436 (2008).;;Shinojima et al., “Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme”, Cancer Research 63(20) 6962-6970 (2003).;;Simons et al., “Exosomes—vesicular carriers for intercellular communication”, Burr Opin Cell Biol 21(4) 575-581 (2009).;;Skog et al., “Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide liagnostic biomarkers”, Nat Cell Biol 10(12) 1470-1476 (2008).;;Sliva et al., “Selective gene silencing by viral delivery of short hairpin RNA”, Virol J 7;248 (2010).;;Srikantan et al., “PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer”, Proc Natl Acad Sci USA 97(22) 12216-12221 (2000).;;Steemers et al., “Whole-genome genotyping with the single-base extension assay”, Nat Methods 3(1) 31-33 (2006).;;Stoorvogel et al., “The Biogenesis and Functions of Exosomes”, Traffice 3(5) 321-330 (2002).;;Tam, “The emergent role of microRNAs in molecular diagnostics of cancer”, J Mol Diagn 10(5) 411-414 (2008).;;Taylor et al., “Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects”, Br J Cancer 92(2) 305-311 (2005).;;Taylor et al., “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer”, Gynecol Oncol 110(1) 13-21 (2008).;;Valadi et al., “Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells”, Nat Cell Biol 9(6) 654-659 (2007).;;Van Dijk et al., “Human cell growth requires a functional cytoplasmic exosome, which is involved in various mRNA decay pathways”, RNA 13(7) 1027-1035 (2007).;;Velculescu et al., “Serial analysis of gene expression”, Science 270(5235) 484-487 (1995).;;Voisset et al., “Human RNA “rumor” viruses: the search for novel human retroviruses in chronic disease”, Microbial Mol Biol Rev 72(1) 157-196 (2008).;;Wang-Johanning et al., “Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients”, Cancer Res 68(14) 5869-5877 (2008).;;Went et al., “Frequent EpCam protein expression in human carcinomas”, Hum Pathol 35(1) 122-128 (2004).;;Wieckowski et al., “Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles”, Immunol Res 36(2006) 247-254 (2006).;;Wong et al., “Circulating placental RNA in maternal plasma is associated with a preponderance of 5′ mRNA fragments: implications for noninvasive prenatal diagnosis and monitoring”, Clin Chem 51(10) 1786-1795 (2005).;;Wood et al., “The genomic landscapes of human breast and colorectal cancers”, Science 318(5853) 1108-1113 (2007).;;Wright et al., “Newer potential biomarkers in prostate cancer”, Rev Urol 9(4) 207-213 (2007).;;Yan et al., “IDH1 and IDH2 mutations in gliomas”, N Engl J Med 360(8) 765-773 (2009).;;Yu et al., “Oncogenic events regulating tissue factor expression”, Hematology Meeting Reports 1(9) (2009).;;Yuan et al., “Transfer of microRNAs by embryonic stem cell microvesicles”, PLoS One 4(3) e4722 (2009).;;Biernat et al., “Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas”, Brain Pathol 14(2) 131-136 (2004).;;Chabert et al., “Cell culture of tumors alters endogenous poly(ADPR)polymerase expression and activity”, Int J Cancer 53(5) 837-842 (1993).;;Choi et al., “Proteomic analysis of microvesicles derived from human colorectal cancer ascites.”, Proteomic 11(13) 2745-2751 (2011).;;Cooperberg et al., “The changing face of low-risk prostate cancer: trends in clinical presentation and primary management”, J Clin Oncol 22(11) 2141-9 (2004).;;Dermer “Another anniversary for the war on cancer.” Nature Biotechnology 12(3):320 (1994).;;Diehl et al., “Detection and quantification of mutations in the plasma of pateitns with colorectal tumors” PNAS 102 (45) 16268-16373 (2005).;;Eastham et al., “Relationship between clonogenic cell survival, DNA damage and chromosomal radiosensitivity in nine human cervix carcinoma cell lines” Int. Journal Radiat. Biol 77(3) 295-302 (2001).;;Gene Annot, “Probes for MYC availible on Affymetrix arrays HG-U95, HG-U133, HG-U133 Plus 2.0”, Weizmann Institue of Science found at URL http://genecards.weizmann.aci.il/cgi-bin/geneannot/ga_search.pl (Apr. 20, 2001, retrieved from the Internet on May 21, 2003).;;Keller et al., “Exosomes: from biogenesis and secretion to biological function”, Immunol Lett 107(2) 102-8 (2006).;;May “How Many Species Are there on Earth?”, Science 241(1) 1441-1449 (1998).;;Mellinghoff et al., “Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors”, N Engl J Med 353(19) 2012-2024 (2005).;;Mitchell et al., “Can urinary exosomes act as treatment response markers in prostate cancer?”, J Transl Med 7:4 (2009).;;Moderk et al., “Genome-wide detection of alternatives splicing in expressed sequences of human genes”, Nucleic Acids Research 29(13) 2850-2859 (2001).;;Moscatello et al., “Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors”, Cancer Res 55(23) 5536-5539 (1995).;;Nishikawa et al., “Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma”, Brain Tumor Pathol 21(2) 53-56 (2004).;;Ruprecht et al., “Human endogenous retrovirus family HERV-K(HML-2) RNA transcripts are selectively packaged into retroviral particles produced by the human germ cell tumor line Tera-1 and originate mainly from a provirus on chromosome 22q11.21” J Virol 82(20) 10008-10016 (2008).;;Saito-Hisaminto et al., “Genome-Wide Profiling of Gene Expression in 29 Normal Human Tissues with cDNA Microarray”, DNA Research 9 35-45 (2002).;;Schmidt et al., “Quantitative multi-gene expression profiling of primary prostate cancer”, Prostate 66(14) 1521-34 (2006).;;Singh et al., “Gene Expression correlates of clinical prostate cancer behavior”, Cancer Cell 1(2) 203-209 (2002).;;The International SNP Map Working Group., “A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms” NATURE 409 928-933 (2001).;;Thery et al. “Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids” Curr Protoc Cell Biol Chapter 3 Unit 3.22 1-29 (2006).;;Tomlins et al., “Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer”, Science 310 (5748) 644-648 (2005).;;Yoshimoto et al., “Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples”, Clin Cancer Res 14(2) 488-493 (2008).;;Yu et al., “Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells”, J Throm Haemost 2(11) 2065-2067 (2004).;;Bess et al., “Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations.” Virology 230(1):134-144 (1997).;;Grant et al., “The proteins of normal urine.” Journal of Clinical Pathology 10(4):360-367 (1957).;;Tullis et al., “Calcium protects DNase I from proteinase K: a new method for the removal of contaminating RNase from DNase I.” Analytical Biochemistry 107(1):260-264 (1980).;;Johnstone. “Exosomes biological significace: A concise review.” Blood Cells, Molecules, and Diseases 36(2): 315-321 (2006).;;Lotvall at al. “Cell to Cell Signalling via Exosomes Through esRNA.” Cell Adhesion & Migration 1(3): 156-158 (2007).;;Perkel. “Finding Points to Possible Blood Test for Brain Tumors.” Medicine Net HealthDay News [retrieved Apr. 18, 2019] https://www.medicinenet.com/script/main/art.asp?articlekey=94287 1-3 (2008).",ACTIVE
30,US,A1,US 2014/0302025 A1,008-087-168-862-145,2014-10-09,2014,US 201214239687 A,2012-08-17,US 201214239687 A;;US 201161525278 P;;US 2012/0051412 W,2011-08-19,VEGF-BINDING PROTEIN FOR BLOCKADE OF ANGIOGENESIS,"Provided are chimeric VEGF-binding proteins and nucleic acids (e.g., a vector) encoding chimeric VEGF-binding proteins, methods and host cells for producing these proteins and nucleic acids, and pharmaceutical compositions containing these proteins and nucleic acids. Also provided are methods of treating an angiogenic disease or disorder that include administering at least one of the chimeric VEGF-binding proteins or at least one of the nucleic acids (e.g., a vector) encoding a chimeric VEGF-bind ing protein.",CARTER BOB;;LEE JENG-SHIN;;BULLAIN SZOFIA S;;MULLIGAN RICHARD C;;CHILDRENS MEDICAL CENTER;;GEN HOSPITAL CORP;;HARVARD COLLEGE,CARTER BOB;;LEE JENG-SHIN;;BULLAIN SZOFIA S;;MULLIGAN RICHARD C,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2014-02-15);;CHILDREN'S MEDICAL CENTER CORPORATION (2014-03-17);;THE GENERAL HOSPITAL CORPORATION (2014-03-25),https://lens.org/008-087-168-862-145,Patent Application,yes,1,1,12,12,8,A61K38/00;;C07K14/475;;C07K2319/30;;A61P35/00;;A61K38/00;;C07K14/475;;C07K2319/30;;A61K48/00;;C12N15/11;;A61K39/001109;;C07K2317/24;;C12N15/1136;;A61K35/42;;C07K14/71,C07K14/71,424/134.1;;530/387.3;;536/23.4;;X514 44  R;;435/320.1;;435/69.6;;435/328;;435/254.2;;435/252.3;;435/419;;435/257.2;;435/254.23;;435/254.21;;435/252.33,2,2,059-047-140-038-449;;042-579-115-970-808,10036766;;10.1016/s0168-1656(98)00134-5;;11578098;;10.1211/0022357011776603,"PalÃ¹ et al. (1999). In pursuit of new developments for gene therapy. Journal of Biotechnology. 68:1-13.;;Phillips, A.J. (2001). The challenge of gene therapy and DNA delivery. Journal of Pharmacy and Pharmacology. 53:1169-1174.",ACTIVE
31,EP,A1,EP 2744508 A1,089-288-478-002-350,2014-06-25,2014,EP 12826108 A,2012-08-17,US 201161525278 P;;US 2012/0051412 W,2011-08-19,VEGF-BINDING PROTEIN FOR BLOCKADE OF ANGIOGENESIS,,CHILDRENS MEDICAL CENTER;;HARVARD COLLEGE;;GEN HOSPITAL CORP,CARTER BOB;;LEE JENG-SHIN;;BULLAIN SZOFIA S;;MULLIGAN RICHARD C,,https://lens.org/089-288-478-002-350,Patent Application,yes,0,0,12,12,9,A61K38/00;;C07K14/475;;C07K2319/30;;A61P35/00;;A61K38/00;;C07K14/475;;C07K2319/30;;A61K48/00;;C12N15/11;;A61K39/001109;;C07K2317/24;;C12N15/1136;;A61K35/42;;C07K14/71,A61K38/18;;A61K39/395;;A61P35/00;;C07K14/515,,0,0,,,,ACTIVE
32,EP,B1,EP 3461912 B1,056-715-370-354-14X,2022-07-13,2022,EP 18199345 A,2010-09-09,US 24101409 P;;EP 10816090 A;;US 2010/0048293 W,2009-09-09,USE OF MICROVESICLES IN ANALYZING NUCLEIC ACID PROFILES,,MASSACHUSETTS GEN HOSPITAL,NOERHOLM MIKKEL;;SKOG JOHAN KARL OLOV;;BREAKEFIELD XANDRA O;;CARTER BOB,,https://lens.org/056-715-370-354-14X,Granted Patent,yes,4,0,11,11,0,G01N33/57407;;C12Q1/6806;;C12Q2600/158;;C12Q1/6886;;C12Q2600/158;;C12Q1/6806;;G01N33/57407;;C12Q1/6886,C12Q1/6806;;C12Q1/6886;;G01N33/48,,3,0,,,"SKOG JOHAN ET AL: ""Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers"", NATURE CELL BIOLOGY, MACMILLAN MAGAZINES LTD, vol. 10, no. 12, 1 December 2008 (2008-12-01), pages 1470-1476, XP002526160, ISSN: 1465-7392, DOI: 10.1038/NCB1800 [retrieved on 2008-11-16];;MIRANDA K C ET AL: ""Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease"", KIDNEY INTERNATIONAL, NATURE PUBLISHING GROUP, NEW YORK, vol. 78, no. 2, 1 July 2010 (2010-07-01), pages 191-199, XP002686137, ISSN: 1523-1755, DOI: 10.1038/KI.2010.106 [retrieved on 2010-04-28];;MIKKEL NOERHOLM ET AL: ""RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls"", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 17 January 2012 (2012-01-17), page 22, XP021118100, ISSN: 1471-2407, DOI: 10.1186/1471-2407-12-22",ACTIVE
33,US,A1,US 2020/0017920 A1,153-708-379-592-794,2020-01-16,2020,US 201916520130 A,2019-07-23,US 201916520130 A;;US 201514792212 A;;US 201213395284 A;;US 2010/0048293 W;;US 24101409 P,2009-09-09,USE OF MICROVESICLES IN ANALYZING NUCLEIC ACID PROFILES,"The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The determination of a biological condition may aid, for example, the diagnosis, prognosis, and therapy treatment selection for disease in a subject.",MASSACHUSETTS GEN HOSPITAL,NOERHOLM MIKKEL;;SKOG JOHAN KARL OLOV;;BREAKEFIELD XANDRA O;;CARTER BOB,THE GENERAL HOSPITAL CORPORATION (2012-05-25),https://lens.org/153-708-379-592-794,Patent Application,yes,0,0,11,11,0,G01N33/57407;;C12Q1/6806;;C12Q2600/158;;C12Q1/6886;;C12Q2600/158;;C12Q1/6806;;G01N33/57407;;C12Q1/6886,C12Q1/6886;;C12Q1/6806;;G01N33/574,,0,0,,,,ACTIVE
34,US,B2,US 10259862 B2,191-631-286-632-262,2019-04-16,2019,US 201715619917 A,2017-06-12,US 201715619917 A;;US 201414239687 A;;US 2012/0051412 W;;US 201161525278 P,2011-08-19,VEGF-binding protein for blockade of angiogenesis,"Provided are chimeric VEGF-binding proteins and nucleic acids (e.g., a vector) encoding chimeric VEGF-binding proteins, methods and host cells for producing these proteins and nucleic acids, and pharmaceutical compositions containing these proteins and nucleic acids. Also provided are methods of treating an angiogenic disease or disorder that include administering at least one of the chimeric VEGF-binding proteins or at least one of the nucleic acids (e.g., a vector) encoding a chimeric VEGF-binding protein.",CHILDRENS MEDICAL CENTER;;MASSACHUSETTS GEN HOSPITAL;;HARVARD COLLEGE,CARTER BOB;;LEE JENG-SHIN;;BULLAIN SZOFIA S;;MULLIGAN RICHARD C,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2014-02-15);;CHILDREN'S MEDICAL CENTER CORPORATION (2014-03-17);;THE GENERAL HOSPITAL CORPORATION (2014-03-25),https://lens.org/191-631-286-632-262,Granted Patent,yes,6,4,12,12,8,A61K38/00;;C07K14/475;;C07K2319/30;;A61P35/00;;A61K38/00;;C07K14/475;;C07K2319/30;;A61K48/00;;C12N15/11;;A61K39/001109;;C07K2317/24;;C12N15/1136;;A61K35/42;;C07K14/71,A61K38/00;;A61K38/16;;C07K14/00;;C07K14/475;;C07K14/71;;C07K19/00,,38,32,082-030-421-328-058;;008-143-527-277-233;;127-861-233-397-521;;015-680-387-839-237;;020-413-940-276-383;;044-135-659-393-274;;047-244-419-712-119;;022-843-989-846-490;;007-162-670-158-912;;085-051-035-249-265;;046-566-185-640-006;;020-714-847-964-914;;109-974-585-608-837;;008-498-336-394-659;;090-460-004-972-58X;;129-244-884-577-63X;;079-725-496-815-734;;053-453-087-648-015;;085-528-415-223-353;;073-614-865-710-154;;140-562-976-790-990;;059-047-140-038-449;;013-094-728-517-718;;051-389-130-698-194;;042-579-115-970-808;;022-126-576-934-730;;042-838-870-694-53X;;076-649-834-185-907;;060-957-594-177-919;;045-708-790-881-865;;032-437-527-638-24X;;002-262-303-908-829,10.3892/ijo.27.2.563;;16010440;;15757482;;10.1517/14728222.9.1.63;;11177544;;10.1089/104303401450988;;10.1158/1535-7163.mct-10-0813;;21252283;;9099677;;10.1074/jbc.272.16.10382;;10.1073/pnas.91.6.2076;;pmc43312;;8134351;;10.1161/01.res.0000132745.76882.70;;15155527;;10.1006/bbrc.1997.6156;;9070853;;10688913;;pmc16256;;10.1073/pnas.050581197;;10.1073/pnas.97.7.3428;;10.1002/j.1460-2075.1996.tb00872.x;;pmc452229;;8890165;;14965381;;10.1089/10430340460732490;;pmc1850001;;10.1016/s0002-9440(10)65280-7;;10027392;;10.1093/humupd/4.5.736;;10027628;;12177445;;10.1073/pnas.172398299;;pmc123267;;15175435;;10.1056/nejmoa032691;;10500044;;10.1161/01.cir.100.13.1423;;11606410;;10.1136/ard.59.suppl_1.i65;;pmc1766630;;11053092;;10.1073/pnas.081615298;;11274374;;pmc31881;;10.1097/00001756-200107030-00037;;11435930;;10.1186/ar575;;12110126;;pmc3240151;;10036766;;10.1016/s0168-1656(98)00134-5;;10.1016/s0021-9258(18)47298-5;;7929268;;10.1038/gt.2008.115;;18633446;;11578098;;10.1211/0022357011776603;;16821113;;10.1007/s10456-006-9030-4;;9445046;;10.1128/jvi.72.2.1438-1445.1998;;pmc124624;;10.1038/8470;;10229239;;10.1158/0008-5472.can-04-1833;;15867360;;9393862;;10.1016/s0092-8674(00)80456-0;;10.1152/ajpheart.00616.2005;;16172161;;10.1038/nm1428;;16799557,"Benouchan et al. (2005). Anti-angiogenic strategies for cancer therapy (review). Intl. J. Oncology. 27:563-571.;;Shumizu et al. (2005). Antineovascular therapy, a novel antiangiogenic approach. Expert. Opin. Ther. Targets. 9(1):63-76.;;Auricchio et al., “Isolation of Highly Infectious and Pure Adeno-Associated Virus Type 2 vectors with a Single-Step Gravity-Flow Column,” Human Gene Therapy 12:71-76 (2001).;;Bagley et al., “sFLT01: A Novel Fusion Protein with Antiangiogenic Activity,” Molecular Cancer Therapeutics 10:404-415 (2011).;;Barleon et. al., “Protein Chemistyr and Structure: Mapping of the Sites for Ligand Binding and Receptor Dimerization at the Extracellular Domain of the Vascular Endothelial Growth Factor Receptor FLT-1,” J. Biol. Chern. 272:10382-10388 (1997).;;Bobo et al., “Convection-enhanced delivery of macromolecules in the brain,” Proc. Natl. Acad. Sci. U.S.A. 91(6):2076-2080 (1994).;;Bråkenhielm et al., “Angiogenesis Inhibitor, TNP-470, Prevents Diet-Induced and Genetic Obesity in Mice,” Circulation Research 94:1579-1588 (2004).;;Cunningham et al., “Identification of the Extracellular Domains of Flt-1 That Mediate Ligand Interactions,” Biochem. Biophys. Res. Comm. 231:596-599 (1997).;;Davidson et al., “Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system,” Proc. Natl. Acad. Sci. U.S.A. 97(7):3428-3432 (2000).;;Davis-Smyth et. al., “The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade,” EMBO J. 15:4919-4927 (1996).;;Flotte et al., “Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAt-deficient adults,” Human Gene Therapy 15:93-128 (2004).;;Grammas et al., “Microvessels from Alzheimer's Disease Brains Kill Neurons in Vitro,” Am. J. Pathol. 154(2):337-342 (1999).;;Healy et al., “Angiogenesis: a new theory for endometriosis,” Human Reproduction Update 4:736-740 (1998).;;Holash et al., “VEGF-Trap: A VEGF blocker with potent antitumor effects,” Proc. Natl. Acad. Sci. U.S.A. 99:11393-11398 (2002).;;Hurwitz et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” New Engl. J. Med. 350:2335-2342 (2004).;;International Preliminary Report on Patentability issued in PCT/US2012/051412 dated Feb. 25, 2014 (6 pages).;;International Search Report and Written Opinion issued in PCT/US2012/51412 dated Dec. 7, 2012 (8 pages).;;Iruela-Arispe et al., “Inhibition of Angiogenesis by Thrombospondin-1 Is Mediated by 2 Independent Regions Within the Type 1 Repeats,” Circulation 100:1423-1431 (1999).;;Kisker et al., “Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model,” Cancer Research 61:7669-7674 (2001).;;Koch, A. E., “The role of angiogenesis in rheumatoid arthritis: recent developments,” Ann. Rheum. Dis. 59(Suppl. 1):i65-i71 (2000).;;Kuo et al., “Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer,” Proc. Natl. Acad. Sci. U.S.A. 98:4605-4610 (2001).;;Nguyen et al., “Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain,” Neuroreport 12(9):1961-1964 (2001).;;Paleolog, E. M., “Angiogenesis in rheumatoid arthritis,” Arthritis Res. 4(Suppl. 3), S81-S90 (2002).;;Palu et al., “In pursuit of new developments for gene therapy,” Journal of Biotechnology. 68:1-13 (1999).;;Park et al., “Placenta Growth Factor: Potentiation of Vascular Endothelial Growth Factor Bioactivity, In Vitro and In Vivo, and High Affinity Bidning to Flt-1 But Not To Flk-1KDR,” J. Biol. Chem. 269:25646-25654 (1994).;;Passini et al., “Intraventricular Brain Injection of Adeno-Associated Virus Type 1 (AAV1) in Neonatal Mice Results in Complementary Patterns of Neuronal Transduction to AAV2 and Total Long-Term Correction of Storage Lesions in the Brains of β-Glucuronidase-Deficient Mice,” J. Virol. 77(12):7034-7040 (2003).;;Pechan et al., “Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization,” Gene Therapy 16:10-16 (2009).;;Phillips, A.J., “The challenge of gene therapy and DNA delivery,” J. Pharm. Pharmacol. 53:1169-1174 (2001).;;Schultheiss et al., “In vivo characterization of endothelial cell activation in a transgenic mouse model of Alzheimer's disease,” Angiogenesis 9(2):59-65 (2006).;;Summerford and Samulski, “Membrain-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions,” J. Virol. 72:1438-1445 (1998).;;Summerford and Samulski, “Viral receptors and vector purification: New approaches for generating clinical-grade reagents,” Nat. Med. 5:587-588 (1999).;;Tjin Tham Sjin et al., “A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity,” Cancer Res. 65:3656-3663.;;Wiesmann et al., “Crystal Structure at 1.7 Å Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor,” Cell 91:695-704 (1997).;;Baffert et al., “Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling,” Am. J. Physiol. Heart Circ. Physiol. 290:H547-H559 (2006).;;Tam et al., “VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis,” Nature Med. 12(7):793-800 (2006).;;European Search Report issued in EP12826108.8 dated May 20, 2015 (4 pages).;;Communication issued in European Patent Appl. No. 12826108.8, mailed on Jun. 2, 2015 (5 pages).;;Communication issued in European Patent Appl. No. 12826108.8, mailed on Feb. 24, 2016 (4 pages).",ACTIVE
35,ES,T3,ES 2664224 T3,051-966-291-182-751,2018-04-18,2018,ES 12826108 T,2012-08-17,US 201161525278 P;;US 2012/0051412 W,2011-08-19,Proteína de unión a VEGF para el bloqueo de la angiogénesis,"Una proteína quimérica de unión a VEGF, que comprende una secuencia de aminoácidos de SEQ ID NO: 3.",CHILDRENS MEDICAL CENTER;;HARVARD COLLEGE;;MASSACHUSETTS GEN HOSPITAL,CARTER BOB;;LEE JENG-SHIN;;BULLAIN SZOFIA S;;MULLIGAN RICHARD C,,https://lens.org/051-966-291-182-751,Granted Patent,no,0,0,12,12,0,A61K38/00;;C07K14/475;;C07K2319/30;;A61P35/00;;A61K38/00;;C07K14/475;;C07K2319/30;;A61K48/00;;C12N15/11;;A61K39/001109;;C07K2317/24;;C12N15/1136;;A61K35/42;;C07K14/71,A61K38/18;;A61K39/395;;A61P35/00;;C07K14/515,,0,0,,,,ACTIVE
36,US,A1,US 2016/0002736 A1,028-645-115-499-257,2016-01-07,2016,US 201514792212 A,2015-07-06,US 201514792212 A;;US 201213395284 A;;US 2010/0048293 W;;US 24101409 P,2009-09-09,USE OF MICROVESICLES IN ANALYZING NUCLEIC ACID PROFILES,"The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The determination of a biological condition may aid, for example, the diagnosis, prognosis, and therapy treatment selection for disease in a subject.",GEN HOSPITAL CORP,NOERHOLM MIKKEL;;SKOG JOHAN KARL OLOV;;BREAKEFIELD XANDRA O;;CARTER BOB,THE GENERAL HOSPITAL CORPORATION (2012-05-25),https://lens.org/028-645-115-499-257,Patent Application,yes,0,3,11,11,0,G01N33/57407;;C12Q1/6806;;C12Q2600/158;;C12Q1/6886;;C12Q2600/158;;C12Q1/6806;;G01N33/57407;;C12Q1/6886,C12Q1/68,,0,0,,,,ACTIVE
37,WO,A1,WO 2011/031877 A1,076-280-747-644-645,2011-03-17,2011,US 2010/0048293 W,2010-09-09,US 24101409 P,2009-09-09,USE OF MICROVESICLES IN ANALYZING NUCLEIC ACID PROFILES,"The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The determination of a biological condition may aid, for example, the diagnosis, prognosis, and therapy treatment selection for a disease in a subject.",GEN HOSPITAL CORP;;NOERHOLM MIKKEL;;SKOG JOHAN KARL OLOV;;BREAKEFIELD XANDRA O;;CARTER BOB,NOERHOLM MIKKEL;;SKOG JOHAN KARL OLOV;;BREAKEFIELD XANDRA O;;CARTER BOB,,https://lens.org/076-280-747-644-645,Patent Application,yes,32,17,11,11,0,G01N33/57407;;C12Q1/6806;;C12Q2600/158;;C12Q1/6886;;C12Q2600/158;;C12Q1/6806;;G01N33/57407;;C12Q1/6886,G01N33/48,,42,39,096-297-459-857-191;;096-756-470-790-629;;091-106-410-640-235;;038-967-031-002-391;;006-635-819-665-420;;098-975-268-154-365;;074-448-800-565-123;;056-649-011-137-95X;;033-155-296-715-092;;117-777-238-559-353;;033-916-592-216-662;;011-332-943-473-533;;092-084-934-441-087;;037-047-957-053-389;;146-606-185-618-094;;068-716-621-588-961;;044-998-298-479-606;;029-238-328-272-724;;040-796-118-388-539;;109-340-557-373-319;;050-961-782-167-741;;014-524-302-477-134;;109-553-992-963-291;;007-668-424-494-396;;104-779-719-063-110;;014-252-478-665-343;;094-463-059-022-302;;089-155-244-656-088;;064-520-071-952-414;;140-591-885-755-375;;115-663-447-615-245;;084-525-238-501-841;;003-870-745-672-716;;081-905-315-069-593;;137-253-096-323-115;;046-201-607-879-85X;;043-885-019-636-545;;034-821-953-053-761;;008-453-634-162-718,7534908;;pmc306737;;10.1093/nar/23.4.675;;10.1038/ncb1725;;18425114;;10963673;;pmc27718;;10.1073/pnas.97.18.10101;;10.1007/s001099900038;;10606205;;10.1111/j.2517-6161.1995.tb02031.x;;10.1016/j.bios.2006.06.023;;16891110;;10.1152/ajprenal.00434.2006;;17229675;;pmc2271070;;pmc280436;;3260032;;10.1073/pnas.85.12.4397;;pmc1859890;;10.1073/pnas.0608651103;;17090687;;10.1093/bioinformatics/bti681;;16174683;;9843981;;10.1073/pnas.95.25.14863;;pmc24541;;10.1016/0092-8674(79)90200-9;;369706;;232212;;10.1016/0076-6879(79)68013-8;;10.1038/nbt1385;;18278033;;2308948;;10.1073/pnas.87.5.1874;;pmc53586;;10.1002/bies.950150707;;7691058;;pmc1253826;;16203992;;10.1073/pnas.0409904102;;10.1021/ac701688q;;18186614;;10.1016/s0140-6736(78)91629-x;;pmc393021;;281713;;10.1073/pnas.75.11.5631;;10.1038/sj.ki.5002486;;17700640;;pmc286648;;10.1073/pnas.86.4.1173;;2919166;;10.1126/science.3413476;;3413476;;10.1038/nm1708;;18408729;;17174896;;10.1016/j.cell.2006.10.037;;6655695;;10.1016/0022-2836(83)90094-3;;10.1038/ki.2010.106;;pmc4451567;;20428099;;10.1126/science.4071043;;4071043;;18097410;;10.1038/nature06385;;pmc3090667;;8278394;;pmc42947;;10.1073/pnas.91.1.360;;10.1073/pnas.86.8.2766;;2565038;;pmc286999;;pmc2192324;;10.1084/jem.183.3.1161;;8642258;;19011622;;pmc3423894;;10.1038/ncb1800;;16369550;;10.1038/nmeth842;;10.1016/j.ygyno.2008.04.033;;18589210;;pmc1894934;;10.1261/rna.575107;;17545563;;10.1126/science.270.5235.484;;7570003;;10.1016/j.humpath.2003.08.026;;14745734;;8472349;;0008472349;;10.1093/clinchem/39.4.561,"JOSEPH SAMBROOK, DAVID W. RUSSEL, AND JOE SAMBROOK,: ""Molecular Cloning: A Laboratory Manual, 3rd edition"", 15 January 2001, COLD SPRING HARBOR LABORATORY, ISBN: 0879695773;;""PCR Basics: From Background to Bench"", 15 October 2000, SPRINGER VERLAG, ISBN: 0387916008;;ABRAVAYA, K.; J.J. CARRINO; S. MULDOON; H.H. LEE: ""Detection of point mutations with a modified ligase chain reaction (Gap-LCR"", NUCLEIC ACIDS RES., vol. 23, 1995, pages 675 - 82, XP002210106;;AL-NEDAWI, K.; B. MEEHAN; J. MICALLEF; V. LHOTAK; L. MAY; A. GUHA; J. RAK: ""Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells"", NAT CELL BIOL., vol. 10, 2008, pages 619 - 24, XP002526161, DOI: doi:10.1038/ncb1725;;ALTER, O.; P.O. BROWN; D. BOTSTEIN: ""Singular value decomposition for genome-wide expression data processing and modeling"", PROC NATL ACAD SCI US A., vol. 97, 2000, pages 10101 - 6, XP002962133, DOI: doi:10.1073/pnas.97.18.10101;;BALZAR, M.; M.J. WINTER; C.J. DE BOER; S.V. LITVINOV: ""The biology of the 17-1A antigen (Ep-CAM"", JMOLMED, vol. 77, 1999, pages 699 - 712, XP000925817, DOI: doi:10.1007/s001099900038;;BENJAMINI, J.; Y. HOCHBERG: ""Controlling the false discovery rate: a practical and powerful approach to multiple testing"", J ROY STATIST SOC SER B (METHODOLOGICAL), vol. 57, 1995, pages 289 - 300;;BOSSI, A.; F. BONINI; A.P. TURNER; S.A. PILETSKY: ""Molecularly imprinted polymers for the recognition of proteins: the state of the art"", BIOSENS BIOELECTRON, vol. 22, 2007, pages 1131 - 7, XP005730920, DOI: doi:10.1016/j.bios.2006.06.023;;CHERUVANKY, A.; H. ZHOU; T. PISITKUN; J.B. KOPP; M.A. KNEPPER; P.S. YUEN; R.A. STAR: ""Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator"", AM JPHYSIOL RENAL PHYSIOL., vol. 292, 2007, pages F1657 - 61, XP002736097, DOI: doi:10.1152/ajprenal.00434.2006;;COTTON, R.G.; N.R. RODRIGUES; R.D. CAMPBELL: ""Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations"", PROC NATL ACAD SCI USA., vol. 85, 1988, pages 4397 - 401, XP002086182, DOI: doi:10.1073/pnas.85.12.4397;;CRISTOFANILLI, M.; J. MENDELSOHN: ""Circulating tumor cells in breast cancer: Advanced tools for ''tailored'' therapy?"", PROC NATL ACAD SCI USA., vol. 103, 2006, pages 17073 - 4;;DABNEY, A.R.: ""Classification of microarrays to nearest centroids"", BIOINFORMATICS, vol. 21, 2005, pages 4148 - 54;;EISEN, M.B.; P.T. SPELLMAN; P.O. BROWN; D. BOTSTEIN: ""Cluster analysis and display of genome-wide expression patterns"", PROC NATL ACAD SCI USA., vol. 95, 1998, pages 14863 - 8, XP002939285, DOI: doi:10.1073/pnas.95.25.14863;;FISCHER, S.G.; L.S. LERMAN: ""Length-independent separation of DNA restriction fragments in two-dimensional gel electrophoresis"", CELL, vol. 16, 1979, pages 191 - 200, XP023910996, DOI: doi:10.1016/0092-8674(79)90200-9;;FISCHER, S.G.; L.S. LERMAN: ""Two-dimensional electrophoretic separation of restriction enzyme fragments of DNA"", METHODS ENZYMOL., vol. 68, 1979, pages 183 - 91, XP009066767, DOI: doi:10.1016/0076-6879(79)68013-8;;GEISS, G.K.; R.E. BUMGARNER; B. BIRDITT; T. DAHL; N. DOWIDAR; D.L. DUNAWAY; H.P. FELL; S. FERREE; R.D. GEORGE; T. GROGAN: ""Direct multiplexed measurement of gene expression with color-coded probe pairs"", NAT BIOTECHNOL., vol. 26, 2008, pages 317 - 25, XP002505107, DOI: doi:10.1038/NBT1385;;GUATELLI, J.C.; K.M. WHITFIELD; D.Y. KWOH; K.J. BARRINGER; D.D. RICHMAN; T.R. GINGERAS: ""Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication"", PROC NATL ACAD SCI USA., vol. 87, 1990, pages 1874 - 8, XP000368702, DOI: doi:10.1073/pnas.87.5.1874;;HAHN, P.J.: ""Molecular biology of double-minute chromosomes"", BIOESSAYS, vol. 15, 1993, pages 477 - 84, XP002908185, DOI: doi:10.1002/bies.950150707;;HAKONARSON, H.; U.S. BJORNSDOTTIR; E. HALAPI; J. BRADFIELD; F. ZINK; M. MOUY; H. HELGADOTTIR; A.S. GUDMUNDSDOTTIR; H. ANDRASON; A.: ""Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients"", PROC NATL ACADSCI USA, vol. 102, 2005, pages 14789 - 94;;JOHNSON, S.; D. EVANS; S. LAURENSON; D. PAUL; A.G. DAVIES; P.K. FERRIGNO; C. WALTI: ""Surface-immobilized peptide aptamers as probe molecules for protein detection"", ANAL CHEM., vol. 80, 2008, pages 978 - 83, XP002536007, DOI: doi:10.1021/AC701688Q;;KAN, Y.W.; A.M. DOZY: ""Antenatal diagnosis of sickle-cell anaemia by D.N.A. analysis of amniotic-fluid cells"", LANCET, vol. 2, 1978, pages 910 - 2;;KAN, Y.W.; A.M. DOZY: ""Polymorphism of DNA sequence adjacent to human beta-globin structural gene: relationship to sickle mutation"", PROC NATL ACAD SCI USA., vol. 75, 1978, pages 5631 - 5, XP009021082, DOI: doi:10.1073/pnas.75.11.5631;;KELLER, S.; C. RUPP; A. STOECK; S. RUNZ; M. FOGEL; S. LUGERT; H.D. HAGER; M.S. ABDEL-BAKKY; P. GUTWEIN; P. ALTEVOGT: ""CD24 is a marker of exosomes secreted into urine and amniotic fluid"", KIDNEY INT., vol. 72, 2007, pages 1095 - 102, XP009106564, DOI: doi:10.1038/sj.ki.5002486;;KWOH, D.Y.; G.R. DAVIS; K.M. WHITFIELD; H.L. CHAPPELLE; L.J. DIMICHELE; T.R. GINGERAS: ""Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format"", PROC NATL ACAD SCI USA., vol. 86, 1989, pages 1173 - 7, XP000368676, DOI: doi:10.1073/pnas.86.4.1173;;LANDEGREN, U.; R. KAISER; J. SANDERS; L. HOOD: ""A ligase-mediated gene detection technique"", SCIENCE, vol. 241, 1988, pages 1077 - 80, XP000676556, DOI: doi:10.1126/science.3413476;;LI, J.; L. WANG; H. MAMON; M.H. KULKE; R. BERBECO; G.M. MAKRIGIORGOS: ""Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing"", NAT MED., vol. 14, 2008, pages 579 - 84, XP055001155, DOI: doi:10.1038/nm1708;;LIU, Q.; J.C. GREIMANN; C.D. LIMA: ""Reconstitution, activities, and structure of the eukaryotic RNA exosome"", CELL, vol. 127, 2006, pages 1223 - 37;;MIELE, E.A.; D.R. MILLS; F.R. KRAMER: ""Autocatalytic replication of a recombinant RNA"", JMOL BIOL, vol. 171, 1983, pages 281 - 95, XP024020805, DOI: doi:10.1016/0022-2836(83)90094-3;;MIRANDA, K.C.; D.T. BOND; M. MCKEE; J. SKOG; T.G. PAUNESCU; N. DA SILVA; D. BROWN; L.M. RUSSO: ""Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease"", KIDNEY INT., vol. 78, 2010, pages 191 - 9, XP055107901, DOI: doi:10.1038/ki.2010.106;;MYERS, R.M.; Z. LARIN; T. MANIATIS: ""Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes"", SCIENCE, vol. 230, 1985, pages 1242 - 6, XP001022204, DOI: doi:10.1126/science.4071043;;NAGRATH, S.; L.V. SEQUIST; S. MAHESWARAN; D.W. BELL; D. IRIMIA; L. ULKUS; M.R. SMITH; E.L. KWAK; S. DIGUMARTHY; A. MUZIKANSKY: ""Isolation of rare circulating tumour cells in cancer patients by microchip technology"", NATURE, vol. 450, 2007, pages 1235 - 9, XP002681217;;NAKAZAWA, H.; D. ENGLISH; P.L. RANDELL; K. NAKAZAWA; N. MARTE; B.K. ARMSTRONG; H. YAMASAKI: ""UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement"", PROC NATL ACAD SCI USA., vol. 91, 1994, pages 360 - 4;;ORITA, M.; H. IWAHANA; H. KANAZAWA; K. HAYASHI; T. SEKIYA: ""Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms"", PROC NATL ACAD SCI USA., vol. 86, 1989, pages 2766 - 70, XP000310584;;RAPOSO, G.; H.W. NIJMAN; W. STOORVOGEL; R. LIEJENDEKKER; C.V. HARDING; C.J. MELIEF; H.J. GEUZE: ""B lymphocytes secrete antigen-presenting vesicles"", J EXP MED., vol. 183, 1996, pages 1161 - 72, XP002060486, DOI: doi:10.1084/jem.183.3.1161;;SKOG, J.; T. WURDINGER; S. VAN RIJN; D.H. MEIJER; L. GAINCHE; M. SENA-ESTEVES; W.T. CURRY, JR.; B.S. CARTER; A.M. KRICHEVSKY; X.O.: ""Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers"", NAT CELL BIOL., vol. 10, 2008, pages 1470 - 6, XP002633335, DOI: doi:10.1038/ncb1800;;STEEMERS, F.J.; W. CHANG; G. LEE; D.L. BARKER; R. SHEN; K.L. GUNDERSON: ""Whole-genome genotyping with the single-base extension assay"", NAT METHODS., vol. 3, 2006, pages 31 - 3, XP009155366, DOI: doi:10.1038/nmeth842;;TAYLOR, D.D.; C. GERCEL-TAYLOR: ""MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer"", GYNECOL ONCOL, vol. 110, 2008, pages 13 - 21, XP022795052, DOI: doi:10.1016/j.ygyno.2008.04.033;;VAN DIJK, E.L.; G. SCHILDERS; G.J. PRUIJN: ""Human cell growth requires a functional cytoplasmic exosome, which is involved in various mRNA decay pathways"", RNA, vol. 13, 2007, pages 1027 - 35;;VELCULESCU, V.E.; L. ZHANG; B. VOGELSTEIN; K.W. KINZLER: ""Serial analysis of gene expression"", SCIENCE, vol. 270, 1995, pages 484 - 7, XP001024449, DOI: doi:10.1126/science.270.5235.484;;WENT, P.T.; A. LUGLI; S. MEIER; M. BUNDI; M. MIRLACHER; G. SAUTER; S. DIRNHOFER: ""Frequent EpCam protein expression in human carcinomas"", HUM PATHOL., vol. 35, 2004, pages 122 - 8, XP002592037, DOI: doi:10.1016/S0046-8177(03)00502-1;;ZWEIG, M.H.; G. CAMPBELL: ""Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine"", CLIN CHEM., vol. 39, 1993, pages 561 - 77, XP009041551;;See also references of EP 2475988A4",PENDING
38,EP,A1,EP 2475988 A1,142-690-634-997-827,2012-07-18,2012,EP 10816090 A,2010-09-09,US 24101409 P;;US 2010/0048293 W,2009-09-09,USE OF MICROVESICLES IN ANALYZING NUCLEIC ACID PROFILES,,GEN HOSPITAL CORP,NOERHOLM MIKKEL;;SKOG JOHAN KARL OLOV;;BREAKEFIELD XANDRA O;;CARTER BOB,,https://lens.org/142-690-634-997-827,Patent Application,yes,0,0,11,11,0,G01N33/57407;;C12Q1/6806;;C12Q2600/158;;C12Q1/6886;;C12Q2600/158;;C12Q1/6806;;G01N33/57407;;C12Q1/6886,C12Q1/68;;G01N33/48,,0,0,,,,ACTIVE
39,EP,A4,EP 2744508 A4,161-814-199-121-564,2015-06-17,2015,EP 12826108 A,2012-08-17,US 201161525278 P;;US 2012/0051412 W,2011-08-19,VEGF-BINDING PROTEIN FOR BLOCKADE OF ANGIOGENESIS,,CHILDRENS MEDICAL CENTER;;HARVARD COLLEGE;;GEN HOSPITAL CORP,CARTER BOB;;LEE JENG-SHIN;;BULLAIN SZOFIA S;;MULLIGAN RICHARD C,,https://lens.org/161-814-199-121-564,Search Report,no,1,0,12,12,0,A61K38/00;;C07K14/475;;C07K2319/30;;A61P35/00;;A61K38/00;;C07K14/475;;C07K2319/30;;A61K48/00;;C12N15/11;;A61K39/001109;;C07K2317/24;;C12N15/1136;;A61K35/42;;C07K14/71,A61K38/18;;A61K39/395;;A61P35/00;;C07K14/515,,4,3,008-498-336-394-659;;002-262-303-908-829;;032-437-527-638-24X,12177445;;10.1073/pnas.172398299;;pmc123267;;10.1038/nm1428;;16799557;;10.1152/ajpheart.00616.2005;;16172161,"HOLASH JOCELYN ET AL: ""VEGF-Trap: A VEGF blocker with potent antitumor effects"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 99, no. 17, 20 August 2002 (2002-08-20), pages 11393 - 11398, XP002300698, ISSN: 0027-8424, DOI: 10.1073/PNAS.172398299;;BETTY Y Y TAM ET AL: ""VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis"", NATURE MEDICINE, vol. 12, no. 7, 25 June 2006 (2006-06-25), pages 793 - 800, XP055188501, ISSN: 1078-8956, DOI: 10.1038/nm1428;;F. BAFFERT: ""Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling"", AJP: HEART AND CIRCULATORY PHYSIOLOGY, vol. 290, no. 2, 7 October 2005 (2005-10-07), pages H547 - H559, XP055188503, ISSN: 0363-6135, DOI: 10.1152/ajpheart.00616.2005;;See also references of WO 2013028541A1",ACTIVE
40,AU,A1,AU 2003/232075 A1,034-896-991-366-079,2003-11-11,2003,AU 2003/232075 A,2003-05-07,US 37870602 P;;US 0314343 W,2002-05-07,MODIFIED T LYMPHOCYTES AND USES THEREFOR,,CHILDRENS MEDICAL CENTER,GHOGAWALA ZOHER;;CARTER BOB S;;MULLIGAN RICHARD C;;NIEDERMAN THOMAS M J,,https://lens.org/034-896-991-366-079,Patent Application,no,0,0,5,5,0,A61K39/0005;;A61K39/0005;;A61K2039/5156;;A61K2039/5156;;A61K2039/5158;;A61K2039/5158;;C12N15/86;;C12N15/86;;C07K14/7051;;C07K14/7051;;C12N2740/10043;;C12N2740/10043;;G01N33/505;;G01N33/505;;G01N33/6893;;G01N33/6893,A61K39/00;;C07K14/725;;C12N15/867;;G01N33/50;;G01N33/68,,0,0,,,,DISCONTINUED
41,US,A,US 6003658 A,136-853-850-920-097,1999-12-21,1999,US 45625195 A,1995-05-31,US 45625195 A;;US 34926894 A,1994-12-05,Telescoping rigid frame and scissor conveyor with suspension,"Telescoping rigid frame/scissor conveyors with suspension structures to accommodate less than totally flat surfaces, and for easy and ergonomic repositioning. Such conveyors are formed of a plurality of telescoping frame segments which may be positioned at any number of desired nested/unnested configurations. The frame segments bear a lazy tong or scissors conveyor structure which assures uniform roller spacing, and rollers positioned at one height along the conveyor rather than at different heights for each frame segment. The conveyors are adapted to bear greater weight than conventional lazy tongs conveyors, but contain suspension systems in order to conform to irregularities in factory and warehouse floors and slabs and for easy movement. The suspension systems may include motorized drive units, swivel mounted roller units, jacking roller units and more conventional rigid legs that contain springs or other suspension members to distribute the loads of and borne by the conveyors evenly and efficiently, and to allow the conveyors to positioned, expanded and retracted easily and efficiently.",NORTHSTAR IND INC,BEST JOHN W;;FLIPPO BOB K;;WALKER JAMES D;;CARTER GARY D,NORTHSTAR INDUSTRIES INC (1995-07-17);;FMH CONVEYORS LLC (2012-04-02),https://lens.org/136-853-850-920-097,Granted Patent,yes,13,38,2,2,0,B65G13/12;;B65G13/12;;B65G21/14;;B65G21/14;;B65G41/008;;B65G41/008,B65G13/12;;B65G21/14;;B65G41/00,198/588;;X193 35 TE,0,0,,,,EXPIRED
42,WO,A3,WO 2003/095663 A3,160-402-718-978-563,2004-08-19,2004,US 0314343 W,2003-05-07,US 37870602 P,2002-05-07,MODIFIED T LYMPHOCYTES AND USES THEREFOR,Modified T lymphocytes that express a chimeric T cell receptor reactive with two or more different cell surface angiogenic marker are disclosed. The modified T lymphocytes are useful in methods in controlling angiogenesis and in therapeutic methods in controlling tumor growth.,CHILDRENS MEDICAL CENTER;;GEN HOSPITAL CORP;;NIEDERMAN THOMAS M J;;GHOGAWALA ZOHER;;CARTER BOB S;;MULLIGAN RICHARD C,NIEDERMAN THOMAS M J;;GHOGAWALA ZOHER;;CARTER BOB S;;MULLIGAN RICHARD C,,https://lens.org/160-402-718-978-563,Search Report,yes,1,0,5,5,0,A61K39/0005;;A61K39/0005;;A61K2039/5156;;A61K2039/5156;;A61K2039/5158;;A61K2039/5158;;C12N15/86;;C12N15/86;;C07K14/7051;;C07K14/7051;;C12N2740/10043;;C12N2740/10043;;G01N33/505;;G01N33/505;;G01N33/6893;;G01N33/6893,A61K39/00;;C07K14/725;;C12N15/867;;G01N33/50;;G01N33/68,,4,4,013-614-008-078-514;;085-528-415-223-353;;156-041-827-297-091;;009-279-071-005-342,pmc124519;;10.1073/pnas.092562399;;11997459;;10.1073/pnas.081615298;;11274374;;pmc31881;;7545086;;10.1089/10430340252809793;;11874628,"NIEDERMAN T.M.J. ET AL: ""Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors"", PNAS, vol. 99, 14 May 2002 (2002-05-14), pages 7009 - 7014, XP002971569;;KUO K.J. ET AL: ""Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer"", PNAS, vol. 96, 2001, pages 4605 - 4610, XP002205625;;FREEMAN M.R. ET AL: ""Peripheral blood T lymphocytes and lymphocyes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis"", CANCER RESEARCH, vol. 55, 1995, pages 4140 - 4145;;JIN N. ET AL: ""Gene therapy of murine solid tumors wit T cells transduced with a retroviral vascular endothelial growth factor-immunotoxin target gene"", HUM GENE THER., vol. 13, 1 March 2002 (2002-03-01), pages 497 - 508, XP002978072",PENDING
43,WO,A2,WO 2003/095663 A2,086-516-559-651-873,2003-11-20,2003,US 0314343 W,2003-05-07,US 37870602 P,2002-05-07,MODIFIED T LYMPHOCYTES AND USES THEREFOR,Modified T lymphocytes that express a chimeric T cell receptor reactive with two or more different cell surface angiogenic marker are disclosed. The modified T lymphocytes are useful in methods in controlling angiogenesis and in therapeutic methods in controlling tumor growth.,CHILDRENS MEDICAL CENTER;;GEN HOSPITAL CORP;;NIEDERMAN THOMAS M J;;GHOGAWALA ZOHER;;CARTER BOB S;;MULLIGAN RICHARD C,NIEDERMAN THOMAS M J;;GHOGAWALA ZOHER;;CARTER BOB S;;MULLIGAN RICHARD C,,https://lens.org/086-516-559-651-873,Patent Application,yes,0,0,5,5,0,A61K39/0005;;A61K39/0005;;A61K2039/5156;;A61K2039/5156;;A61K2039/5158;;A61K2039/5158;;C12N15/86;;C12N15/86;;C07K14/7051;;C07K14/7051;;C12N2740/10043;;C12N2740/10043;;G01N33/505;;G01N33/505;;G01N33/6893;;G01N33/6893,A61K39/00;;C07K14/725;;C12N15/867;;G01N33/50;;G01N33/68,,0,0,,,,PENDING
44,US,A,US 5490592 A,028-938-330-765-991,1996-02-13,1996,US 34926894 A,1994-12-05,US 34926894 A,1994-12-05,Telescoping rigid frame and scissor conveyor,"Telescoping rigid frame/scissor conveyors. Such conveyors are formed of a plurality of telescoping frame segments which may be positioned at any number of desired nested/unnested configurations. The frame segments bear a lazy tong or scissors conveyor structure which assures uniform roller spacing, and rollers positioned at one height along the conveyor rather than at different heights for each frame segment. Counterintuitively, the increased structural complexity is more than outweighed by the benefits resulting from the uniformly positioned rollers of a uniform height, which are thus adapted to convey articles in a reliable and jam-free fashion unlike previous expandable rigid frame conveyors. Conveyors according to the present invention may contain automatic locks to prevent overextension, powered rollers and motive devices for automatic and reliable extension and retraction.",NORTHSTAR IND INC,BEST JOHN W;;FLIPPO BOB K;;WALKER JAMES D;;CARTER GARY D,NORTHSTAR INDUSTRIES INC (1994-12-02);;FMH CONVEYORS LLC (2012-04-02),https://lens.org/028-938-330-765-991,Granted Patent,yes,10,28,2,2,0,B65G13/12;;B65G13/12;;B65G21/14;;B65G21/14;;B65G41/008;;B65G41/008,B65G13/12;;B65G21/14;;B65G41/00,198/812,0,0,,,,EXPIRED
45,AU,A8,AU 2003/232075 A8,067-895-141-785-00X,2003-11-11,2003,AU 2003/232075 A,2003-05-07,US 37870602 P;;US 0314343 W,2002-05-07,Modified t lymphocytes and uses therefor,,GEN HOSPITAL CORP;;CHILDRENS MEDICAL CENTER,GHOGAWALA ZOHER;;CARTER BOB S;;MULLIGAN RICHARD C;;NIEDERMAN THOMAS M J,,https://lens.org/067-895-141-785-00X,Patent Application,no,0,0,5,5,0,A61K39/0005;;A61K39/0005;;A61K2039/5156;;A61K2039/5156;;A61K2039/5158;;A61K2039/5158;;C12N15/86;;C12N15/86;;C07K14/7051;;C07K14/7051;;C12N2740/10043;;C12N2740/10043;;G01N33/505;;G01N33/505;;G01N33/6893;;G01N33/6893,A61K39/00;;C07K14/725;;C12N15/867;;G01N33/50;;G01N33/68,,0,0,,,,DISCONTINUED
46,US,A,US 5632371 A,012-546-248-227-680,1997-05-27,1997,US 34954494 A,1994-12-05,US 34954494 A;;US 34146294 A;;US 2201293 A,1993-02-24,Expandable redundantly powered conveyors,"Expandable powered conveyors featuring a number of roller power motors located externally of the rollers. The conveyors include a pair of lazy tong trusses which may be supplemented, as desired, by telescoping rigid frames, leg structures or other structures. The motors are mounted between the trusses so that their drive pulleys are located substantially coaxial to the middle connection points of the scissor bars in the trusses and thus maintain a substantially constant distance from rollers connected to those scissor bars. Drive belts connect the motor drive pulleys to power such rollers. The conveyors also include a number of transfer pulleys which are also mounted substantially coaxial to corresponding middle connection points of the trusses. A single motor may thus power one or more rollers directly, and other rollers indirectly via motor drive belts and transfer drive belts. Use of a number of motors allows grouping of rollers into zones with the same advantages enjoyed in more expensive internally powered roller conveyors, but with greater reliability, ease of maintenance and savings and expense. Among those advantages are independent control of roller zones for accumulation of product and other purposes.",NORTHSTAR IND INC,BEST JOHN W;;FLIPPO BOB K;;WALKER JAMES D;;CARTER GARY D,NORTHSTAR INDUSTRIES INC (1994-12-02);;FMH CONVEYORS LLC (2012-04-02),https://lens.org/012-546-248-227-680,Granted Patent,yes,13,55,1,4,0,B65G13/07;;B65G13/12;;B65G2203/042;;B65G13/07;;B65G2203/042;;B65G13/12,B65G13/07;;B65G13/12,198/781.1;;X193 35 TE,0,0,,,,EXPIRED
47,US,A1,US 2011/0004342 A1,076-894-547-505-516,2011-01-06,2011,US 81371710 A,2010-06-11,US 81371710 A;;US 18622209 P,2009-06-11,Trainable Multi-Mode Floor Cleaning Device,"A floor cleaning device that is manually trainable for subsequent automatic operation. Prior to automatic operation, a user trains the cleaning device by manually manipulating the device through one or more desired cleaning paths. After training of the device, the device is configured to automatically initiate subsequent cleaning operations in accordance with the trained routine(s). Preferably, the training routine includes user specification of one of a number of cleaning modalities that are supported by the flooring cleaning device. In addition to automatic navigation, the floor cleaning device is configured to initiate a desired cleaning modality as a function of the device's position with respect to one or more of the trained routine(s).",JOHNSON & SON INC S C,KNOPOW JEREMY F;;CURTIS DAVID;;CARTER JR EVERETT F;;LARSON TED;;ALLEN BOB,S.C. JOHNSON & SON INC (2010-08-23);;TAYGETA SCIENTIFIC INC (2010-08-25);;THINKERBLOX LLC (2010-08-23);;OLOGIC INC (2010-09-03),https://lens.org/076-894-547-505-516,Patent Application,yes,20,56,2,2,0,G05D1/0221;;G05D1/0225;;G05D1/0242;;G05D1/0255;;G05D1/0272;;A47L5/28;;G05B15/02;;G05B2219/45098;;A47L2201/04;;G05D1/0221;;G05D1/0225;;G05D1/0242;;G05D1/0255;;G05D1/0272;;A47L5/28;;G05B15/02;;G05B2219/45098;;A47L2201/04,A47L11/00;;G05B19/04;;G05D1/00,700/253;;15/4;;701/25,0,0,,,,ACTIVE
48,US,B2,US 8774970 B2,004-770-047-583-079,2014-07-08,2014,US 81371710 A,2010-06-11,US 81371710 A;;US 18622209 P,2009-06-11,Trainable multi-mode floor cleaning device,"A floor cleaning device that is manually trainable for subsequent automatic operation. Prior to automatic operation, a user trains the cleaning device by manually manipulating the device through one or more desired cleaning paths. After training of the device, the device is configured to automatically initiate subsequent cleaning operations in accordance with the trained routine(s). Preferably, the training routine includes user specification of one of a number of cleaning modalities that are supported by the flooring cleaning device. In addition to automatic navigation, the floor cleaning device is configured to initiate a desired cleaning modality as a function of the device's position with respect to one or more of the trained routine(s).",KNOPOW JEREMY F;;CURTIS DAVID;;CARTER JR EVERETT F;;LARSON TED;;ALLEN BOB;;JOHNSON & SON INC S C,KNOPOW JEREMY F;;CURTIS DAVID;;CARTER JR EVERETT F;;LARSON TED;;ALLEN BOB,S.C. JOHNSON & SON INC (2010-08-23);;TAYGETA SCIENTIFIC INC (2010-08-25);;THINKERBLOX LLC (2010-08-23);;OLOGIC INC (2010-09-03),https://lens.org/004-770-047-583-079,Granted Patent,yes,119,58,2,2,0,G05D1/0221;;G05D1/0225;;G05D1/0242;;G05D1/0255;;G05D1/0272;;A47L5/28;;G05B15/02;;G05B2219/45098;;A47L2201/04;;G05D1/0221;;G05D1/0225;;G05D1/0242;;G05D1/0255;;G05D1/0272;;A47L5/28;;G05B15/02;;G05B2219/45098;;A47L2201/04,G05B19/18;;A47L5/28;;G05B15/02;;G05D1/02,700/253;;700/245;;701/1;;15/42;;15/83;;15/98;;15/319;;15/320;;15/325;;15/331;;15/339;;15/353;;15/385;;340/540;;422/5;;55/345,3,1,012-238-227-985-840,10.1007/978-3-540-30473-9_1,"Svetlana Domnitecheva: ""Smart Vacuum Cleaner-An Autonomous Location-Aware Cleaning Device"" International Conference on Ubiquitous Computing (Online) Sep. 10, 2004 Nottingham, England Retrieved from the Internet: URL:http://ubicomp.org/ubicomp2004/adjunct/posters/domnitch.pdf.;;Jurgen Bohn and Friedemann Mattern: ""Super-distributed RFID Tag Infrastructures"" Second European Symposium, EUSAI 2004 (Online) Nov. 1, 2004 Eindhoven, The Netherlands Retrieved from the Internet: URL :http//www.springerlink.com/content/lrqp441x6mcf3ktm/fulltext.pdf.;;International Search Report Opinion of PCT/US2006/025037.",ACTIVE
49,US,A1,US 2005/0000065 A1,112-062-664-378-837,2005-01-06,2005,US 61184403 A,2003-07-01,US 61184403 A,2003-07-01,Process for attachment and/or disengagement of components,"Processes for providing rapid release of a hook and loop type releasable fastener system comprise preconditioning the releasable fastener system to effect rapid release. In this manner, minimal energy and time is required for disengagement of the releasable fastener system.",BROWNE ALAN LAMPE;;JOHNSON NANCY L.;;POWELL BOB ROSS;;BARVOSA-CARTER WILLIAM;;MOMODA LESLIE A.;;STANFORD THOMAS B.,BROWNE ALAN LAMPE;;JOHNSON NANCY L;;POWELL BOB ROSS;;BARVOSA-CARTER WILLIAM;;MOMODA LESLIE A;;STANFORD THOMAS B,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2005-01-19);;GENERAL MOTORS CORPORATION (2003-07-24),https://lens.org/112-062-664-378-837,Patent Application,yes,13,12,2,2,0,A44B18/0096;;C08L2201/12;;Y10T24/2758;;Y10T24/27;;Y10T29/49821;;Y10T24/2758;;Y10T24/27;;Y10T29/49821;;A44B18/0096;;C08L2201/12,A44B18/00,24/442,0,0,,,,EXPIRED
50,US,A1,US 2004/0074062 A1,034-626-816-538-101,2004-04-22,2004,US 30537502 A,2002-11-26,US 30537502 A;;US 27369102 A,2002-10-19,Releasable fastener system,"
   A releasable fastener system comprises a loop portion and a hook portion. The loop portion includes a support and a loop material disposed on one side thereof. The hook portion generally includes a support and a plurality of closely spaced upstanding hook elements extending from one side thereof, wherein the plurality of hook elements comprises or incorporates a shape memory alloy fiber. When the hook portion and loop portion are pressed together they interlock to form a releasable engagement. The resulting joint created by the engagement is relatively resistant to shear and pull forces and weak in peel strength forces. Introducing a thermal activation signal to the plurality of hook elements causes a change in shape orientation, flexural modulus property, or a combination thereof that effectively reduces the shear and/or pull off forces in the releasable engagement. In this manner, disengagement of the releasable fastener system provides separation of the hook portion from the loop portion under controlled conditions. Also disclosed herein are processes for operating the releasable fastener system. 
",STANFORD THOMAS B.;;BROWNE ALAN L.;;JOHNSON NANCY L.;;MOMODA LESLIE A.;;BARVOSA-CARTER WILLIAM;;POWELL BOB R.,STANFORD THOMAS B;;BROWNE ALAN L;;JOHNSON NANCY L;;MOMODA LESLIE A;;BARVOSA-CARTER WILLIAM;;POWELL BOB R,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2005-01-19);;GENERAL MOTORS CORPORATION (2003-01-30),https://lens.org/034-626-816-538-101,Patent Application,yes,96,36,6,6,0,A41D2300/326;;A44B18/0003;;A44B18/0096;;A44D2203/00;;C08L2201/12;;F16B5/07;;F16F2224/045;;Y10T24/27;;Y10T428/24017;;Y10T24/2783;;F16B2200/83;;F16B2200/81;;F16B2200/77;;Y10T24/27;;Y10T428/24017;;Y10T24/2783;;A41D2300/326;;A44B18/0003;;A44B18/0096;;F16B5/07;;F16F2224/045;;A44D2203/00;;C08L2201/12;;F16B2200/77;;F16B2200/81;;F16B2200/83,A44B18/00;;A44B99/00;;B64C33/02;;F16B1/00;;F16B5/07;;H02N2/00,24/442,0,0,,,,EXPIRED
51,WO,A1,WO 2009/129078 A1,017-742-309-619-291,2009-10-22,2009,US 2009/0039608 W,2009-04-06,US 10375508 A,2008-04-16,METHOD OF DIE CASTING AN ALUMINUM ALLOY ARTICLE USING SACRIFICIAL SLEEVE,"Some die cast aluminum alloy articles have internal cylindrical surfaces such as the round internal cylinder surfaces of a cylinder block for an internal combustion engine. During casting solidification molten aluminum alloys shrink against the metallic permanent mold tools used to mold and define such internal surfaces, and tend to stick to the tool surfaces making it difficult to remove the casting. The tendency of some aluminum casting alloys to solder to the tool can further intensify sticking, hi this invention, an aluminum alloy sleeve is placed on and over the tool surface before casting and the sleeve isolates the tool from the molten aluminum. The sleeve becomes bonded to the casting and facilitates removal of the casting from the tool. The sleeve may be (and preferably is) fully machined from the internal casting surface. The sleeve may be of the same composition as the casting, in which case handling and recycling of machining chips would be facilitated. The practice of the invention is also applicable to die casting of magnesium alloys using magnesium sacrificial sleeves.",GM GLOBAL TECH OPERATIONS INC,SHIN JONGCHEOL;;PARK JONGWON B;;HWANG INWOOK;;POWELL BOB R;;PERRY THOMAS;;SACHDEV ANIL K;;CARTER JON T,,https://lens.org/017-742-309-619-291,Patent Application,yes,3,0,7,7,0,B22D15/02;;B22D15/02;;B22D19/0009;;B22D19/0009;;B22D21/04;;B22D21/04,B22D17/20;;B22D15/02;;B22D21/04,,0,0,,,,PENDING
52,US,B2,US 6920675 B2,070-791-661-784-934,2005-07-26,2005,US 61184403 A,2003-07-01,US 61184403 A,2003-07-01,Process for attachment and/or disengagement of components,"Processes for providing rapid release of a hook and loop type releasable fastener system comprise preconditioning the releasable fastener system to effect rapid release. In this manner, minimal energy and time is required for disengagement of the releasable fastener system.",GEN MOTORS CORP,BROWNE ALAN LAMPE;;JOHNSON NANCY L;;POWELL JR BOB ROSS;;BARVOSA-CARTER WILLIAM;;MOMODA LESLIE A;;STANFORD THOMAS B,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2005-01-19);;GENERAL MOTORS CORPORATION (2003-07-24),https://lens.org/070-791-661-784-934,Granted Patent,yes,21,17,2,2,0,A44B18/0096;;C08L2201/12;;Y10T24/2758;;Y10T24/27;;Y10T29/49821;;Y10T24/2758;;Y10T24/27;;Y10T29/49821;;A44B18/0096;;C08L2201/12,A44B18/00,29/426.4;;24/448,0,0,,,,EXPIRED
53,EP,A2,EP 1424023 A2,043-535-846-631-342,2004-06-02,2004,EP 03026259 A,2003-11-14,US 30537502 A,2002-11-26,Releasable fastener system,"A releasable fastener system (10) comprises a loop portion (12) and a hook portion (14). The loop portion (12) includes a support (16) and a loop material (18) disposed on one side thereof. The hook portion (14) generally includes a support (20) and a plurality of closely spaced upstanding hook elements (22) extending from one side thereof, wherein the plurality of hook elements (22) comprises or incorporates a shape memory alloy fiber. When the hook portion (14) and loop portion (12) are pressed together they interlock to form a releasable engagement. The resulting joint created by the engagement is relatively resistant to shear and pull forces and weak in peel strength forces. Introducing a thermal activation signal (24) to the plurality of hook elements (22) causes a change in shape orientation, flexural modulus property, or a combination thereof that effectively reduces the shear and/or pull off forces in the releasable engagement. In this manner, disengagement of the releasable fastener system provides separation of the hook portion from the loop portion under controlled conditions. Also disclosed herein are processes for operating the releasable fastener system.",GEN MOTORS CORP,STANFORD THOMAS B JR;;BROWNE ALAN L;;JOHNSON NANCY L;;MOMODA LESLIE A;;BARVOSA-CARTER WILLIAM;;POWELL BOB R JR,,https://lens.org/043-535-846-631-342,Patent Application,yes,0,2,6,6,0,A41D2300/326;;A44B18/0003;;A44B18/0096;;A44D2203/00;;C08L2201/12;;F16B5/07;;F16F2224/045;;Y10T24/27;;Y10T428/24017;;Y10T24/2783;;F16B2200/83;;F16B2200/81;;F16B2200/77;;Y10T24/27;;Y10T428/24017;;Y10T24/2783;;A41D2300/326;;A44B18/0003;;A44B18/0096;;F16B5/07;;F16F2224/045;;A44D2203/00;;C08L2201/12;;F16B2200/77;;F16B2200/81;;F16B2200/83,A44B18/00;;A44B99/00;;B64C33/02;;F16B1/00;;F16B5/07;;H02N2/00,,0,0,,,,EXPIRED
54,CN,A,CN 102006951 A,083-830-750-824-134,2011-04-06,2011,CN 200980113503 A,2009-04-06,US 2009/0039608 W;;US 10375508 A,2008-04-16,Method of die casting an aluminum alloy article using sacrificial sleeve,"Some die cast aluminum alloy articles have internal cylindrical surfaces such as the round internal cylinder surfaces of a cylinder block for an internal combustion engine. During casting solidification molten aluminum alloys shrink against the metallic permanent mold tools used to mold and define such internal surfaces, and tend to stick to the tool surfaces making it difficult to remove the casting. The tendency of some aluminum casting alloys to solder to the tool can further intensify sticking, hi this invention, an aluminum alloy sleeve is placed on and over the tool surface before casting and the sleeve isolates the tool from the molten aluminum. The sleeve becomes bonded to the casting and facilitates removal of the casting from the tool. The sleeve may be (and preferably is) fullymachined from the internal casting surface. The sleeve may be of the same composition as the casting, in which case handling and recycling of machining chips would be facilitated. The practice of theinvention is also applicable to die casting of magnesium alloys using magnesium sacrificial sleeves.",GM GLOBAL TECH OPERATIONS INC,JONGCHEOL SHIN;;PARK JONGWON B;;INWOOK HWANG;;POWELL BOB R JR;;PERRY THOMAS A;;SACHDEV ANIL K;;CARTER JON T,,https://lens.org/083-830-750-824-134,Patent Application,no,0,4,7,7,0,B22D15/02;;B22D15/02;;B22D19/0009;;B22D19/0009;;B22D21/04;;B22D21/04,B22D17/20;;B22D15/02;;B22D21/04,,0,0,,,,INACTIVE
55,EP,A3,EP 1424023 A3,089-465-984-537-184,2005-08-03,2005,EP 03026259 A,2003-11-14,US 30537502 A,2002-11-26,Releasable fastener system,"A releasable fastener system (10) comprises a loop portion (12) and a hook portion (14). The loop portion (12) includes a support (16) and a loop material (18) disposed on one side thereof. The hook portion (14) generally includes a support (20) and a plurality of closely spaced upstanding hook elements (22) extending from one side thereof, wherein the plurality of hook elements (22) comprises or incorporates a shape memory alloy fiber. When the hook portion (14) and loop portion (12) are pressed together they interlock to form a releasable engagement. The resulting joint created by the engagement is relatively resistant to shear and pull forces and weak in peel strength forces. Introducing a thermal activation signal (24) to the plurality of hook elements (22) causes a change in shape orientation, flexural modulus property, or a combination thereof that effectively reduces the shear and/or pull off forces in the releasable engagement. In this manner, disengagement of the releasable fastener system provides separation of the hook portion from the loop portion under controlled conditions. Also disclosed herein are processes for operating the releasable fastener system.",GEN MOTORS CORP,STANFORD THOMAS B JR;;BROWNE ALAN L;;JOHNSON NANCY L;;MOMODA LESLIE A;;BARVOSA-CARTER WILLIAM;;POWELL BOB R JR,,https://lens.org/089-465-984-537-184,Search Report,yes,4,0,6,6,0,A41D2300/326;;A44B18/0003;;A44B18/0096;;A44D2203/00;;C08L2201/12;;F16B5/07;;F16F2224/045;;Y10T24/27;;Y10T428/24017;;Y10T24/2783;;F16B2200/83;;F16B2200/81;;F16B2200/77;;Y10T24/27;;Y10T428/24017;;Y10T24/2783;;A41D2300/326;;A44B18/0003;;A44B18/0096;;F16B5/07;;F16F2224/045;;A44D2203/00;;C08L2201/12;;F16B2200/77;;F16B2200/81;;F16B2200/83,A44B18/00;;A44B99/00;;B64C33/02;;F16B1/00;;F16B5/07;;H02N2/00,,0,0,,,,EXPIRED
56,EP,B1,EP 1424023 B1,183-530-549-248-375,2008-09-03,2008,EP 03026259 A,2003-11-14,US 30537502 A,2002-11-26,Releasable fastener system,,GEN MOTORS CORP,STANFORD THOMAS B JR;;BROWNE ALAN L;;JOHNSON NANCY L;;MOMODA LESLIE A;;BARVOSA-CARTER WILLIAM;;POWELL BOB R JR,,https://lens.org/183-530-549-248-375,Granted Patent,yes,2,0,6,6,0,A41D2300/326;;A44B18/0003;;A44B18/0096;;A44D2203/00;;C08L2201/12;;F16B5/07;;F16F2224/045;;Y10T24/27;;Y10T428/24017;;Y10T24/2783;;F16B2200/83;;F16B2200/81;;F16B2200/77;;Y10T24/27;;Y10T428/24017;;Y10T24/2783;;A41D2300/326;;A44B18/0003;;A44B18/0096;;F16B5/07;;F16F2224/045;;A44D2203/00;;C08L2201/12;;F16B2200/77;;F16B2200/81;;F16B2200/83,A44B18/00;;A44B99/00;;B64C33/02;;F16B1/00;;F16B5/07;;H02N2/00,,0,0,,,,EXPIRED
57,US,A1,US 2009/0260774 A1,011-669-590-319-621,2009-10-22,2009,US 10375508 A,2008-04-16,US 10375508 A,2008-04-16,SACRIFICIAL SLEEVES FOR DIE CASTING ALUMINUM ALLOYS,"Some die cast aluminum alloy articles have internal cylindrical surfaces such as the round internal cylinder surfaces of a cylinder block for an internal combustion engine. During casting solidification molten aluminum alloys shrink against the metallic permanent mold tools used to mold and define such internal surfaces, and tend to stick to the tool surfaces making it difficult to remove the casting. The tendency of some aluminum casting alloys to solder to the tool can further intensify sticking. In this invention, an aluminum alloy sleeve is placed on and over the tool surface before casting and the sleeve isolates the tool from the molten aluminum. The sleeve becomes bonded to the casting and facilitates removal of the casting from the tool. The sleeve may be (and preferably is) fully machined from the internal casting surface. The sleeve may be of the same composition as the casting, in which case handling and recycling of machining chips would be facilitated. The practice of the invention is also applicable to die casting of magnesium alloys using magnesium sacrificial sleeves.",GM GLOBAL TECH OPERATIONS INC,SHIN JONGCHEOL;;PARK JONGWON B;;HWANG INWOOK;;POWELL JR BOB R;;PERRY THOMAS A;;SACHDEV ANIL K;;CARTER JON T,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2008-03-26),https://lens.org/011-669-590-319-621,Patent Application,yes,4,4,7,7,0,B22D15/02;;B22D15/02;;B22D19/0009;;B22D19/0009;;B22D21/04;;B22D21/04,B22D29/00,164/132,0,0,,,,INACTIVE
58,DE,B4,DE 112009000915 B4,130-235-322-631-041,2014-04-10,2014,DE 112009000915 T,2009-04-06,US 10375508 A;;US 2009/0039608 W,2008-04-16,Verfahren zum Druckgießen eines Aluminium- oder Magnesiumlegierungsgegenstandes mithilfe einer Opferhülse,"Verfahren zum Druckgießen eines Aluminiumlegierungsgegenstandes oder eines Magnesiumlegierungsgegenstandes mit einer vorbestimmten Zusammensetzung, der eine innere runde Zylinderwandfläche aufweist, wobei die runde Zylinderwandfläche zumindest einen vorbestimmte/n innere/n Durchmesser und Höhe aufweist, wobei das Verfahren umfasst, dass: ein Druckgusswerkzeug mit einem runden Zylinderflächenabschnitt vorgesehen wird, wobei der runde Zylinderabschnitt eine Höhe zum Bilden der runden Zylinderfläche des Gegenstandes und einen Durchmesser aufweist, der kleiner ist als der Innendurchmesser der Zylinderfläche; eine hohle runde zylindrische Buchse auf der runden Zylinderwerkzeugfläche angeordnet wird, wobei die Buchse eine Höhe und eine äußere Fläche mit einem Außendurchmesser aufweist, um die innere runde Zylinderwandfläche des Gegenstandes zu definieren; eine Schmelze aus der Aluminiumlegierung oder der Magnesiumlegerung gegen die äußere Fläche der Buchse gegossen wird, wobei die Schmelze gegen die Buchsenfläche erstarrt und daran bindet, wobei die Dicke der Buchse vorbestimmt ist, um einem Schmelzen oder einer Verformung durch die Gussaluminiumlegierung oder die Gussmagnesiumlegierung standzuhalten, bevor die Gusslegierung erstarrt; der Gussgegenstand und die gebundene Buchse von dem Druckgusswerkzeug entfernt werden; und die gesamte zylindrische Buchse maschinell von der inneren Fläche des Gussgegenstandes herausgearbeitet wird, um die runde innere zylindrische Fläche des Gegenstandes zu bilden.",GM GLOBAL TECH OPERATIONS INC,SHIN JONGCHEOL;;PARK JONGWON B;;HWANG INWOOK;;POWELL JR BOB R;;PERRY THOMAS A;;SACHDEV ANIL K;;CARTER JON T,"GM GLOBAL TECHNOLOGY OPERATIONS LLC (N. D. GES, US (2011-03-23);;GM GLOBAL TECHNOLOGY OPERATIONS LLC , ( N. D. , US (2011-05-26)",https://lens.org/130-235-322-631-041,Granted Patent,no,4,0,7,7,0,B22D15/02;;B22D15/02;;B22D19/0009;;B22D19/0009;;B22D21/04;;B22D21/04,B22D17/20;;B22D15/02;;B22D21/04;;F02F1/00,,0,0,,,,INACTIVE
59,DE,D1,DE 60323317 D1,170-073-607-659-461,2008-10-16,2008,DE 60323317 T,2003-11-14,US 30537502 A,2002-11-26,Lösbare Befestigungsvorrichtung,,GEN MOTORS CORP,STANFORD THOMAS B JR;;BROWNE ALAN L;;JOHNSON NANCY L;;MOMODA LESLIE A;;BARVOSA-CARTER WILLIAM;;POWELL BOB R JR,,https://lens.org/170-073-607-659-461,Granted Patent,no,0,0,6,6,0,A41D2300/326;;A44B18/0003;;A44B18/0096;;A44D2203/00;;C08L2201/12;;F16B5/07;;F16F2224/045;;Y10T24/27;;Y10T428/24017;;Y10T24/2783;;F16B2200/83;;F16B2200/81;;F16B2200/77;;Y10T24/27;;Y10T428/24017;;Y10T24/2783;;A41D2300/326;;A44B18/0003;;A44B18/0096;;F16B5/07;;F16F2224/045;;A44D2203/00;;C08L2201/12;;F16B2200/77;;F16B2200/81;;F16B2200/83,A44B18/00;;A44B99/00;;B64C33/02;;F16B1/00;;F16B5/07;;H02N2/00,,0,0,,,,EXPIRED
60,DE,T5,DE 112009000915 T5,007-695-750-292-478,2011-03-03,2011,DE 112009000915 T,2009-04-06,US 10375508 A;;US 2009/0039608 W,2008-04-16,Verfahren zum Druckgießen eines Aluminiumlegierungsgegenstandes mithilfe einer Opferhülse,,GM GLOBAL TECH OPERATIONS INC,SHIN JONGCHEOL;;PARK JONGWON B;;HWANG INWOOK;;POWELL BOB R JR;;PERRY THOMAS A;;SACHDEV ANIL K;;CARTER JON T,"GM GLOBAL TECHNOLOGY OPERATIONS LLC (N. D. GES, US (2011-03-23);;GM GLOBAL TECHNOLOGY OPERATIONS LLC , ( N. D. , US (2011-05-26)",https://lens.org/007-695-750-292-478,Patent Application,no,0,0,7,7,0,B22D15/02;;B22D15/02;;B22D19/0009;;B22D19/0009;;B22D21/04;;B22D21/04,B22D17/20;;B22D15/02;;B22D21/04,,0,0,,,,INACTIVE
61,CN,B,CN 102006951 B,052-110-886-017-542,2013-08-14,2013,CN 200980113503 A,2009-04-06,US 2009/0039608 W;;US 10375508 A,2008-04-16,Method of die casting an aluminum alloy article using sacrificial sleeve,,GM GLOBAL TECH OPERATIONS INC,SHIN JONGCHEOL;;PARK JONGWON B;;HWANG INWOOK;;POWELL BOB R JR;;PERRY THOMAS A;;SACHDEV ANIL K;;CARTER JON T,,https://lens.org/052-110-886-017-542,Granted Patent,no,0,0,7,7,0,B22D15/02;;B22D15/02;;B22D19/0009;;B22D19/0009;;B22D21/04;;B22D21/04,B22D17/20;;B22D15/02;;B22D21/04,,0,0,,,,INACTIVE
62,US,B2,US 7146690 B2,094-997-713-457-535,2006-12-12,2006,US 30537502 A,2002-11-26,US 30537502 A;;US 27369102 A,2002-10-19,Releasable fastener system,"A releasable fastener system comprises a loop portion and a hook portion. The loop portion includes a support and a loop material disposed on one side thereof. The hook portion generally includes a support and a plurality of closely spaced upstanding hook elements extending from one side thereof, wherein the plurality of hook elements comprises or incorporates a shape memory alloy fiber. When the hook portion and loop portion are pressed together they interlock to form a releasable engagement. The resulting joint created by the engagement is relatively resistant to shear and pull forces and weak in peel strength forces. Introducing a thermal activation signal to the plurality of hook elements causes a change in shape orientation, flexural modulus property, or a combination thereof that effectively reduces the shear and/or pull off forces in the releasable engagement. In this manner, disengagement of the releasable fastener system provides separation of the hook portion from the loop portion under controlled conditions. Also disclosed herein are processes for operating the releasable fastener system.",GEN MOTORS CORP,STANFORD JR THOMAS B;;BROWNE ALAN L;;JOHNSON NANCY L;;MOMODA LESLIE A;;BARVOSA-CARTER WILLIAM;;POWELL JR BOB R,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2005-01-19);;GENERAL MOTORS CORPORATION (2003-01-30),https://lens.org/094-997-713-457-535,Granted Patent,yes,108,21,6,6,0,A41D2300/326;;A44B18/0003;;A44B18/0096;;A44D2203/00;;C08L2201/12;;F16B5/07;;F16F2224/045;;Y10T24/27;;Y10T428/24017;;Y10T24/2783;;F16B2200/83;;F16B2200/81;;F16B2200/77;;Y10T24/27;;Y10T428/24017;;Y10T24/2783;;A41D2300/326;;A44B18/0003;;A44B18/0096;;F16B5/07;;F16F2224/045;;A44D2203/00;;C08L2201/12;;F16B2200/77;;F16B2200/81;;F16B2200/83,B23P19/04;;A44B18/00;;A44B99/00;;B64C33/02;;F16B1/00;;F16B5/07;;H02N2/00,24/451;;428/100,0,0,,,,EXPIRED
63,US,B2,US 7921901 B2,192-765-103-792-838,2011-04-12,2011,US 10375508 A,2008-04-16,US 10375508 A,2008-04-16,Sacrificial sleeves for die casting aluminum alloys,"Some die cast aluminum alloy articles have internal cylindrical surfaces such as the round internal cylinder surfaces of a cylinder block for an internal combustion engine. During casting solidification molten aluminum alloys shrink against the metallic permanent mold tools used to mold and define such internal surfaces, and tend to stick to the tool surfaces making it difficult to remove the casting. The tendency of some aluminum casting alloys to solder to the tool can further intensify sticking. In this invention, an aluminum alloy sleeve is placed on and over the tool surface before casting and the sleeve isolates the tool from the molten aluminum. The sleeve becomes bonded to the casting and facilitates removal of the casting from the tool. The sleeve may be (and preferably is) fully machined from the internal casting surface. The sleeve may be of the same composition as the casting, in which case handling and recycling of machining chips would be facilitated. The practice of the invention is also applicable to die casting of magnesium alloys using magnesium sacrificial sleeves.",GM GLOBAL TECH OPERATIONS INC,SHIN JONGCHEOL;;PARK JONGWON B;;HWANG INWOOK;;POWELL JR BOB R;;PERRY THOMAS A;;SACHDEV ANIL K;;CARTER JON T,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2008-03-26),https://lens.org/192-765-103-792-838,Granted Patent,yes,5,1,7,7,0,B22D15/02;;B22D15/02;;B22D19/0009;;B22D19/0009;;B22D21/04;;B22D21/04,B22D29/00,164/132,2,1,075-124-917-666-580,10.4271/2006-01-0983,"Peter Krug et al., New Aluminum Alloys for Cylinder Liner Applications, SAE Technical Paper Series, 2006-01-0983; Apr. 2006; Detroit, MI.;;Written Opinion & International Search Report for PCT/US09/039608, Jul. 29, 2009, 7 pages.",INACTIVE
